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Immunity to malaria, where antibodies play a critical role, is acquired slowly, rarely sterile, 
and poorly maintained. The quality than just the quantity of antibodies may provide more 
insight into the slow acquisition and poor maintenance of immunity to malaria.  
I hypothesized that frequent P. falciparum infections interrupt avidity maturation and IgG 
subclass composition, which affects the acquisition and maintenance of immunity to malaria. 
In the first aim, the avidity index to AMA-1 and MSP1-19 was compared across three cross-
sectional malaria transmission intensity sites. In the second and third aims, avidity index, total 
IgG, and IgG1 – 4 against 18 P. falciparum blood-stage antigens were measured in a 
longitudinal cohort at 4-time-points; 2 before and 2 after interruption of malaria transmission 
by IRS.     
Results showed that avidity to both AMA-1 and MSP1-19 was significantly lower at the site of 
highest P. falciparum transmission in children above 5 years and adults.  
In all 18 malaria blood-stage antigens, the avidity index was positively associated with days 
since the last infection independent of age and heterogeneous across antigens. 
There was heterogeneity in antibody half-life estimation across antigens and IgG subclasses. 
IgG3 had the shortest half-life of the IgG subclasses. The predominance of IgG subclass in the 
absence of infection shifted from IgG1 to IgG3 with age. IgG3 improved the specificity of 
antigens as a marker of recent infection compared to total IgG.  
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Results provide supporting evidence to our hypothesis by demonstrating (i) preferential 
expansion of non-avid antibody pool that rapidly wane in the absence of infection (ii) slow 
acquisition of the avid antibody pool that persists in the absence of infection. (iii) slow 
acquisition of IgG3 memory.  
The thesis provides the rationale for further investigation of malaria-specific MBC phenotypes, 
class switching, somatic hypermutation, the avidity of antibodies, and the antibody in vitro 
function. These further studies will provide more knowledge in the acquisition and 
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Chapter 1  
 
1.1 Introduction to Malaria  
 
Malaria is a mosquito-borne disease caused by obligate parasites of Apicomplexa phylum (1). 
There are 5 species known to cause malaria in humans, including Plasmodium falciparum, 
Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and most recently, zoonotic 
Plasmodium knowlesi, whose natural hosts are Macaques (2–4). Most deaths are caused by P. 
falciparum in endemic sub-Saharan Africa, and P. vivax contributes significantly to the disease 
burden outside of sub-Saharan Africa (4).  
This section describes the malaria life cycle and global malaria trends (with a focus on Uganda). 
Also, the section describes malaria elimination efforts, interventions, and new global elimination 
targets and obstacles. 
This thesis will focus on P. falciparum unless mentioned otherwise. 
1.2 Malaria parasite and life cycle  
 
Malaria infection is transmitted from one person to another by the bite from an infected female 
Anopheles mosquito, primarily Anopheles gambiae in Africa (5,6). The life cycle can be divided 
into three phases; (i) asexual liver-stage, (ii) asexual blood-stage, and (iii) sexual mosquito stage. 
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1.2.1 Asexual liver-stage  
 The asexual liver stage is initiated when an infective female Anopheles mosquito injects P. 
falciparum parasites in the form of sporozoites under the skin (7,8). It is estimated that 
mosquitoes generally transmit fewer than 100 sporozoites per bite (9) (Figure 1.1, stage 1). 
The sporozoites pass quickly into the bloodstream, migrate through Kupffer cells, and translocate 
into several hepatocytes before infecting the final hepatocyte. This process happens in about nine 
minutes after injection into the skin to establish the liver stage infection. The speed at which it 
happens poses a challenge to immune interventions (10,11). The liver infection stage is 
asymptomatic, and sporozoites undergo cycles of asexual amplification called schizogony that 
lasts 5 to 10 days. Schizogony results in developing the exoerythrocytic schizont containing as 
many as 30,000 blood-stage merozoites (12) (Figure 1.1, stage 2-4).  
1.2.2 Asexual blood-stage 
The asexual blood-stage starts when membrane-bound merosomes, carrying clusters of 1000 - 
2000 merozoites, are released into the bloodstream, where they rupture to release the merozoites 
(13). The merozoites quickly invade red blood cells (RBC) through elaborate interaction and 
processing of parasite antigens, resulting in attachment on RBC receptors, reorientation, 
irreversible junction formation between the parasite and RBC membranes, and eventually 
complete invasion (14,15).  The RBC invasion starts the inflammatory asexual blood-stage 
responsible for the clinical symptoms (16) (Figure1.1 stage 5). Merozoites inside the RBC 
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transform into ring stage trophozoites and then to schizonts containing 6 – 36 merozoites (17). 
After approximately 48 hours, the schizonts rupture in a synchronized manner, releasing 
merozoites into the bloodstream that quickly infect new RBC to repeat the blood-stage cycle(18).  
Some parasites infecting RBC differentiate into male or female gametocytes that circulate 
independently in the peripheral blood. P. falciparum gametocytes appear in peripheral 
circulation after about 7 to 15 days after the initial invasion of erythrocytes (19) (Figure 1.1, 
stage 6) and are not associated with clinical symptoms. 
1.2.3 Sexual mosquito stage 
Anopheles mosquito feeding on infected human blood ingests gametocytes to initiate the sexual 
mosquito stage (Figure 1.1, stage 7-8). The mosquitos are attracted to infected humans by 
volatile compounds that are either secreted by the parasite or skin bacteria, and this co-
evolutionary adaptation increases parasite transmission success (20,21). A decrease in 
temperature triggers male gametes to flagellate within minutes of ingestion by mosquitos and 
fuse with the female gamete to form a diploid zygote where meiosis occurs to form haploid 
zygotes (22) (Figure 1.1, stage 9). The haploid zygote differentiates into an invasive ookinete 
that penetrates the gut wall and attaches to the mosquito gut's outer aspect (23) (Figure 1.1, stage 
10-11). The ookinete differentiates into oocyst that matures and ruptures to release sporozoites 
(Figure 1.1, stage 12). The sporozoites penetrate the salivary glands and rest in the channels 
bearing saliva, awaiting access to the next human bite for the cycle to start again (24) (Figure 
1.1, stage 13). 
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1Figure 1.1 Life Cycle of Malaria describing the three stages 
The asexual liver and blood-stage s complete in humans, and the sexual stage in mosquitos. The blood-
stage  is responsible for the pathology of the infection  (25)  
 
1.3 Global Malaria Trends 
 
The global malaria burden has progressively declined over the last decade and a half, with the 
most remarkable progress seen between 2010 and 2015. An estimated 1.3 billion fewer malaria 
cases and 6.8 million fewer deaths occurred globally during this period(4). Malaria incidence 
declined by 21% and deaths by 29% globally (Figure 1.2 a&b). In the same period, up to 13 
countries were declared malaria-free after reporting no indigenous case for at least three 
consecutive years.  
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Much of the progress we can attribute to the increased investment resulted in improved health 
care systems and scale-up of preventive, vector control, and case management interventions, 
especially in endemic countries (26).  
Despite the previous progress, malaria remains a significant burden were 3.4 billion people in 
91 countries are still at risk. WHO malaria report of 2017 indicated a setback in previous gains 
where more malaria cases were estimated at 216 million in 2016 compared to 211 million in 




Figure 1.2 Reduction in malaria incidence (a) and mortality (b) by WHO regions between 2010 and 
2015. African east Mediterranean areas with P. falciparum registered the least reductions in both 
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1.4 Malaria status in Uganda  
 
In the eastern part of Africa, Uganda is the 9th of the 15 countries, contributing 80% of the P 
.falciparum infections in 2016 (27). Uganda has an estimated population of 41 million by 2018, 
all at risk of malaria. In 2016 alone, 7.7 million malaria cases accounted for 4% of the world 
malaria cases and 12,060 deaths, mainly in children under five years (27). The annual numbers 
implied 16 malaria cases per minute, and one malaria-related death occurred every 35 minutes 
in 2016 alone. Hospital records suggest that malaria is responsible for 30 to 50% percent of 
outpatient visits, 15 to 20% of admissions, and 9 to 14% of inpatient deaths.  
Uganda was among the countries that registered a 40% reduction in incidence between 2010 and 
2015. In the same period, there was procurement and distribution of over 30 million free bed 
nets, which increased net ownership by up to 62%. Uganda is among the countries that threatened 
to lose the gains due to increased malaria cases by over 50,000 in 2015 – 2016.  
Malaria transmission in Uganda is majorly by the vectors A. gambiae and A. funestus. Malaria 
is highly endemic in almost all parts of the country. Transmission occurs throughout the year, 
with seasonal variation peaks occurring at the end of the two rainy seasons (September to 
November and March to May)(28). Very high entomological inoculation rates (EIR) , a measure 
of the infective mosquito bites per person per year, have been recorded in Uganda. EIR  rates as 
high as 1,586 were recorded in Apac in 2006 (29), and 306 in Tororo District in 2012 (30).  
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1.5 Malaria control strategies 
 
Substantial progress has been made over the past few years to reduce the global malaria burden 
through vector control and case management. The most widely used vector control measures 
include insecticide-treated nets (ITN), indoor insecticide residual spraying (IRS).  Malaria cases 
are managed using artemisinin-based combination therapies (ACT) and intermittent preventive 
therapy for pregnant women using sulphadoxine-pyrimethamine.  
The Roll Back Malaria initiative began in 1998 (31), followed by the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria (GF). The later stimulated funding targeted towards meeting the 
United Nations millennium development goal C6, which aimed to halt by 2015 and begin to 
reverse the incidence of malaria and other major diseases (32). These initiatives resulted in a 
gradual scale-up of mainly insecticide-treated bed nets (ITN) and limited insecticide indoor 
residual spraying (IRS) in all malaria-endemic countries in the last decade. ITN use increased 
from below 3% to 53% between 2011 and 2015. IRS use rose from 5% to 11% covering 153 
million people at risk, and approximately 50% of these living in high burden countries of sub-
Saharan Africa. In the same period, over 56% of the population in sub Saharan Africa at risk of 
malaria slept under a mosquito net in 2015 mainly through mass distribution campaigns (27). It 
is estimated that 70% of the malaria cases averted between 2001 and 2015 were due to the 
implementation of malaria control interventions (Figure1.4).  ITN, ACT, and IRS contributed 
78%, 19%, and 13% respectively to the malaria cases averted due to the interventions ACT and 
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IRS interventions had larger proportional contributions where their coverage was high 
(Figure1.4) (26) 
Not all the reductions in malaria are attributed to preventative interventions. There is evidence 
to suggest that increased urbanization and overall economic development, which led to improved 
housing and nutrition, contributed to the decline in malaria prevalence (33–35).  
The current interventions do not directly target asymptomatic and sub-patent infections, which 
promote a sizeable human reservoir. This reservoir fuels new infections when interventions are 
relaxed, and this is a big obstacle for countries to progress from malaria control to the malaria 
elimination phase. Other interventions like mass drug administration and intermittent preventive 
treatment provide high prospects. However, they pose prohibitive cost barriers and risks of drug 
resistance. Vaccinations against the liver stage infection and gametocytes are other prospects, 
although they face suboptimal efficacy and short-lived immunity challenges.
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1Figure 1.4 Reduction in P. falciparum malaria burden and contribution of interventions in endemic African countries 
between 2000 and 2015.  1.4a show predicted parasite rate among children 2 – 10 years. The black line shows the expected 
rate if no interventions (counterfactual), and the red shows the actual rates with interventions. The different colors show the 
contribution of each of the three interventions. The parasite rate is estimated to have reduced by 50%, from 32% in 2000 to 
16% by 2015. 1.4b shows the cumulative number of malaria cases averted in same endemic Africa due to the three 
interventions and their relative contribution by the different colors. Over 650 million malaria cases were prevented by 2015 
(26) The figure was reproduced under a Creative Commons license. 
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1.6 Malaria elimination campaigns; the past, the present, and the future 
 
WHO initiated Malaria eradication campaigns in the late 1940s to set the foundation for the 
global eradication of malaria. This campaign succeeded in eliminating malaria from Europe, 
North America, the Caribbean, and Asia and South-Central America (36,37). The campaign 
registered little success in Africa due to technical and political limitations, including high 
illiteracy levels, poor health infrastructure, and civil wars (38). Increased malaria burden in the 
1980s and 1990s renewed the call to control malaria. It led to initiatives like Roll Back Malaria, 
Global Fund to fight HIV, malaria, tuberculosis, and the Presidential Malaria Initiative. These 
global frameworks set targets and strategies, increased advocacy, and funding that promoted 
increased investments towards malaria control and elimination. The approach and investments 
guided by the millennium goal C6 led to a scale-up of malaria control interventions and reduced 
malaria observed between 2000 and 2015.  
The new UN Sustainable Development Goal 3C calls for reducing malaria mortality and 
morbidity by at least 90%, eliminating malaria in 35 counties, and preventing reestablishment in 
those with confirmed elimination by 2030 (39). WHO further outlined the strategy in the WHO 
Global Technical Development Goals for Malaria 2016-2030.  The strategy included three 
pillars: (1) ensuring universal access to malaria prevention, diagnosis, and treatment, (ii) 
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accelerating efforts towards elimination and attainment of malaria-free status, (iii) and 
transforming malaria surveillance into a core intervention (40).  
However, the new goals face challenges, especially in high malaria transmission intensity areas 
where recent WHO findings reported stalled progress or tendency towards increased malaria 
incidence and deaths in the 2017 malaria report. Such challenges include (i) stalled investment, 
(ii) political/civil unrest, uneven elimination progress by counties or within a country, (iii) risk 
of drug resistance against ACT and slow discovery pipeline of new cost-effective drugs (41),  
(iv) lack of drugs that effectively target gametocytes (42,43), (v) lack of cost-effective rapid 
diagnostic and surveillance tools (vi) insecticide resistance (44–46). 
Overcoming the challenges calls for advocacy to promote funding, additional new and highly 
rigorous interventions, and surveillance tools. There is a need to identify asymptomatic and sub-
patent infections known to fuel transmission and are not detected by the current conventional 
methods (47,48). Secondly, uneven progress towards elimination poses a high risk of epidemic 
outbreaks of severe malaria in non-immune populations. Therefore, it is critical to understand 
how immunity to malaria is acquired, maintained, evaded, or interrupted by the parasite, to 
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1.7 Malaria Pathogenesis, Diagnosis, and Treatment 
 
Malaria is one of the leading causes of death globally. The interaction of the host immune 
reaction and the asexual blood-stage is the primary cause of malaria pathology. The disease 
diagnosis and treatment strategies target its highly inflammatory asexual blood-stage.   
This section will describe malaria pathogenesis, diagnosis, and treatment. 
1.7.1 Malaria pathogenesis   
Symptoms in malaria develop when the asexual blood-stage cycle emerges. Malaria is 
characterized by general symptoms such as fever, headache, fatigue, muscle pain, and diarrhea, 
mainly due to the parasite's inflammatory immune response and toxins (49,50).  The onset of 
fever is associated with a parasite load above a threshold referred to as pyrogenic threshold. In 
high malaria-endemic regions, the pyrogenic parasite threshold increase with age and exposure 
(51,52). Malaria can present as severe or uncomplicated based on the life-threatening pathology. 
The risk of occurrence of severe forms of malaria such as cerebral malaria (CM), lactic acidosis, 
respiratory distress and failure, severe anemia, among others, reduce with age (51,53,54) and with 
the number of pregnancies in the case of placental malaria (55). Severe malaria in P. falciparum 
infection is mainly due to; (i) sequestration of infected red blood cells in the microvasculature, 
mediated by cyto-adhesion molecules (ii) anemia direct destruction of erythrocytes, 
dyserythropoietic, and autoimmunity.  
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Parasite sequestration occurs inside small and medium-sized blood vessels and in tissues like the 
brain and placenta. Variants of P. falciparum erythrocyte membrane protein 1 (PfEMP1) mediate 
the sequestration (56) and host adhesion molecules such as CD36, ICAM-1, VCAM (57,58). 
PfEMP1 is a clonally variant set of proteins exported on infected erythrocytes' surfaces and 
encoded by the var gene family (59–61). The sequestration results in high parasite load due to 
parasite avoidance of clearance in the spleen (62), leading to detrimental local inflammation, host 
endothelial cell injury, and microvascular obstructions (63). The clinical effect of parasite 
sequestration depends on the organ involved and different PfEMP1 variants associated with a 
particular complication. In the brain, parasite sequestration is associated with cerebral malaria 
characterized by coma, and in the lungs, it results in respiratory distress or failure (64). In 
pregnancy, the PfEMP1 variant VARCSA causes cytoadherence to chondroitin sulfate A  in the 
placenta to cause placental malaria (65,66). Placental malaria is characterized by an increased 
risk of abortion and stillbirth, preterm labor, and low birth weight (55,67).  
Chronic anemia is a common feature of P. falciparum infection pathology. It results from direct 
destruction of erythrocytes, increased hemolysis of uninfected RBC, and bone marrow 
suppression resulting in dyserythropoiesis (68,69). On the other hand, Anaemia is linked to the 
host protective mechanism against the parasite, dependent on a high iron requirement for liver 
and blood-stage growth (70). 
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1.7.2 Malaria diagnosis and treatment  
Malaria diagnosis is usually made using thin or thick blood smear and light microscopy, which 
is regarded as the standard gold method. The shortfall to microscopy requires a 1000x 
magnification, a highly trained microscopist, and failure to detect sub patent infection below 50-
100parasites/µl (71).   
Rapid diagnostic tests (RDT) that test for parasitic proteins such as histidine-rich protein-2 
(HRP2) and lactate dehydrogenase aldolase in blood samples are more widely used have 
improved access to malaria diagnosis. The limitation to the HRP2 RDT is the protein deletion, 
especially in Southeast Asia (72,73). Some studies in several African countries, including Kenya, 
Rwanda, and Eretria, reported HRP2 deletions (74–76). Its distribution and prevalence in sub-
Saharan Africa are not fully known, and increased use of HRP2 for diagnosis poses a potential 
risk for selecting HRP2 deletions (77). The second limitation is the persistence of the protein 
after parasite clearance, especially in ACT-based treatment, resulting in the accumulation of 
previously infected cells and can lead to false-positive readings (78). 
For malaria control interventions that require active identification of malaria cases for treatment, 
microscopy, and parasite protein RDT are adequate. However, in the new era of malaria 
elimination, identifying any infections form is essential and renders the two methods inadequate. 
Current molecular techniques such as loop-mediated isothermal amplification (LAMP) and 
quantitative polymerase chain reaction  (qPCR) can detect down to 0.01parasites/µl (79,80). 
These molecular methods are expensive, labor-intensive, and not suitable for massive public 
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health diagnosis. In the wake of malaria elimination, simple, cheaper, and rapid tests with the 
capacity to diagnose sub patent infections are required. 
1.8 Acquired immune responses to malaria 
In a typical malaria-endemic area, severe malaria occurs mainly in children, and as they grow 
older, they continue to suffer but from uncomplicated forms of malaria. By middle school, these 
children endure a high parasite burden without fevers. Eventually, in adulthood, the prevalence 
of chronic infection and parasite density reduces, and rarely do adults safer from clinical malaria. 
In a typical household in endemic areas, the children will suffer from many malaria episodes but 
hardly any among their parents despite having the same risk of exposure. Despite these 
epidemiological indications of the gradual acquisition of immunity to malaria, correlates and 
mechanisms that mediate immunity are not fully understood.  
This section describes the malaria immunity manifesting in distinct and overlapping forms, the 
role and evidence of humoral immunity, and efforts towards developing malaria vaccines and 
serological tools for diagnosis and surveillance. 
1.8.1 Immunity to severe disease 
In endemic areas, infants are highly susceptible to life-threatening malaria once they are infected. 
They rapidly overcome the severity of the disease but continue to serve from milder forms. The 
reduction in risk of severe disease is termed as severe malaria immunity. The relationship 
between age and severe malaria immunity is dependent on the transmission setting. Immunity to 
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severe forms of malaria is acquired very early in life in the high transmission area and delayed 
with age in the low and unstable transmission areas. Severe malaria manifests, most commonly 
as cerebral malaria, severe anemia, and respiratory distress. Immunity to non-cerebral forms of 
severe malaria is acquired earlier after one to two infections, but immunity to cerebral malaria is 
acquired much later (81). Maternal transfer of immunity may explain early immunity's rare 
occurrence to the non-cerebral severe malaria forms among infants from high endemicity regions 
(54). These children emerge from maternal protection with the significant acquisition of their 
severe malaria protection associated with acquiring antibodies against PfEMP1(81,82).  
Cerebral malaria is associated with the sequestration of the parasite in the brain, mediated by 
parasite PfEMP1 and intercellular adhesion molecule 1 (ICAM-1) receptor, among others that 
lead to inflammatory pathology (83,84). A discrete set of PfEMP1antigenic types that are not 
only common but also induce strain-specific immunity are thought to cause Cerebral malaria 
(85).  Severe malaria occurs in a small proportion of the population, and this may be due to host 
immunological and genetic factors (86,87). Haemoglobin S has long been known to play an 
essential role in severe malaria.  Polymorphisms in other genes like the tumor necrosis factor-
alpha, major histocompatibility complex, interleukin receptors, toll-like receptor-4, among 
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1.8.2 Anti-disease Immunity  
As the children grow older in endemic areas, they increasingly become tolerant to high parasite 
load without developing a fever.  The ability to tolerate high parasite load upon infection without 
developing clinical symptoms or having a high pyrogenic threshold is anti-disease immunity 
(92). This phenomenon is more pronounced among children to adolescents in high endemic areas 
where the pyrogenic parasite threshold can exceed 60,000 parasites/µl (51,52,92). Malaria 
symptoms result from the inflammatory response against parasite antigens and toxins. Therefore,  
immune tolerance or regulatory mechanisms, among others, are thought to mediate anti-disease 
immunity. Several studies show that chronic asymptomatic infection is associated with lower 
levels of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), 
interferon-gamma (IFN-γ), interleukin (IL)-1β, IL-2, IL-6, IL-8, and IL-12 (93–95). 
On the other hand, asymptomatic infections characterized by high parasite density are associated 
with increased anti-inflammatory cytokines, including IL-4, IL-7, IL-10, and IL-13 (96–98). 
Furthermore, loss of innate-like γδ T-cells and alteration of their pro-inflammatory cytokine 
secretion profiles is associated with reduced clinical disease risk (99). anti-disease immunity is 
thought to be short-lived and may require continuous exposure to maintain. A study in Papua 
New Guinea showed that the odds of children presenting with malaria increased by 4 times after 
8 years of malaria control, implying loss of anti-disease immunity. However, this study did not 
indicate whether the children's pyrogenic threshold was lowered (100). (100)(100)While adults 
are less likely to develop symptomatic malaria when infected in endemic areas, when they do, 
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the parasite density associated with fever is lower than in children (101). This observation may 
imply loss of anti-disease immunity at the cost of anti-parasite immunity in adults. It is important 
to note that no vaccine or therapeutic intervention currently in the development pipeline targets 
anti-disease immunity.  Such a vaccine can play an essential role in preventing severe disease 
burden in case of reemergence in areas that have eliminated or are near elimination.  
1.8.3 Anti-parasite immunity  
In a typical endemic area, the prevalence of parasite and geometric mean parasite density 
decrease with age. Some adults will harbor parasites below the microscopic level but detectable 
by molecular methods(sub-patent).   The ability to control parasite density to very low levels, up 
to sub-patent level, is anti-parasite immunity. This form of immunity is observed mainly in adults 
living in endemic areas, and there is a tendency of early acquisition in areas of high compared to 
low transmission (102). Anti-parasite immunity is acquired cumulatively as a function of age and 
exposure (92). In Papua New Guinea, the age at which P. falciparum density peaked shifted from 
10 to 15 years after 4 years of sustained malaria control, implying a delayed acquisition of anti-
parasite immunity when exposure is lowered (100). Anti-parasite immunity is targeted mainly 
against the blood-stage and mediated by innate and adaptive effector mechanisms where 
antibodies play a significant role (24,103,104). 
Furthermore, immune tolerance thought to mediate anti-disease immunity can contribute to anti-
parasite immunity by preventing activation of endothelial cells resulting in down-regulation of 
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adhesion molecules hence preventing P. falciparum cyto-adhesion.  Failure of infected red blood 
cells to sequester in the microenvironments increases their clearance in the spleen, resulting in a 
reduction in parasite density. Anti-parasite immunity is not efficient at parasite elimination and 
does not seem to protect from new infection. Superinfection or complexity of infections are 
commonly observed in individuals who maintain low parasite densities, and the same conditions 
can last up to 180 days (105,106).   One possible explanation is the inefficient acquisition of 
immunity to the asexual liver-stage, which allows for superinfections to occur. Lack of immunity 
to asexual-stage is supported by observing the clearance of chronic parasitemia in some 
individuals when the transmission is interrupted (107). It is also likely that the tolerance 
mechanisms that drive anti-disease immunity result in inefficient parasite clearance (108,109).  
Failure to develop sterile immunity bears the consequence of maintaining parasite reservoirs that 
fuel new infections and, therefore, a significant obstacle to malaria elimination. The anti-disease 
immunity and anti-parasite immunity are both acquired in parallel as a function of age and 
exposure (92). While immune tolerance may potentially hamper effector mechanisms that 
mediate parasite clearance, there is no information about how the acquisition of anti-disease 
immunity affects the acquisition and maintenance of anti-parasite immunity.  
1.8.4 Sterile immunity 
The ability to abort or extinguish infection is defined as sterile immunity. It is rare and difficult 
to demonstrate in a natural setting. Sterile immunity has been shown in controlled human malaria 
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infection (CHMI) after vaccination with irradiated sporozoites (110,111) and in live non-
attenuated sporozoites under chloroquine or mefloquine chemotherapy (112). The duration and 
efficacy of sterile immunity against natural exposure to many variant strains are poorly 
understood. This form of immunity is mediated by mechanisms that target the liver stage and 
prevent the emergence of blood-stage infection or arrest the early blood-stage emergence.  
Immune compartments such as CD4 T cells, CD8 T cells, γδ T cells, and antibodies are involved 
in mechanisms that mediate sterile immunity(112–114). Sterile immunity is rare and difficult to 
demonstrate in natural infections due to lack of a direct measure of exposure and lack of 
protection correlations. However, there is still a proportion of individuals in high transmission 
areas, mostly adults, who are free from infection even by sensitive molecular tests and for an 
extended period even when they share households with chronically infected children. Both 
genetic and immunological mechanisms likely contribute to sterile immunity, but their 
independent effects are not known. Vaccination and CHMI studies indicate that sterile immunity 
protection is likely short-lived and may be strain-specific (115,116). 
1.8.5 Evidence for the role of antibody responses in immunity to malaria 
Antibody-mediated immune responses contribute significantly to the acquired immunity 
phenotypes against P. falciparum (described above; 1.81- 1.84). The importance of the antibody 
response is demonstrated by (i) the passive transfer of immunoglobulin that reduces parasitemia 
(anti-disease and anti-parasite immunity ) (117,118), (ii) the role of maternal transferred IgG in 
protecting newborns from severe disease (anti-disease) (119–121)  (iii) epidemiological studies 
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that show a positive association between parasite-specific antibodies with protection from 
symptomatic or severe malaria (61,122–128). (iv) in-vitro antibody-mediated function assays 
show parasite growth inhibition and destruction of infected red blood cells by complement-
fixing, phagocytosis, and antibody-dependent cytotoxicity (ADCC) (129–134).  
Overwhelming evidence for antibodies' role in natural immunity has led to a quest for vaccine 
strategies targeting antibody response across different life cycle stages. 
1.9 Malaria vaccine 
Vaccination is the holy grail of immunology, but the development of a malaria vaccine has 
eluded immunologists for more than 50 years since the proof of concept with irradiated 
sporozoites in mice (135). While antimalarial chemotherapies suffer from repeated medication, 
drug resistance, and drug tolerance, toxicities, and poor adherence, vaccination has been superior 
in containing infection when it is available. Near eradication of polio and smallpox diseases has 
been due to successful and effective vaccination campaigns (136,137). The rationale for a malaria 
vaccine is based on the epidemiological observation of the naturally acquired immunity 
previously described. Furthermore, the rationale is supported by the acquisition of immunity 
following the transfer of purified immunoglobulin from immune individuals to malaria-ridden 
children that drastically reduced parasite density and improved clinical prognosis (117,118,138).  
This section provides updates on the different malaria vaccine approaches targeting various 
malaria life cycle stages and the current vaccine development status. 
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1.9.1 Vaccines targeting liver Stage: RTS, S/AS01 as an example of a subunit vaccine 
The malaria vaccine concept was first demonstrated in mice using Irradiated sporozoite, 
followed by a challenge with P.berghei parasites.  The vaccination challenge arrested the 
appearance of blood-stage merozoites responsible for the clinical disease (135). Similar 
challenges with irradiated sporozoites in humans, followed by controlled human malaria 
infection, yielded comparable results (110,111,116). However, sporozoites' mass production's 
difficulty led to the search for subunit vaccines. RTS, S/AS01 is the most advanced malaria 
subunit vaccine evaluated for efficacy in Phase III human clinical trial. RTS, S/AS01 is made up 
of a virus-like particle comprised of two components; 18 copies of the central repeat and the C-
terminal domain of CSP fused to hepatitis B virus surface antigen (HBsAg) with extra HBsAg 
in a 1:4 ratio (139). In phase III clinical trial, RTS, S/AS01 failed to induce sterile immunity in 
endemic areas, but it showed protection from severe disease forms. The vaccine efficacy varied 
across malaria transmission intensity sites; protection waned within 18 months and was age-
dependent (139). The mechanisms that mediated partial RTS, S/AS01 immune-protection are not 
fully understood.  Nonetheless, existing data strongly suggest that high antibody concentrations 
against the NANP amino acid repeats are strongly associated with protection (140). The waning 
of such antibody responses is likely to be responsible for decreasing efficacy. In addition to 
antibody, CD8+ and CD4+ T cell responses play some role in protection (140). Different 
vaccination strategies reveal additional insight into mechanisms that mediate RTS, S/AS01, 
pointing towards the innate immune cells, early B-cell transcription signature, IgG subclass, 
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among others(141,142).  The impairments of the different immune compartments, immune-
tolerance, and exposure to multiple parasite strains in endemic areas may contribute to the 
vaccine's low efficacy of the vaccine observed in endemic areas. 
Reviewed in (143), several design strategies to improve RTS, S/AS01 efficacy, and protection 
are underway. These include (i) use of improved adjuvants to enhance the longevity of high 
antibody titer, (ii) modification of dose and schedule that seem to affect isotope switching 
associated with improvement in protection in the preliminary phase II clinical trial findings (141) 
(iii) reduction of 4-fold excess HBsAg to increase anti-NANP IgG and reduce anti-HBsAg IgG 
to increase CSP antibody target epitopes per dose, (iv) use of full-length CSP containing the N-
terminal non-repeat region to increase antibody targets for epitopes not present in RTS,S (144) 
(v) structure-based vaccine design that involve isolation of monoclonal antibodies from humans 
exposed to an infection or by a vaccine that shows potent neutralizing function. The structure of 
the epitope bound by the monoclonal antibody is determined at atomic resolution. This 
information is used to design immunogens to elicit antibodies with functional activity (145).  
1.9.2 Whole sporozoite vaccines 
In addition to subunit vaccines, exploration of whole sporozoite vaccination strategies is 
underway. These involve the administration of live-attenuated sporozoites that cease 
development at various stages before the appearance of blood-stage infection or live sporozoites 
that reach the blood but are eliminated by drugs. Strategies attempted in human clinical trials 
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under CHMI include (i) irradiated attenuated sporozoites (PfSPZ vaccine) that arrest 
development at random points early in liver-stage development.  PfSPZ vaccine conferred 
protection in humans in CHMI trials administered by mosquito bites. Its protection was 
associated with tissue-resident PfSPZ-specific CD8+ T cell responses (115,116). (ii) Genetically 
attenuated parasite (GAP), targeting sporozoite gene knockout like p52-/p36-/sap1, arrest early 
liver-stage development and was reported as fully attenuated (146–148). (iii) Wild-type 
sporozoites under chloroquine drug cover allow liver-stage parasite development before being 
killed upon entry into the blood-stage (149,150). This method was free of clinical disease in 
CHMI when challenged with homologous, although not heterologous parasites after two years. 
Overall, whole sporozoite vaccines seem to suffer from the requirement of multiple vaccination 
boosts, strain specificity, and short-lived protection.   
1.9.3 Vaccines targeting blood-stage  
Blood-stage vaccines are likely not to induce sterile immunity but to mimic naturally acquired 
immune phenotypes like anti-disease or anti-parasite. These vaccines will play an essential role 
in complementing the liver-stage vaccines. Besides, they will boost or maintain naturally 
acquired immunity in highly endemic areas during elimination campaigns and prevent malaria 
epidemics if transmission outbreaks occur. Antibodies remain the primary target for these 
vaccines due to their role demonstrated in naturally acquired immunity and involvement on the 
effector mechanisms at mediate anti-parasite immunity. In blood-stage malaria, antibodies are 
essential in mediating protective mechanisms such as blocking red blood cell invasion, 
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opsonization for phagocytosis, and complement-mediated effector mechanisms, among others 
(151–153). 
Several blood-stage antigens have been tried for vaccine development over the decades but 
yielded undesirable outcomes mainly due to polymorphisms and redundant invasion pathways 
(154–156). Advances in high throughput antigen expression and probing technologies like 
microarray have improved the identification of new vaccine candidates that target highly 
conserved merozoite epitopes critical to parasite function (157,158). 
The most advanced and promising blood-stage vaccine is the P. falciparum reticulocyte-binding 
protein homolog 5 (PfRH5). It is highly conserved hence overcoming the problems of 
polymorphism. It forms an essential interaction with Basigin (CD147), a receptor on the 
erythrocyte surface during the invasion; therefore, overcoming limitations associated with 
redundant invasion pathways (159). 
Other promising vaccines include subunits against pregnancy-associated malaria using 
VAR2CSA (160) and chemically attenuated whole-parasite blood-stage vaccine to mimic 
naturally acquired immunity (161,162). Table 1.5 summarizes leading vaccine candidates in the 
human clinical trial. 
1.9.4 Transmission-blocking Vaccine targeting the sexual Stages 
These vaccines target the gametocytes and aim to induce antibodies taken up by mosquitoes 
during a blood meal, blocking sexual development inside the mosquito. This kind of vaccine will 
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most likely not induce protection in the individual but will protect the community by reducing 
mosquito transmission. The leading transmission-blocking vaccine candidates include the 
ookinete surface protein Pfs25 and the gametocyte antigens Pfs48/45, Pfs230, Pfs47 PfHAP2 
(163,164). Antibodies against all these gametocyte antigens have yielded a sound reduction in 
sporozoite development in membrane feeding assays. 
Table 1.5 Summary of the malaria vaccines in human clinical trials targeting different P. 





Vaccine Target Vaccine Candidate Targeted Mode of Action Development Phase 
Killing of Infected 
hepatocytes, Lever Stage 
PfSPZ Vaccine T cell Phase IIb 
PfGAP3KO T cell Phase I/IIa 
PfSPZ-GA1 T cell Phase I/IIa 
ChAd63 or MVA ME-TRAP T cell Phase IIb 
ChAd63 or MVA ME-TRAP (IV route) T cell Phase Ia 
ChAdOx1-MVA LS2 T cell Phase I/IIa 
Inhibition of Merozoite, 
Blood Stage 
ChAd63-MVA Antibody Phase Ia/Ib 
RH5.1/AS01 Antibody Phase I/IIa 
PfAMA1-DiCo/Alhydrogel or GLA-SE Antibody Phase Ia/b 
P27A/Alhydrogel or GLA-SE Antibody Phase Ia/b 
BK-SE36 [PfSERA5]/Alhydrogel ± CpG Antibody Phase Ia/b 
PfPEBS/Alhydrogel Antibody Phase I/IIa 
ChAd63-MVA PvDBP_RII Antibody Phase I/IIa 
PvDBPII/GLA-SE Antibody Phase Ib 
Prevention of iRBC-mediated 
pathology, Blood Stage 
PAMVAC/Alhydrogel or GLA-SE or GLA-LSG Antibody Phase Ia/b 
PRIMVAC/Alhydrogel or GLA-SE Antibody Phase Ia/b 
Inhibition of sporozoite 
infection, transmission 
blocking 
RTS,S/AS01 Antibody Pilot implementation 
RTS,S/AS01 “Fractional Dose” Antibody Phase IIb 
R21/Matrix-M Antibody Phase I/IIa and Ib 
R21/AS01 Antibody Phase I/IIa 
FMP012 [PfCelTOS]/GLA-SE or AS01 Antibody Phase I/IIa 
Inhibition of sexual-stage 
development, Mosquito 
Stage 
ChAd63-MVA Pfs25-IMX313 Antibody Phase Ia 
Pfs25-EPA/Alhydrogel or AS01 Antibody Phase Ia/b 
Pfs230D1M-EPA/Alhydrogel Antibody Phase Ia/b 
Pfs25 VLP-FhCMB/Alhydrogel Antibody Phase Ia 
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1.10 IgG structural features that determine the function 
 
There are five immunoglobulin isotypes in humans: IgM, IgD, IgG, IgA, and IgE. IgG is the 
most abundant, accounting for about 10 - 20% of plasma protein (165). IgG is the primary 
antibody type secreted by plasma cells derived from memory B-cell and is the major isotype 
involved in adaptive immune responses. Like the other isotypes, IgG is a heterodimeric protein 
composed of two identical 50 kDa heavy and two 25kDa light chains, which are paired by both 
non-covalent and inter-chain disulfide bonds (Figure 1.6a). The light chain consists of either 
kappa (k) or lambda (λ) chains. The N-terminal of each of the chains contains a variable region 
that determines the antibody's specificity (Figure 1.6a). The C-terminal consists of the constant 
region made up of constant (C) domains. Both light chains contain only 1 CL domain, whereas 
heavy chains contain 3CH domains. The heavy chains include a spacer hinge region between the 
first (CH1) and second (CH2) constant domains. The CH2 and CH3 of the heavy chains make up 
the crystallizable component (Fc) of the antibody, which mediates the antibody's effector 
function (Figure 1.6a). The VL, CL, VH, and CH1 make up the antibody binding fraction (Fab) 
that mediates the antibody's specificity. 
IgG can be subdivided further into subclasses that differ structurally and functionally (Figure 
1.6b).  
This section will highlight the different properties of IgG subclasses that are important in 
acquiring, function, and maintaining immunity.  
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1.11 Differences in IgG subclasses structures that affect half-life and function.  
 
There are four IgG subclasses named in order of decreasing abundance IgG1 > IgG2 >IgG3> 
IgG4 (166). All four subclasses have the same basic IgG structure and share more than 90% 
homology (165). However, there are differences in surfaces of exposed amino acid residues on 
the CH1, CH2, and CH3 and substantially higher variation in the hinge region (165) (Figure1.6b). 
These variations define the differences of IgG subclasses' unique profiles for antigen binding, 
immune complex formation, complement activation, triggering of antibody-mediated effector 
cell function, susceptibility to proteolytic enzyme activity, half-life, and placental transport. The 
subclasses exhibit variations in asparagine N-linked glycan composition between the CH2-CH3  
junction (N297) that forms the overlapping regions of engagement for complement C1q and Fc-
 receptors and that result in variation in subclass effector function (167,168). The Fc region of 
IgG3 has the most elongate hinge region, followed by IgG1, with IgG2 and IgG4 having the 
shortest (Figure 1.6b). The length of the hinge confers flexibility and easy accessibility to 
effector function. As a result, IgG3 has the highest affinity for the Fc- receptors (FcR) (169). 
The CH2-CH3 domains also contain the binding region for the neonatal Fc receptor (FcRn) 
responsible for recovering IgG from scavenging epithelial, endothelial, and myeloid cells, 
translocation of IgG at mucosal sites, and placental transfer (170). The interaction between the 
CH2-CH3 binding site and FcRn is mediated by histidine residual at amino acid position 434 at 
acidic pH <6.5 of the endocytic vacuoles. IgG3 allotypes (except for H434 containing g3m) with 
a substitution in this position have remarkably reduced half-life and placental transfer (171). The 
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low binding of IgG3 to the FcRn result in a shorter half-life of IgG3 of 7 days compared to other 
subclasses at 21 days (172) and low placental transfer (173).  
 
 
3 Figure 1.6 Schematic layout of IgG features and subclasses a) Basic structure of IgG 
composed of two  heavy chains and two light chains linked together by disulfide bonds. The two identical 
heavy chains are composed of variable regions, the constant domains CH1, CH2 joined by the hinge 
region and CH3. The heavy and light chains' variable regions make up the antigen binding and define the 
antibody's specificity. The hinge, CH2, and CH3 make up the Fc that define the subclasses and contain 
the Fc receptors C1q receptor, FcnR, and glycosylation sites that determine the functionality of the 
antibody.  (b) IgG subclasses show their differences in the amino acids and disulfide bonds in hinge 
regions that influence receptors' subclass affinity.  The hinge length is the longest in IgG3 11 disulfide 
bonds, followed by  IgG2  with four and IgG1&4 with two bonds. The hinge size determines the flexibility 
of FC than enhancing FcR binding and stability of the complex. 
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Table 1.7 summarize the properties of IgG subclasses (165) 
 General IgG1   IgG2   1gG3   1gG4   
Molecular mass (kD) 146   146   170   146   
Amino acids in the hinge region 15   12   62   12   
Inter-heavy chain disulfide bonds 2   4   11   2   
Mean adult serum level (g/l) 6.96   3.8   0.51   0.56   
Relative abundance (%) 60   32   4   4   
Half-life (days) 21   21   7/~2   21   
Placental transfer ++++   ++   ++/++++   +++   
Antibody response to:                 
Proteins ++   +/-   ++   ++   
Polysaccharides +   +++   +/-   +/-   
Allergens +   (-)   (-)   ++   
Complement activation                 
C1q binding ++   +   +++   -   
Fc receptors                 
FcyRI +++ 65 - - ++++ 61 ++ 34 
FcyRIIaH131 +++ 5.2 ++ 0.45 ++++ 0.89 ++ 0.71 
FcyRIIaR131 +++ 3.5 + 0.1 ++++ 0.91 ++ 0.21 
FcyRII b/c + 0.12 - 0.02 ++ 0.17 + 0.2 
FcyRIIIaf168 ++ 1.2 - 0.03 ++++ 7.7 - 0.2 
FcyRIIIav158 +++ 2 + 0.07 ++++ 9.8 ++ 0.25 
FcyRIIIb +++ 0.2 - - ++++ 1.1 - - 
FcRn(at Ph<6.5) +++   +++   ++/+++ᵅ   +++   
 
1.12 Antibody affinity and avidity 
 
The variable region of the antibody facilitates binding with the antigen and mediates the 
specificity of the antibody. Binding between antibody and antigen is mediated by non-covalent 
forces such as Van der Waals forces, ionic force, hydrophobic force, and hydrogen bond. The 
strength of binding between epitope (single antigenic binding site) and paratope (single antibody 
binding site) is referred to as affinity. When more than one paratope binds to an antigen's multi-
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epitopes, the total binding force is called avidity. Avidity can also be referred to as functional 
affinity and plays a critical role in the antibody's functioning. For antibodies to mediate functions 
such as neutralization, it must strongly bind to the antigen and long enough to prevent 
displacement by the pathogen's competing antigen ligand that mediates cell attachment or entry. 
Antibodies work in cooperation when interacting with their legends on effector receptors.   For 
example, during complement fixing, the Cq1 molecule binds up to 6 antibodies via the FcR, 
which improves the complex's stability and allows time to recruit and activate the complement 
cascade that results in membrane attack complex (174,175). Avidity has been shown to improve 
following secondary exposure to infection and is associated with naturally acquired vaccines' 
immunity and efficacy (176–178).  
Antibody avidity is commonly measured by disruption of antibody-antigen complexes on the 
ELISA platform by chaotropic agents (e.g., Urea, sodium thiocyanate, and guanidine 
hydrochloride) such that they interrupt physical biding forces without affecting the nature of the 
proteins. The measurement outcome is either the avidity index –the proportion of residue binding 
antibodies of the total, or the plasma concentration at which 50% of antibody is displaced- 
functional affinity index (179).   This method has been successfully used to measure avidity 
maturation in vaccination like rubella and MUMPS that induce protective neutralizing antibodies 
(180–184).  It has also been shown to correlate with affinity maturation and the accumulation of 
antigen-specific MBC populations following cholera (185),  Haemophilus influenza (176) 
infections, and Haemophilus influenzae type b vaccinations (186). Furthermore, the avidity index 
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has been shown to distinguish between primary and chronic infection in cytomegalovirus (187), 
human herpesvirus (188), west Nile virus (189), and estimating HIV incidence (190).     
More recently, antibody kinetics based assays such as surface Plasmon resonance (SPR, Biacore) 
and Bio-Layer Interferometry (Octet System, Pall Life Sciences) are becoming popular 
applications to measure antibody binding properties such as the on and off-rate constants 
(191,192).  The differentiation constant is derived from the titrated antibody concentration and 
the association and dissociation constants from the kinetic equilibrium. The methods are 
susceptible to mass transport limitation where the antibodies can rebind on surfaces that have 
just dissociated, which distort the dissociation constant (191). This method has been used in HIV 
studies to gain insight into the function of neutralizing antibodies and the viral immune evasion 
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4 Figure 1.9 illustration of affinity and avidity.  
Antibody-antigen interaction is mediated by reversible physical forces such as hydrogen bonds, 
hydrophobic bonds, and Van-der-Waals forces. There is a continuous association and dissociation 
between the epitope (antibody binding site on antigen) paratope (antigen-binding antibody site). Affinity 
is high when the association rate is higher than the dissociation rate at equilibrium. When more than one 
paratope of the same antibody or different antibodies is binding, the total association rate significantly 
increases at equilibrium, which increases total affinity or avidity. Avidity stabilizes antibody binding and 
increases Antibody cooperation in the mediation of effector functions like complement activation and 
phagocytosis, which require more than one antibody binding. The different antibody colors symbolize 
additional specificity  
  
1.13 B-cell reaction pathways; the source of affinity and class switching 
 
B cell responses are initiated when a specific antigen activates a B cell via the B cell receptor 
(BCR). BCR is a complex trans-membrane form of antibody made by the B cell and a 
heterodimer of Ig-α and Ig-β chains. Primary activation of the B cell results mainly in IgM and 
limited IgG antibody production. However, a secondary response results in class switching and 
affinity maturation that is characteristic of a robust, highly effective secondary response.  
This section describes the B cell's alternative pathways in response and the germinal center 
reaction, affecting antibody affinity and isotype composition. 
54 
Chapter 1:  Introduction 
P. falciparum Transmission Intensity and the Quality of Antimalarial Antibodies                                                            Isaac Ssewanyana 
 
 
 Upon activation by recognition of specific antigen by the BCR, B cells can take three pathways. 
(i) Directly differentiate into plasma cell in the T-independent extra-follicular response.  (ii) 
Receive T-cell help, proliferate, and differentiate into plasma cells or MBC in the T-dependent 
extra-follicular response.  (iii) Receive T-cell help, enter germinal center reaction in the T-
dependent response. 
1.13.1 T-independent extra-follicular response of B-cell 
Direct differentiation into plasma cells is mainly driven by T-independent antigens (TI) that can 
directly activate B cells. These antigens activate the B cells via crosslinking the BCR and Toll-
like receptors (TLR) (194). There are two types of TI antigens, namely TI-1 and TI-2. The TI-1 
are sometimes referred to as mitogens due to their ability to stimulate B cells nonspecifically via 
the TLR resulting in low-affinity polyclonal IgM and, to a lesser extent, IgG antibodies. TI-1 
antigens are not known to generate MBC. TI-2, on the other hand, are specific for BCR and 
activate B cells through cross-linking of several BCRs. These antigens are mainly 
polysaccharides of encapsulated bacteria and proteins that consist of highly repetitive epitopes. 
TI-2 antigens induce class-switched antibodies and memory B cells (195).   
1.13.2 T-dependent extra-follicular B cell response  
The T-dependent B cell response initiate when a B cell recognizes an antigen via its BCR 
undergoes activation and receives an additional signal from a T helper cell. The B cell 
endocytoses the antigen through their BCR processes and presents the peptides via the major 
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histocompatibility complex class II (MHC II) to the T helper cell. The presentation of the 
antigens to a specific T helper cell activates it. The activation promotes the B and T helper cells' 
intricate interaction via co-stimulatory signaling of the CD40 on the T cell and CD40L on the B 
cell(196,197). The B cell receives additional signaling via the T cell's cytokine secretion, which 
influences its proliferation, limited somatic mutation, isotype switching, and destiny. 
From the B: T interaction, the B cell undergoes extrafollicular proliferation (198). Its progenies 
differentiate into plasma cells that secrete low-affinity IgM or IgG antibodies, essential during 
early infection containment. The second alternative is to differentiate into early memory B cell 
(MBC). These early MBC have limited or no somatic mutation and mostly with IgM BCR(199–
201). The third alternative is to enter the follicle, proliferate, and establish a germinal center. The 
drivers of these choices are not fully understood. Still, we know that B cells that commit to 
germinal center reaction upregulate the transcriptional factor Bcl-6, and those that commit to 
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1.13.3 Germinal center reaction  
A germinal center reaction is seeded when activated B cells that previously received T cell help 
migrate back to the follicle and undergo proliferation to form a mass of noticeable cells after 4-
5 days. Other cell types like the follicular dendritic cell (FDC) and follicular helper T cell (Tfh) 
are an integral part of the germinal center and play a critical role in structural organization, 
affinity maturation, and class switching. The germinal center consists of dark and light zones 
(Figure1.8). In the dark zone, cells undergo proliferation and somatic hyper-mutation in the 
immunoglobulin gene's variable region, resulting in varied affinities and specificities (202). 
Activation-induced cytidine deaminase (AID) is up-regulated in B cells located in the germinal 
center, mediating both isotype switching and somatic hypermutation (203,204).  B cell progenies 
from the dark zone interact with antigens (in immune complexes) presented on FDC to select 
specificity and affinity in the light zone. During this process, referred to as affinity maturation, 
B cell progenies compete for antigens presented on FDC in antibody-antigen complex via the Fc 
receptor, complement receptors, or lectin receptors for positive selection survival signal (205). 
Because the antigen is presented in the antigen-antibody complex, a successful B cell must have 
a higher affinity to displace the existing antibody from the binding site. The successful B cell 
extracts antigen from the FDC, initiates endocytosis, and presents the peptides via the MHC II 
to T-follicular helper. The T-follicular helper and the B cell's intricate interaction provides 
signaling for survival through CD40-CD40L and cytokines such as Il-21(202). The low-affinity 
B cell progeny undergo apoptosis while the high-affinity ones either migrate back to the dark 
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zone for additional proliferation and hyper-mutation or exit the germinal center to differentiate 
into MBC and plasma cells. Some plasma cells are long-lived plasma cells (LLPC) that migrate 
to the survival niches in the bone marrow from where they secrete antibodies for a long time.  
Others are short lived plasma cells (SLPC) that migrate into peripheral tissue and secrete 
antibodies for a short period (206). 
Germinal center reactions are highly organized, thought to last for weeks to months, and 
demonstrated to have temporal output. SLPC exit the germinal center earliest, followed by MBC 
and much later LLPC with extensive mutations compared to MBC, indicating intensive somatic 
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5 Figure 1.8 Schematic representation of Germinal center reaction (207).  When activated, one 
B cell initiates a germinal center reaction.  It receives T-cell help, underdoes proliferation, and somatic 
hypermutation in the B cell receptor gene to form a mass of progenies.  The germinal center is a highly 
organized architectural structure that consists of two zones. The dark zone, densely packed with B cells 
that undergo proliferation and hypermutation.  The light zone, where B cells interact with follicular helper 
cells (TFH) and follicular dendritic cells (FDC) for positive affinity selection, survival signal, and 
differentiation into SLPC, MBC, or LLPC. The low-affinity B cells can recirculate back into the dark 
zone to undergo additional proliferation and hypermutation or undergo apoptosis. The germinal center 
output is temporally defined.  The initial output is the SLPC, followed by MBC and later LLPC. The 
commitment of cells to either fate is influenced by affinity, Tfh signal, and differential expression of 
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2.1 Background and rationale  
 
This thesis focuses on two IgG properties critical for antibody function; antibody avidity and 
subclasses in relation to P. falciparum transmission intensity. The focus of the thesis was 
inspired by the following observations; (i) Slow acquisition of immunity to malaria that is 
rarely complete (ii) Apparent failure to maintain natural or vaccine-induced immunity (iii) 
evidence of the critical role antibodies play in immunity to malaria. (iv) Inconsistent 
association of antibody titers with protection in natural and vaccine modals.  
These observations lead to two major hypotheses that have generated increasing supporting 
evidence 
1. P. falciparum infection interferes with acquisition and maintenance of immunity to 
malaria 
2. The quantity together with the quality of antimalarial antibody than just the quantity 
provides better insight into acquisition and maintenance of immunity to malaria  
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For a long time, the dogma supporting hypothesis 1 was the highly polymorphic P. falciparum 
antigen repertoire (208). However, there is increasing evidence to suggest parasite interference 
and impairment of acquired immunity. Several observations indicate that frequent P. falciparum 
infection may interfere with the acquisition of effective immunologic memory (209). P. 
falciparum infection may detrimentally affect the generation and maintenance of an effective 
antibody immune response through (i) impairment of antigen presentation by dendritic cell 
populations (210,211), (ii) impairment of T-helper cells populations (212), (iii) interruption of 
B cell response and germinal center reaction (213), (iv) impairment of innate effector cells 
function (213–216), (v) interruption of temporal and spatial microenvironments that affect the 
differentiation and survival of antibody-forming cells and memory cell populations(68). The 
overall effects manifest in the quality of antibodies in terms of breadth of response, affinity 
maturation, isotypes and subclass composition, rapid antibody decay in the absence of infection 
and the ability of antibodies to mediate effector function. 
In support of hypothesis 2, several epidemiological studies have shown inconsistent associations 
between antibody levels and the different forms of malaria immunity, even for leading vaccine 
candidates like Rh5, EBA175 RIII-V, CSP, among others. Furthermore, vaccine trials and 
controlled human malaria infection (CHMI) that show protection, an association of antibody titer
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with malaria, protection is rarely demonstrated. Different adjuvants, vaccine vector, and 
immunization boost schedules of the CSP based RTS have resulted in differences in efficacy and 
duration of the protection(217). The different vaccine delivery models have also resulted in 
differences in antibody titer and antibody avidity, and subclass composition(141). This 
observation may imply that the differences in avidity and subclass composition may partly 
contribute to observed differences in efficacy and protection duration.   Furthermore, in-vitro 
assays increasingly show antibody-mediated effector functions such as phagocytosis, 
complement-fixing, and respiratory bursts as correlates of protection.  Antibody affinity and IgG 
subclass are known determinants of antibody effector function, and their composition may 
influence protection outcome. 
2.2 Hypothesis and aim  
 
This thesis hypothesized that frequent P. falciparum infections interrupt avidity maturation and 
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2.3 Study aim 
I  pursued three aims to test the hypothesis. 
1. To determine the associations between age and P. falciparum transmission intensity with 
P. falciparum specific antibody avidity. 
2. To determine the effect of the interruption of exposure to P. falciparum infection by IRS 
on the avidity of antibodies against a large number of P. falciparum antigens.  
3. To determine the effect of the interruption of exposure to P. falciparum infection by IRS 
on the IgG subclass responses against a large number of P. falciparum antigens.  
Understanding the dynamics of antibody avidity and IgG subclass in relation to P. falciparum 
transmission intensity or during transmission interruption and with age will provide useful 
insight into the acquisition and maintenance of naturally acquired immunity. This 
information can be crucial in understanding how to define immunity and longevity, design 
better vaccine strategies to induce durable immunity, and use antibody kinetics to develop 
tools to measure recent infection for surveillance diagnostics. Serological tools can be cost-
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I performed all the laboratory experiments and data analysis included in this chapter. The PRISM 
study conducted cross-sectional and cohort surveys where samples for this thesis were obtained. 
Kigozi provided the maps in figure 3.1that show the three study sites, Isabel Rodrigez provided 
figure 3.3 that summarises the cohort malaria status, Simon Peter and Lindsay Wu performed 
the normalization of the Luminex data in chapters 5 and 6 to adjust for inter-plate variations.  
3.1.0 Study Population 
3.1.1 Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in 
Uganda 
My Ph.D. was nested in a larger study titled Program for Resistance, Immunology, Surveillance, 
and Modeling of Malaria (PRISM) in Uganda. The PRISM program's overall strategy was to 
apply a comprehensive, iterative approach to malaria surveillance that aimed to generate a 
foundation of evidence to maximize the impact of control interventions across a wide range of 
epidemiological settings. The study was designed to address the complexity of interactions 
between the mosquito vector, malaria parasite, and human host. The study combined standard 
malaria surveillance techniques and metrics with cutting-edge methods, and this was aimed to 
improve surveillance. Also, PRISM aimed to develop human resources and infrastructure 
towards sustainable research capacity and help translate research findings into policy. The 
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project brought together a strong collaborative team, including Infectious Diseases Research 
Collaboration (IDRC) and Makerere University in Uganda, London School of Hygiene and 
Tropical Medicine, and Liverpool School of Tropical Medicine in the UK, University of 
California San Francisco, and the University of Florida in the USA. 
Between 2010 and 2017, PRISM conducted entomological and human cross-sectional surveys 
and human longitudinal cohorts at three different transmission sites in Uganda.  The sites 
included Nagongera sub-county in Tororo District, Walukuba sub-county in Jinja District, and 
Kihihi sub-county in Kanungu District. 
3.1.2 Cross-Sectional Surveys 
Three cross-sectional surveys were conducted in 2012, 2013, and 2015 in three different sub-
counties in Uganda to estimate malaria incidence among children and adults living in different 
epidemiological settings with varying malaria transmission intensity.  Each of the three surveys 
enrolled 200 unique random households for each of the three rounds from a household census 
database.  A comprehensive questionnaire was administered, and finger-prick blood samples 
were collected from all children under 15 years and a random selection of age-stratified adults. 
Thick and thin blood smear microscopy and RDT were performed for the detection of malaria 
infection. Dried blood spots (DBS) were collected and stored at -20 for serological and molecular 
tests (218). Chapter 4 of my study utilized DBS samples from the 2012 cross-sectional surveys.  
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3.1.3 Description of the three epidemiological settings  
Walukuba is a peri-urban sub-county in the Jinja district with an estimated population of 417,243 
people. It is an area of historically medium transmission with an entomologic inoculation rate 
(EIR) of 6 infective bites per person per year in 2002 (29). A recent estimate of transmission 
intensity in the region has shown a marked decrease in EIR to 2 infective bites per person per 
year (Figure 3.1 & Table 3.2) (30).  
The second site is Kihihi, which is a rural sub-county in Kanungu district. The district has an 
estimated population of 252,144 people and is an area that was historically of relatively low EIR 
of 2 infective bites per person per year in 2002. Recent PRISM surveillance indicated an increase 
in malaria transmission intensity, where  EIR was estimated at  6 infective bites per person per 
year (Figure 3.1 & Table 3.2) (30). 
The third site is Nagongera sub-county in Tororo district. This site is predominantly rural with 
very high malaria transmission. Entomology studies conducted in Nagongera in 2012-13 
estimated EIR to be 305 infective bites per person per year (30). The total population of 
Nagongera sub-county is 517,082 people, with children aged 1 to 10 years constituting 37% of 
the population (Figure 3.1 & Table 3.2).  
The study sites (shown on the map of Uganda in Figure 3.1) are summarized in Table 3.2. 
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Figure 3.1. Map of Uganda showing the three study sites (219). Walukuba in Jinja (EIR; 2, population; 
37,714). Nagongera in Tororo (305; population 517,082) is located further east near the border with 
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1 Table 3.2. Characteristics of study Districts 
 
3.1.4 Description of the Longitudinal Cohort at Nagongera 
The main PRISM study conducted three longitudinal cohorts at the study sites described in the 
cross-sectional surveys above (Figure 3.1). Chapters 5 and 6 of this Ph.D. thesis utilized samples 
from the Nagongera longitudinal cohort that is described in this section.  Enrolment included all 
children aged 6 months to less than 11 years and one primary caregiver above 18 years per 
household.  Participants were enrolled from 100 randomly selected households from an earlier 
District Kanungu Jinja Tororo 
Demographics(220)  
Location in Uganda Southwest East East 
Population  252,144 417,243 517,082 
Urbanization level 20% 36.6% 20.3% 
Number of households 55,975 105,463 102,634 
Persons per household 4.5 3.9 5.0 
Historical -Entomology (data collected 2001-2002)(29) 
EIR 2  6  562 
Predominate vector species An. gambiae ss An.gambiae ss  An.gambiae ss  
PRISM Estimated Entomology (data collected 2012-2013)(30) 
EIR 6  2 305 
Predominate vector species An. gambiae ss An.gambiae ss  An.gambiae ss  
PRISM Estimate Measures of infection (data collected in children 2-9 years of age, 
Parasite Rate 11.8% 13% 38.5% 
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household enumeration survey.  The cohort was enrolled in August 2011 and was followed until 
September 2017. The cohort was dynamic, such that all newly eligible children were enrolled 
and exited those who reached 11 years. All study participants were given long-lasting 
insecticide-treated nets at enrollment.  They were encouraged to come to a dedicated study clinic 
that was open 7 days a week any time they were ill. 
Routine evaluations were performed on all 3 months, including blood smears and blood 
collection for future laboratory testing. Passive surveillance to estimate the incidence of 
symptomatic malaria and active surveillance to estimate parasite prevalence were used. As part 
of the routine 3 monthly evaluation, study participants’ parasitemia status was assessed by 
microscopy (221). All negative microscopy samples were further tested by LAMP for 
submicroscopic infections (222). Blood collected in heparin tubes from routine visits was 
processed for plasma and DBS. In November 2014, the frequency of routine visits was reduced 
from 3 to 1 month for an enhanced surveillance amendment to the protocol. In addition to the 
routine visits, participants reported to the clinic whenever they were sick or had a fever and were 
diagnosed. Entomology surveillance of the households was done using CDC light traps and 
human landing catches. Entomological inoculation rates were determined over the follow-up 
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3.1.5 Interruption of transmission by IRS and Enhanced surveillance in Nagongera 
Between November 2014 and January 2015, Indoor residual spraying with carbamate bendiocarb 
was introduced in Tororo for the first time. This intervention led to a dramatic decrease in malaria 
exposure and transmission rates within the cohort. Three additional IRS rounds were performed 
every 6 months. The sustained IRS maintained childhood malaria incidence and parasite 
prevalence at very low levels through the end of the PRISM cohort follow up in September 2017.  
The IRS introduction coincided with the increased frequency of patient follow up from 3 to 1-
month interval that increased the accuracy of evaluation of parasite exposure, dynamics of 
infection, and the frequency with which participants acquired and cleared parasites (219). I 
included 160 participants from the PRISM longitudinal cohort in Nagongera in this thesis at 4-
time-points. 
 3.1.6 IRS schedule and sampling time-points 
Pre-IRS time-points; T1 and T2 were selected 12 and 6 months before the first round of IRS 
from routine plasma samples collected in November 2013 - January 2014 and June- July 2014, 
respectively (Figure3.3). Post-IRS time-points, T3 and T4, were selected at 6 and 12 months 
after the first and during the second round of IRS in June –July 2015 and the third round of IRS 
in December 2015 – January 2016, respectively. T3 coincided with the spike in malaria 
incidence, and T4 was taken when malaria incidence neared zero (Figure3.3).   
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Despite the distribution of long-lasting insecticide-treated bed nets and reported high net usage 
within the cohort, monthly malaria incidence in children under five and asymptomatic infection 
prevalence by microscopy in school going children 5-11 years was high before IRS (221). 
Malaria transmission intensity peaked in July 2014 at monthly malaria incidence and parasite 
prevalence estimation of 6 ppy and 35%, respectively (Figure 3.3).  Following the introduction 
of the first round of IRS, monthly malaria incidence gradually reduced to 1ppy.  Also, there was 
a gradual decline in parasite prevalence from 35% eventually 25%. Malaria incidence spiked at 
the 6 months following the first IRS round, but the trend reversed after the second IRS in July 
2015. Malaria incidence reduced to near 0/ppy and parasite prevalence to 10% by December 
2016 when the third round of IRS was done (Figure3.3). 
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 Figure 3.3. Summary of cohort 
malaria incidence, parasite rate, ITN, 
and IRS schedules in the upper panel.  
The upper panel shows malaria 
incidence (green line), parasite 
prevalence (red line), ITN distribution 
(yellow bar), and IRS spraying 
schedules (pink bars), and the study 
sampling time-points (gray bars) in the 
full cohort. The lower panel represents 
the individual malaria status of the160 
study sampling time-points (black 
diamonds) at Time 1 (T1), T2, T3, and 
T4 (6 & 12 months before first IRS and 
6 & 12 months after first IRS, 
respectively). Participants were 
actively followed initially at 3-month 
intervals, which increased to every 
month in Oct 2016. Green-filled and 
blue-filled circles represent sample 
patents by microscopy and sub-patent 
by LAMP Infections. Red filled and red 
open circles represent malaria and non-
malaria fever, respectively. Blue open 
circles represent LAMP negative.  
Isabel Rodrigez developed this figure as part 
of the PRIMS sturdy. 
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3.1.7 Malaria status within the study population 
A total of 160 participants were enrolled from the PRISM longitudinal cohort in Nagongera, 
including the 4-time-points. The participants were in age categories, 1 - 4 years (40/160), 5 – 
11 years (92/160), and >18 years (28/160) (Table 3.4). Within the study population, the 
incidence was high before the IRS. At T1, 61%, 44%, and 11% in ages 1 - 4, 5 - 11, and >18 
years respectively had at least one malaria episode in the last 90 days (Table 3.4).  Malaria was 
defined by the presence of fever and positive blood smear by microscopy.   Rates of malaria 
peaked at T2, where 73%, 55%, and 10% of the participant in ages 1 - 4, 5 - 11, and >18 years 
respectively had at least 1 malaria episode in the last 90 days.  Gradual reduction of malaria 
among participants in the previous 90 days was observed at 39% and 34% in 1-4 and 5-11 years, 
respectively, at T3. The highest reduction to 0% and 4% in the1-4 and 5-11 years respectively 
who had at least 1 malaria episode in the last 90 days was recorded at T4. No one in the adults 
had any malaria episodes during the previous 90 days at T3 and T4 (Table 3.4). 
The proportion of asymptomatic parasitemia at least once in the last 9 days was high before IRS 
peaking at T2 and gradually reduced to the lowest at T4 after introducing IRS (Table 3.4).  
Asymptomatic parasitemia was defined as the presence of P. falciparum by microscopy and 
LAMP (for microscopy negative) in the absence of fever.  At T1, 76%, 95%, and 58% in ages 
1 - 4, 5 -11, and >18 years respectively had a positive parasitemia at least once in 90 days. Rates 
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of parasitemia peaked at T2, where 80%, 89%, and 70% in age 1 - 4, 5 - 11, and >18 years 
respectively recorded at least one parasitemia in the last 90 days.  After IRS, there was some 
reduction to 58% and 85% and 45% in ages 1 - 4 and 5 - 11 and >18 years respectively at T3. 
Further reduction was recorded at T4, where 14% and 45% and 14% age categories 1-4, 5-11, 
and above 18 years respectively had at least one asymptomatic parasitemia episode in the last 
90 days.  
Other malaria transmission intensity indicators (summarized in Table 3.4) such as parasitemia 
today, the proportion of months free of malaria in the last 12 months, proportion of months free 
of parasitemia in the previous 12 months showed a similar reduction in P. falciparum infection 
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2Table 3.4 Summary of the study population and malaria matrix by time-points  
Malaria Matrix Age (years) Time Point 
T1 T2 T3 T4 
Population 1- 4 40 40 40 38 
5 - 11 93 93 91 93 
>18  28 28 28 28 
The proportion with at least 1 malaria in 
the last 90 days (%) 
1- 4 61 73 39 0 
5 - 11 44 55 34 4 
>18  11 10 0 0 
Proportion parasitic at least once in the 
last 90 days (%) 
1- 4 76 80 58 14 
5 - 11 95 89 85 45 
>18  58 70 45 14 
Mean days since parasitemia  1- 4 51 40 91 240 
5 - 11 9 23 50 146 
>18  77 84 186 322 
Proportion of months free of parasite in 
last 6 months 
1- 4 0.42 0.35 0.62 0.83 
5 - 11 0.27 0.25 0.41 0.62 
>18  0.48 0.53 0.71 0.85 
Proportion of months free of parasite in 
last 12 months 
1- 4 0.45 0.40 0.51 0.75 
5 - 11 0.29 0.29 0.37 0.51 
>18  0.49 0.51 0.64 0.78 
Time-points were relative to the first round of IRS. T1=12, T2=6 months before IRS. T3=6, T2=12 
months after IRS. Malaria was defined by fever and positive blood smear microscopy. Parasitemia 
status was determined by microscopy or LAMP positive at monthly interval  
 
3.1.8 Informed consent  
Before enrollment into the cross-sectional and longitudinal surveillance studies, written 
informed consent was obtained from adults, parents/guardians of children, and assent from 
children aged 8 years and older. Informed follow-up consent was obtained when the enhanced 
monthly surveillance sampling in participants was introduced.  
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3.2 Laboratory methods 
3.2.1 P. falciparum Recombinant Antigens 
A total of 18 recombinant P. falciparum blood-stage antigens and Tetanus toxoid protein (TT) 
(non-malaria control) were used in the experiments reported in Chapters 4, 5, and 6. The 
antigens were mainly of three categories; (i) infected red blood cell-associated antigens, (ii) 
merozoite apical complex expressed proteins, and (iii) merozoite surface antigens. The antigens 
included leading vaccine candidates, recent exposure markers, long-term/cumulative exposure 
markers, and commonly studied antigens. The recombinant antigens were expressed in 
Escherichia coli either as glutathione S-transferase (GST) fusion proteins or histidine-tagged 
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3 Table 3.5 Summary of the P. falciparum Blood-stage  antigens 
Gene ID Description Antigen name Allele AA 
position 
Location Tag 
PF3D7_0501100.1 Heat Shock Protein 40, type II, Antigen1(*KT) - 3D7 71-153 iRBC/Gam GST 




3D7 76-137  iRBC/PVM GST 
PF3D7_0532100 early transcribed membrane protein 5 Antigen1(*KT) ETR MP5Ag1 
Ag2Ag1 
3D7 26-111 iRBC/PVM GST 
PF3D7_1002000 Plasmodium exported protein (hyp2), unknown 
function(*KT) 
Hyp2 3D7 101-418 iRBC/PVM GST 
PF3D7_0501300 Skeleton-Binding Protein 1(*KT) SBP1 3D7 1-239 Scht/MC GST 
PF3D7_1021800 Schizont Egress Antigen 1(*KT) SEA 3D7 810-1083 Scht/MC GST 
PF3D7_1133400 Apical Membrane Antigen 1(153) AMA-1 FVO 97-546 SpZ/Mer Hisx6 
PF3D7_1301600 Erythrocyte Binding Antigen-140 Region III-V (224) EBA140 RIII-V  3D7  Mer -M GST 
PF3D7_0731500  Erythrocyte Binding Antigen-175 Region III-V EBA175 RIII-V   3D7 761-1298 Mer-M GST 
PF3D7_0102500 Erythrocyte Binding Antigen-181 Region III-V (224) EBA181 RIII-V  3D7 769-1365 Mer -M GST 
PF3D7_1335400 Reticulocyte Binding Protein Homologue 2 (225) Rh2  D10 2030-2528 Mer-Rh GST 
PF3D7_0424200 Reticulocyte Binding Protein Homologue 4 (226) Rh4.2 3D7  28-766 Mer-Rh Hisx6 
PF3D7_0424100 reticulocyte binding protein homologue 5 (227) Rh5 3D7 1-526 Mer-Rh C-tag 
PF3D7_1035300 Glutamate Rich Protein R2 (228) GLURP RII F32 816-1091 Mer-S n/a 
PF3D7_1036000 Merozoite Surface Protein 11/H101 (229) H103 3D7 40-243 Mer-S GST 
PF3D7_0930300 19kDa fragment of MSP1 molecule (230) MSP1-19 Wellcome 1631-1726 Mer-S GST 
PF3D7_0206800 Merozoite surface protein 2, Dd2 allele (231) MSP2 Dd2 Dd2 22-247 Mer-S  GST 
PF3D7_0206800 Merozoite surface protein 2, CH150/9 allele (231) MSP2 CH150/9 CH150/9 34-215 Mer-S  GST 
n/a Tetanus Toxoid (Non-adsorbed) TT n/a n/a n/a n/a 
iRBC =Infected red blood cell, Gem- Gametocyte, PVM = parasitophorous vacuole membrane, MC = Maurer's cleft, SPZ = sporozoite, 
Mer-S = merozoite surface, Mer-M = merozoite micronemes, Mer-Rh = merozoite Rhoptry   *KT = Tetteh. K, unpublished 
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3.2.2 Elution of antibodies from DBS 
DBS from the cross-sectional surveys were collected on Whatman 3MM filter paper and stored 
at -20°C.  For this thesis, a 3mm diameter punch of DBS was hydrated in 200µl of phosphate-
buffered saline (PBS) containing 0.005% Tween 20 and 0.01% sodium azide. The excised spot 
was estimated to have approximately 2µl plasma, resulting in a serum dilution factor of 1:200 
(232).   
3.2 3 Avidity ELISA assay 
Immulon-4 microtitre plates (Thermo Labsystems, Basingstoke, UK) were coated overnight at 
4°C with 0.5mg/ml of antigen in coating buffer (0.1M sodium carbonate/bicarbonate, pH 9.6), 
and then washed three times with wash buffer; PBS, 0.05% Tween-20. The plates were blocked 
for 3 hours at room temperature with 200µl/well PBS, 0.05% Tween-20, 1% skimmed dried 
milk, and then washed three times. For each sample, plasma was diluted to a final concentration 
of 1:1000 for MSP1-19 and 1:2000 for AMA1, with 50ul of diluted plasma added per well. Plates 
were incubated overnight at 4°C and washed 6 times. Horseradish peroxidase enzyme (HRP)-
conjugated rabbit anti-human IgG (Dako Ltd, High Wycombe, UK) was diluted 1:5000 in 
blocking buffer, and 50ul was added per well. The plates were incubated for 3 hours at room 
temperature, then washed 6 times, and developed with 100µl/well of o-phenylenediamine 
(OPD)–H2O2. The reaction was stopped after 15 minutes with 25ul 2M sulphuric acid. Optical 
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densities (ODs) were measured at 492 nm using a VERSAmax plate reader with Softmax 
software (Molecular Devices, USA). 
To evaluate antibody avidity, the standard sandwich ELISA assay described above was modified 
to include an antibody disassociation step before the addition of HRP-conjugated secondary 
antibody. Briefly, diluted plasma samples were incubated on the plates overnight at 4oC; 
triplicate wells were treated with 2M or 5M or PBS guanidine hydrochloride (GuHCl) for 10 
minutes and then washed 6 times. PBS well was the control to measure the total antibody 
binding. Test samples with and without GuHCl were run on the same plate to minimize 
variability. The avidity index was defined as the proportion of antibodies binding after treatment 
with GuHCl for each dilution (Avidity Index = [OD following GuHCl treatment / OD without 
GuHCl treatment] X100).  
Only samples with titers above a normalized OD (adjusted OD based on a positive control to 
correct for inter-plate variations) of 0.5 were included in the avidity index assessment to ensure 
detectable binding after antibody binding interruption.  In each plate, hyper-immune sera (CP3) 
based on a Tanzanian endemic adult pool was included at a dilution of 1:3200 as a positive 
control. 
3.2.4 Preparation of Luminex assay reagents  
To prepare wash buffer (0.05% Tween20 PBS, 0.02%NaN3), 250µl of tween20 (Croda 
International, UK) was added to 500ml phosphate-buffered saline (PBS).  Sodium azide 
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(0.1gm) was added to preserve the wash buffer at 0.02%.  The reagent was mixed on a 
magnetic stirrer (AccuPlate, Analog Magnetic Stirrer, USA) for 30 minutes and kept at 4-8oC 
for 2 weeks before expiry. 
To prepare Buffer A (0.5% BSA, wash buffer), 2.5gm bovine serum albumin (BSA) (Sigma-
Aldrich Co. LLC, USA) was added to 500ml wash buffer.  Buffer A was mixed on a magnetic 
stirrer for 30 minutes and kept at 4-8oC for 2 weeks before expiry. 
To prepare Buffer B (0.1% liquid casein, 0.5% PVA, 0.8% PVP, 1/100uL E. coli extract, 
Buffer A), 0.5gm casein, 2.5gm PVA, 4.0gm PVP, and 100ul E.coli extract (Chris lab, London 
school) was added to Buffer A. Buffer B was mixed on a magnetic stirrer overnight and kept at 
4-8oC for 2 weeks before expiry or was kept for at -80oC for a longer period.  
Buffer B was used to reduce background signal due to nonspecific binding and reduce risk of 
measuring E.coli specific responses since most P. falciparum antigens were expressed in 
E.coli. 
3.25 Luminex Bead counting 
The coupled beads were counted to determine the couple's quantity for small couplings and 
determine bead recovery after coupling. 
After suspension by medium vortexing for 30 seconds, 10µl of suspension was injected into a 
disposable hemocytometer and counted under objective lens x100. 
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3.2.6 Determination of optimal antigen coupling concentration 
Antigen coupling titration was done to determine the optimal concentration of antigen required 
to couple beads and achieve the most informative signal. The titration was done using 
hyperimmune sera. Briefly, 5x106 beads were washed twice with 100µl distilled water by 
vortexing for 30 seconds and centrifuged at 16,000g before removing the supernatant on a 
magnetic rack. Beads were divided into 5 aliquots of 1.0 x 106 in a 1.5ml low protein binding 
surface micro-centrifuge tube (Eppendorf, UK). Bead carboxyl surface activation and antigen 
coupling were done as per the coupling procedure in 3.34 below. The stock antigen was diluted 
serially from 1/10 by a factor of 5, and each concentration was coupled to one of the five tubes 
for 2 hours on a rotating shaker. The beads were washed and suspended in the storage buffer. 
The beads were tested with hyperimmune sera at 1/1000 dilution as per the assay procedure 
outlined in section 3.36. The net median fluorescent intensities (MFI) were plotted against the 
antigen concentration. Optimal coupling concentration was selected from a mid-point on the 
curve's linear portion (Figure 3.6). The stock reagent volume required to couple 12.5 x 106 beads 
in a volume of 1ml was derived. Briefly, the optimal coupling concentration of 12.5 x 106 beads 
in 400µl was derived from the selected antigen dilution factor and the antigen stock 
concentration. This was scaled up to the amount of antigen required to couple 12.5 x 106 beads 
in 1,000µl (Table 3.7).   
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6Figure 3.6 Representative Graphs showing the titration of Stock coupling concentration 
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4 Table 3.7 Summary of the antigens concentrations required for large batch coupling 
Antigen Ag stock 
concentration 
(mg/ml) 
 Ag coupling in 
400µl 
(ug/1x10^6)  
Ag needed to 
couple in 400µl 
(ug/12.5x10^6) 
Vol of Ag stock to 
couple 12.5x10^6  
in 1ml 
Vol of Ag 
stock to scale 
up to 1ml 
Vol of PBS top-
up to 1ml 
HSP40 Ag1 0.681 15.0 187.5 275.3 688 311.7 
ETRAMP4Ag2 0.651 5.0 62.5 96.0 240 760.0 
ETRAMP5Ag1 0.539 14.0 175.0 324.7 812 188.3 
Hyp2  0.785 22.0 275.0 350.3 876 124.2 
SBP1 0.700 44.0 550.0 785.7 1964 -964.3 
SEA 5.400 44.0 550.0 101.9 255 745.4 
AMA-1 0.962 1.0 12.5 13.0 32 967.5 
EBA140 RIII-V  0.113 22.0 275.0 2433.6 6084 -5084.1 
EBA175 RIII-V  0.218 1.6 20.0 91.7 229 770.6 
EBA181 RIII-V  1.486 22.0 275.0 185.1 463 537.3 
Rh2  0.604 5.0 62.5 103.5 259 741.3 
Rh 4.2 6.745 1.0 12.5 1.9 5 995.4 
Rh5 1.477 20.0 250.0 169.3 423 576.8 
GLURP RII 1.255 30.0 375.0 298.8 747 253.0 
H103 0.980 15.0 187.5 191.3 478 521.7 
MSP 1-19 2.770 22.0 275.0 99.3 248 751.8 
MSP2 Dd2 7.740 44.0 550.0 71.1 178 822.4 
MSP2 CH150/9 0.807 4.9 61.3 75.9 190 810.3 
TT 0.364 5.0 62.5 171.7 429 570.7 
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3.2.7 Covalent coupling of antigens to magnetic microsphere Bead  
 Antigens were covalently coupled to MagPlex carboxylated magnetic microspheres (Luminex 
Corp, Austin, USA)(233). 12.5×106 beads for each bead region were suspended by sonication for 
60 seconds and vortexing at medium speed for 60 seconds. The beads were transferred from the 
stock bottle into a 1.5ml micro-centrifuge tube with a low protein binding surface (Eppendorf, 
UK) to minimize bead loss and centrifuged at 16,000g for 3 minutes. The bead pellet was pulled 
on the tube side by placing into a magnetic rack for 1 minute before pipetting off the supernatant. 
The beads were washed twice by suspension in 100ul distilled water, vortexed for 30 seconds, 
and centrifuged at 16,000g.  The supernatant was removed after settling the beads on a magnetic 
rack for 2 minutes. Beads were suspended in 80µl monobasic Sodium Phosphate (NaH2PO4, pH 
6.2 activation buffer). To activate the carboxyl surface of the beads, 10µl of 50mg/ml 
Hydroxysulfosuccinimide (Sulfo-NHS) (Thermo Fisher Scientific, UK)  was added, vortexed 
briefly, and immediately followed by the addition of 10µl of 50mg/ml 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC), ), (Thermo Fisher Scientific, UK). 
The beads were incubated for 20 minutes at room temperature in the dark when wrapped in 
aluminum foil on a rotating platform.   During the 10 minute incubation, the beads were vortexed 
for 20 seconds to ensure homogeneous activation. Beads were pelleted by centrifuging at 
16,000g for 5 minutes, placed tubes in a magnetic holder for 1 minute –the supernatant carefully 
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removed, and washed 3 times with 250µl PBS as above. Previously determined antigens were 
added to each bead region in PBS to make a final volume of 500µl (Table 3.7). The appropriate 
amount of antigen for coupling was determined by titration in the method described (3.2.5 
Determination of optimal antigen coupling concentration). The beads/antigen suspension was 
incubated for 2 hours on a rotating shaker in the dark and covered in aluminum foil.  Coupled 
beads were pelleted by centrifugation at 16,000g for 3 minutes and washed of excess antigen 3 
times with 250µl of phosphate-buffered saline 0.05% tween20 (PBS-TBN). The antigen coupled 
beads were suspended in 1ml storage buffer (PBS-TBN plus pefabloc) and stored at 40C. 
3.2.8 Plasma dilution  
A volume of 10µl of plasma was added to 500µl of PBS-TBN in a deep well plate to make a 
1/50 dilution. The deep well plates were stored at -200C until use.  To make the 1/100 dilution 
for the IgG subclass assays, 200µl of 1/50 was added to 200µl buffer B (PBS, 0.05% Tween 20, 
0.1% casein, 0.02% NaN3, 0.5% PVA, 0.8% PVP, 1/100uL E. coli extract. To make 1/1000 
dilution for the total IgG and avidity assays, 40µl of a 1/50 sample dilution was added to 360µl 
of buffer B). The samples were incubated in buffer B overnight before the Luminex assay to 
reduce background binding (nonspecific reactivity in some individuals due to the presence of 
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3.2.9 Construction of hyperimmune control - PRISM pool 4  
Plasma pool 4 (PP4) was constructed based on 22 plasma samples that were positive and broadly 
reactive to the antigens included on my panel.  Based on the previous set of data, the samples' 
reactivity per antigen was divided into 5 percentiles. Each sample was assigned a percentile score 
of 1 to 5 (5 most reactive and 1 least reactive). 
The scores were added, and the 50 top-scored samples were selected.  The list was narrowed 
down to 22 by manually eliminating samples with low reactivity in some antigens, especially 
those with a low frequency of highly reactive samples or those whose maximum MFI was less 
than 8,000 at 1/1,000. An aliquot of 200µl of each of the 22 samples was pooled to construct 
PP4. The PP4 standard curve was constructed from 8 serials dilutions starting from 1/10 and a 
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7 Figure 3.8 Representative PP4 standard curves of 18 P. falciparum antigens and 
Tetanus toxoid PP4 was able to result in a saturation curve for all the antigens on the panel   
 
3.2.10 Luminex MagPex multiplex bead array assay to measure total IgG 
Total IgG responses to 18 P. falciparum blood-stage antigens and TT were measured in plasma 
diluted Buffer Bat 1/1000 on the MagPix (Luminex Corp, Austin, Texas) multiplex bead array 
as previously described (234). The samples were incubated in buffer B overnight at 4-8oC before 
the assay. Tetanus toxoid (National Institute of Biological Service and Control (NIBSC) was 
added as a positive control for both malaria-endemic and non-endemic samples. 
Briefly, 10µl per region of antigen coupled bead stock (MagPex magnetic microsphere) 
(Luminex Corp, Austin, Texas) was added in 5ml of buffer A to make a combined pool of all 
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to each well (~1,000 beads/region/well) of the 96-well plate (Bio-plex Pro, flat bottom) (BioRad, 
UK). The plate was washed, placed on a magnetic block for 2 minutes covered in aluminum foil, 
and the supernatant poured off with the plate still attached to the magnet and gently blotted on a 
paper towel. The beads were washed twice with wash buffer, rested on the magnetic separator 
for 2 minutes, and supernatant poured off. 
Using a multichannel pipette, 50µl of prepared plasma at a dilution of 1/1,000 in Buffer B and 
hyperimmune control PP4 standard was added to the beads. PBS was added to two blank wells.   
The plate was covered with aluminum foil and incubated at room temperature on a shaker at 
600rpm for 90 minutes.  At the end of the incubation period, the plate was placed on a magnetic 
separator for 2 minutes. A rapid inversion poured off the supernatant with a sharp shake followed 
by a gentle blot on a paper towel.  The plate was washed three times, with 100 µl wash buffer. 
Using a multichannel pipette, 50µl of 1/200 R-Phycoerythrin-conjugated AffiniPure F (ab’) 2 
goat anti-human IgG (Jackson Immuno Research Laboratories) diluted in buffer A was added. 
The plate was covered in aluminum foil and incubated at room temperature on a shaker at 
600rpm for 90 minutes. The plate was placed on a magnetic separator for 2 minutes, and the 
supernatant poured off.   
The plate was washed three times with wash buffer.  Buffer A 50µl was added and the plate 
incubated at room temperature on a shaker at 600rpm for 30 minutes before washing once. The 
beads were suspended in 100µl of PBS pH 7.2 per well and suspended on a plate shaker for 5 
minutes. The plate was read on a MagPix machine (Luminex, USA), acquiring at least 100 
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beads/region/ well.  The results were expressed as median fluorescent intensity (MFI). The blank 
well MFI was deducted from each well to determine the net MFI. 
The samples were tested in a single well, where 100 beads were acquired.  The reproducibility 
data informed the choice of a single well of the MFI.  I compared the MFI of duplicate samples 
on the same plate and across plates. The PP4 hyper-immune plasma curve was used for the inter-
plate comparison (Chapter 5, Figure 5.50a & b). There was a high correlation between the 
duplicates expressed by the r-square within the plate (upper panel) and across plates (lower 
panel). 
3.2.11 Luminex Multiplex bead array assay to measure total IgG avidity responses 
Antibody avidity index of 18 malaria antigens was measured in a modified total IgG Luminex 
multiplex assay by adding the GuHCl differentiation step after antibody binding. Tetanus toxoid 
(National Institute of Biological Service and Control (NIBSC) was added as a positive control 
for both malaria-endemic and non-endemic samples.  
Briefly, stock bead regions were vortexed for ~30 minutes to resuspend the beads. The 
resuspension was necessary to disrupt any clumps or aggregated beads that had formed during 
storage. A volume of 10µl was pipetted into 5ml buffer A (~100,000 beads/region). 50µl of the 
bead suspension was added to each well (~1,000 beads/region/well) (BioRad). The plates were 
washed twice with 100µl /well of wash buffer. To minimize bead loss, the plates were placed on 
a magnetic block for 2 minutes to pellet the MagPix beads before removing the supernatant by a 
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rapid inversion of the plate with a single sharp shake. 50µl of 1/1000 plasma in Buffer B was 
added to duplicate wells per sample; the plate was covered in aluminum foil to protect from the 
light and incubated at ~220C on a shaking platform at 600 rpm for 90 minutes., The plate was 
returned to the magnetic block for 2 minutes, and the supernatant was removed as before. The 
plates were washed two times with 100µl wash buffer.  
To assay for avid antibodies, 50µl Guanidine Hydrochloride (GuHCl) was added to one of the 
duplicate wells per sample to dissociate weakly binding antibodies, 50µl PBS was added to the 
second well for total antibody. The plate was incubated at room temperature on a shaker at 
600rpm for 20 minutes. The plate was placed on the magnetic block for 2 minutes, and the 
supernatant was poured off. The plate was washed with wash buffer 3 times.  50µl of 1/200 R-
Phycoerythrin-conjugated AffiniPure F (ab’) 2 goat anti-human IgG (Jackson Immuno Research 
Laboratories) in buffer A was added. The plate was incubated at room temperature on a shaker 
at 600rpm for 90 minutes. The plate was placed on the magnetic block for 2 minutes, and the 
supernatant poured off. The plate was washed 2 times with 100µl wash buffer. 50µl of buffer A 
was added and the plate incubated at room temperature on a shaker at 600rpm for 30 minutes 
before washing once.  100µl of PBS pH 7.2 per well was added. The beads were suspended on 
a shaker for 1 minute and read on a Magpix (Luminex Corp, Austin, Texas), acquiring at least 
100 beads/region/well. The avidity index was defined as the percentage of antibodies that 
remained binding after treatment with GuHCl. (Avidity index = MFI with GuHCl/ MFI with 
PBS)X100. 
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3.2.12 Luminex Multiplex bead array assay to measure IgG1 – 4s 
IgG subclass responses to 18 blood-stage   P. falciparum antigens and TT (non-malaria positive 
control) were measured in plasma diluted at 1/100 on the Luminex MagPix platform and detected 
using a two-step biotinylated anti-human IgG subclass secondary antibody with a streptavidin- 
Phycoerythrin tertiary as previously described (235,236). The platform does not allow the 
multiplexing of labeled antibodies, so each of the IgG subclasses was assayed separately for 
every sample using the same plate layout.  
Briefly, 10µl per region of antigen coupled bead stock (MagPlex magnetic microsphere) 
(Luminex Corp, Austin, Texas) stock was added in 5ml of buffer A to make a combined pool of 
all the 19 regions at a concentration of 100,000beads/region. 50µl of the bead suspension was 
added to each of the wells (~1,000 beads/region/well) of the 96-well plate (Bio-plex Pro flat 
bottom) (BioRad, UK). The plate was washed: placed on a magnetic block for 2 minutes covered 
in aluminum foil. The supernatant poured off while the plate on the magnet and gently blotted 
on a paper towel to remove as much residual as possible. The beads were washed twice with 
100µl wash buffer, rested on the magnetic separator for 2 minutes, and supernatant poured off. 
Using a multichannel pipette, 50µl of prepared plasma at a dilution of 1/100 in Buffer B 
overnight and PP4 standard was transferred from the deep wells into the bead wells. PBS was 
added to two blank wells.   The plate was covered with aluminum foil and incubated at room 
temperature on a shaker at 600rpm for 90 minutes.  The plate was placed on a magnetic separator 
for 2 minutes, and a rapid inversion poured off the supernatant with a sharp shake followed by a 
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gentle blot on a paper towel.  The plate was washed three times with 100µl PBS-TBN.  50µl of 
biotinylated mouse anti-human IgG subtype (mouse anti-human IgG1, clone HP6069, mouse 
anti-human IgG2, clone HP6002, mouse anti-human IgG3, clone HP6050, and mouse anti-
human IgG4, clone HP6023, Thermo Fisher Scientific, UK) in buffer A was added in dilutions 
of 1/400, 1/400, 1/1,000, 1/400 for IgG1 – 4, respectively. The plate was covered in aluminum 
foil and incubated at room temperature on a shaker at 600rpm for 90. The plate was washed three 
times with 100µl wash buffer. 50µl of streptavidin- phycoerythrin conjugate (Thermo Fisher 
Scientific, UK) was added to each well. The plate was covered in aluminum foil and incubated 
at room temperature on a shaker at 600rpm for 90 minutes. The plate was placed on a magnetic 
separator for 2 minutes before pouring off the supernatant.  The plate was washed three times 
with 100µl wash buffer. The plate was read on a Luminex MagPix, acquiring at least 100 
beads/region/ well.  The results were expressed as MFI. The blank well MFI was deducted from 
each well to determine the net MFI. 
3.3 Data Normalization to adjust for plate-to-plate variations.   
 
Lindsay Wu, London School of Hygiene and Tropical Medicine performed the data 
normalization. Data were normalized to adjust for between plate variation using a loess 
normalization method(237). This involved inclusion of PP4 standard curve fits from the plate. A 
composite standard curve was computed for each antigen by calculating the mean MFI values 
for the reference plates for 100 concentrations between the highest and lowest concentration on 
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the standard curve. For each plate, the plate-to-reference standard curve MFI difference (∆MFI) 
was calculated for these 100 concentration points and a loess regression fit to ∆MFI as a function 
of mean MFI. The raw MFI data for all samples on the plate were then adjusted by the predicted 
∆MFI based on the loess regression fit. Data were not corrected for background signal given that 
the between plate variation was already accounted for in the loess normalization and all 
background MFIs were below 30 and therefore negligible. 
3.4 Statistical Analysis.   
 
Non-parametric comparison of unpaired medians across age groups within site or across sites 
was performed assuming a non-gaussian, using the Mann-Whitney test. Correlations were 
performed using the Pearson test. The sensitivity (true positive) and 100 - specificity (false 
positive) were determined by the receiver operating characteristic curve (ROC). The net change 
in total and avid IgG levels and avidity index during the highest and the lowest malaria 
transmission intensity was derived from a paired difference between MFI and AI at T2 and T4.  
The association between antibody levels (MFI) for total IgG and the subclasses 1 - 4 with days 
since the infection was assessed in a generalized estimating equation (GEE) model, adjusted 
for age (373).  The MFI were log10-transformed. All 4-time-points were included, and the 
patient number was used to link the repeated measure. The GEE model assumed the Gaussian 
distribution, the correlations within a group were exchangeable, and the standard errors were 
robust.   The GEE allowed estimation of the mean effect of days since the last infection on 
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antibody levels using repeated measures per individual at a population level. Infections were 
defined as parasite positive if the sample was microscopy positive (patent infections) or LAMP 
positive. The GEE model outcomes were regression coefficient and 95% confidence intervals 
(95%CI). Estimated antibody decay half-life was derived from the GEE model's regression 
coefficient of log 10 antibody levels with days since infection (log antibody loss per day since 
infection) by dividing log10 of 2 by coefficient. The result was the number of days it takes to 
lose half the antibody levels since the last day of infection. 
Analysis and Figures were performed with Stata version 14 (StataCorp LLC, USA), GraphPad 
Prism version 7 (Graphpad Software Inc, USA), and R studio. Changes and associations were 
considered statically significant when 95% confidence intervals did not overlap zero or P-
values were less than 0.05. The P less than 0.05 assumed estimated differences between 
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As part of my Ph.D., I  performed all the laboratory experiments and data analysis in this chapter. 
The PRISM study conducted cross-sectional surveys where samples for this chapter were 
obtained. Eliza assay was performed in the main PRISM study to determine the seroprevalence 
of MSP-1-19 and AMA-1.  I used the seroprevalence data to select the participants in this study, 
as described in the chapter. 
Avidity of Antimalarial Antibodies Inversely Related to Transmission 
Intensity at Three Sites in Uganda 
 
4.1 Introduction 
4.1.1 Slow acquisition of Immunity to malaria 
The striking feature of immunity to malaria in humans is the slow acquisition only after many 
years of continuous exposure in the endemic areas.  In high transmission areas where children 
are exposed to infective bites daily, they continue to suffer from several malaria episodes each 
year, not until their early adolescence (238).  
Children develop immunity to severe malaria around the age of 5 years in stable endemic areas.  
However, they remain susceptible to uncomplicated malaria until the age of 10 -15 years, when 
they manifest anti-disease immunity. During the anti-disease immunity, the children are 
chronically infected with high parasite load without clinical symptoms (24,54).   A period of 10 
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to 15 years of continuous exposure to infection is way too long for malaria to acquire immunity 
compared to other viral and bacterial diseases. For example, the acquisition of protective 
immunity to measles and smallpox is very rapid –often after one or two infections or vaccinations 
with an attenuated virus (239,240). Thus, the acquisition of immunity to malaria in humans is 
slow, complicated, involving the early acquisition of anti-severe disease immunity, followed by 
anti-disease immunity and anti-parasite immunity but rarely leading to sterile immunity (241).   
4.1.2 Role of antibodies in acquired immunity to malaria  
In 1961, Cohen et al. demonstrated the role of antibodies in blood-stage malaria immunity.  In 
his experiment, the transfer of purified IgG from malaria-immune adults to children with acute 
malaria led to rapid reductions in parasite numbers in the blood and the fever's subsequent 
resolution (138). Several epidemiology studies have reported the correlation of different 
immunity to antibody responses against several P. falciparum antigens (238,242–244). In a 
longitudinal study in Gabon and Cameroon, clinical protection was related to elevated antibody 
levels to schizont extract (245).  In another study,  antibodies against the merozoite surface 
protein 1-19 (MSP1-19) were shown to provide approximately 40% protection against clinical 
malaria in Sierra Leone children (246). Osier FH et al. reported that serum antibody levels to 
apical membrane antigen 1 (AMA-1) and merozoites surface protein antigens (MSP1 block 2, 
MSP2, and MSP3) were inversely associated with the probability of developing severe malaria 
in Kenyan children (244).  Consequently, several malaria antibodies inducing vaccine candidate 
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formulations were based on antigens previously correlated with some form of protection or 
protective immunological mechanisms. Unfortunately, most of the vaccine candidates to date 
have not shown promising protective results in clinical trials despite evidence of inducing 
desirable antibody responses (247). Only the circumsporozoite protein (CSP) based RTS, 
S/AS01, has shown short-lived protection from severe forms of the disease with efficacy ranging 
between 30 -50% (139,248). 
We do not fully understand the targets or the properties of antibodies against P.falciparum that 
mediate immune mechanisms to malaria. The quality of the protective antibodies and the precise 
mechanisms by which these antibodies affect their function are barely known. Furthermore, we 
do not understand why antibody-mediated immunity is acquired only after many years of 
exposure and why immunity is poorly maintained.    
The inefficient acquisition of a protective immune response against malaria is partly attributed 
to the huge number of antigens rising from approximately 5,400 genes (249). In addition, there 
is a high degree of genetic diversity and polymorphism associated with parasite genes, including 
the multi-gene families like the var genes. This vast diversity and the complex expression at the 
different life cycle stages can partly explain why it takes an individual living in an endemic area 
a long time to generate a diverse repertoire of protective antibodies (250,251). Therefore, it is 
postulated that it takes years living in an endemic area for an individual to be exposed to a 
sufficient number of parasite clones to generate a protective repertoire of antibodies (243,252). 
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In addition, temporal variation of parasite antigen expression, as exhibited by the var genes and 
other antigens, contributes to successful parasite immune evasion and disease pathology (64). 
Peter Crompton et al. and Scholzen et al. reviewed mounting evidence suggesting P. falciparum 
infection-induced dysregulation of B-cell function. This is thought to play a role in the inefficient 
acquisition and maintenance of antibody-mediated protection against malaria (253,254).  It is 
suggested that P. falciparum infection preferentially induces short-lived plasma cells (SLPC) 
and does not reliably and efficiently induce a stable pool of long-lived plasma cells (LLPC) and 
typical MBC, especially in children (255,256).   
Furthermore, P. falciparum malaria infection is associated with the expansion of atypical MBC 
(257,258) reported having reduced capacity to proliferate and differentiate into antibody-
secreting cells upon in vitro stimulation (257).  Their phenotype is similar to the exhausted MBC 
in HIV infection, but their role in malaria is not fully understood (259,258). These adverse effects 
on the B cells function may bear grave consequences on the critical antibody qualities such as 
maintenance of protective antibody levels, isotype composition, and avidity maturation. 
4.1.3 Antibody affinity, avidity and the role in Antibody function 
Antibodies against P. falciparum clear pathogens via several mechanisms.  These include 
inhibition of pathogen invasion (neutralization), complement fixation, and opsonization of 
pathogens for clearance by innate immune cells (260–263).  However, for antibodies to mediate 
function efficiently, they must bind to their target stably and long enough via the variable 
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antigen-binding site to cooperatively recruit effectors via their Fc receptors. Antibody Affinity 
is the strength of the interaction between a single antigen site - epitope and a single 
antibody-binding site. Thermodynamic principles govern the reversible bimolecular interaction 
between the antigen and antibody hence affinity. The sum of the binding affinities of the 
individual antibodies to a poly-epitope antigen is referred to as antibody avidity.  Avidity is the 
functional affinities and reflects the degree of stability of antibody interaction with antigen (264).  
It is a function of the number of shared binding sites and the total binding energy of an antibody 
and antigen. Efficient antibodies must bind with high avidity to their target and long enough to 
mediate their functions effectively. For example, neutralizing or blocking antibodies must bind 
the pathogen antigens that mediate attachment or entry to the host cell faster than the cell 
receptors. Likewise, antibodies must bind stably and long enough on the pathogen or infected 
cells to effect opsonization and complement activation. Antibody affinity maturation during the 
germinal center reaction in a follicular T- dependent B cell response (205).      
4.1.4 Evidence of acquisition of avidity during infection and role in immunity 
Antibody avidity is an important correlate for immune memory and protection in infections such 
as MUMPS,  rubella (183), toxoplasma (251), and vaccine efficacy such as pneumococcal 
polysaccharide and MUMPS vaccines.    The decreased efficacy of Haemophilus influenzae type 
B  vaccine that has been observed in combination with acellular pertussis vaccine was reported 
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to be a result of lower avidity maturation (265,176,266). Similarly, patients with MUMPS vaccine 
failure were associated with low antibody avidity (181,182). 
 
4.1.5 Evidence of acquisition of avidity maturation during Malaria infection  
 There are very few studies that provide some useful insight into the role of antibody affinity in 
malaria.   Ferreira et al. reported increased antibody avidity to P. falciparum -schizont extracts 
two months following resolution of clinical malaria, in the absence of re-infection in 
Brazilianadult patients (267). Higher avidity of the predominately cytophilic  IgG antibody 
subclasses IgG1 and IgG3 was reported among the immune Senegalese adults compared to non-
immune Brazilian P. falciparum malaria patients (267).  In yet another study, higher avidity to 
P. falciparum blood-stage extract was reported among Brazilian children with uncomplicated 
and asymptomatic malaria, relative to their complicated malaria counterparts (268).  Furthermore, 
high avidity antibodies to full-length VAR2CSA were associated with a reduced risk of placental 
malaria (269).  More recently, antibody avidity to AMA-1 and MSP2 were reported to increase 
with age, and that individuals with the highest antibody avidity to MSP2 at the baseline of a 
prospective study had a prolonged time to clinical malaria (270). These findings are put together 
to provide insight into the acquisition of antibody avidity during malaria infarction and its 
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4.1.6 What influences avidity maturation during Malaria infection?  
In P. falciparum infection, avidity to whole schizont extract and several specific antigens have 
been shown to correlate with protection (267–270). However, the acquisition of high antibody 
avidity to P. falciparum antigens with age and exposure intensity is poorly understood. One 
study performed in an unstable malaria transmission setting showed increased antibody avidity 
following a clinical malaria episode (267). In contrast, two studies of children living in endemic 
areas failed to observe an increase in avidity index to a number of P falciparum antigens with 
increasing exposure (271,272). Overall, it is unclear if repeated exposure to P. falciparum leads 
to increased avidity of antibodies directed against plasmodium antigens. 
4.2 Study aim 
Data presented in this Chapter aimed to determine the influence of P. falciparum exposure 
intensity on the acquisition of antibody avidity to 2 P. falciparum merozoite antigens; AMA-1 
and MSP1-19. Avidity index was measured in individuals across a wide range of ages from 
cross-sectional surveys performed in 3 sites in Uganda with varying malaria transmission 
intensity. Antibody avidity indices were then compared between ages and sites to determine 
whether there were differences in antibody avidity associated with age and P. falciparum 
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4.3 Methods  
4.3.1 Study sites and cross-sectional surveys  
This study utilized DBS samples collected from cross-sectional surveys conducted in 2012, 
described in Chapter 3 at three sub-counties in Uganda.  The three sites had varied P.falciparum 
transmission intensity based on the entomology survey of 2012. Walukuba had relatively low 
transmission intensity, with EIR estimated at 2. Kihihi had fa medium transmission with an 
estimated EIR of 6.  Nagongera had the highest transmission with an estimated EIR of 306. 
Malaria transmission at all three sites was perennial. In all three districts, malaria control 
interventions included using ITN malaria case management with artemisinin-based therapies and 
intermittent presumptive treatment during pregnancy with sulfadoxine-pyrimethamine.  
Cross-sectional surveys were conducted between January and June 2012 at all 3 sites (218). The 
Survey recruited participants from 200 households randomly selected from a population-based 
census. A total of 2,217 participants were recruited in the 3 surveys (Walukuba – 629, Kihihi – 
786, Nagongera – 802). DBS from finger-prick samples were obtained from all children under 
fifteen years of age and from a random selection of age stratified adults in the following 
categories: 15–24 years, 25–34 years, 35–44 years, 45–54 years, and > 55 years. The median and 
interquartile age per site is indicated in Table 3.3. ELISA assay for AMA-1 and MSP1-19 was 
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4.3.2 Study population 
ELISA assay for AMA-1 and MSP1-19 was performed previously, and OD values were obtained 
for the main study.  Only samples with titers above a normalized OD (adjusted OD based on a 
positive control to correct for inter-plate variations) of 0.5 were included in the avidity index 
assessment to ensure detectable binding after antibody binding interruption. A total of 1,186 
samples with OD> 0.5 for either AMA-1 or MSP1-19 were included in this study.  A total of 
424 were positive for both AMA-1 and MSP1-19, 605 AMA-1 only, and 157 MSP1-19 only. 
The total number for AMA-1 was 1029, and MSP1-91 was 581 the detailed summarised in Table 
4.31a in the results section. The exact breakdown is included in figure 4.31b. 
5 Table 4.31a Characteristics for the cross-sectional surveys  
 
Characteristics of cross-sectional Survey Walukuba Kihihi Nagongera Total 
Survey population 629 786 802 2217 
Median Age (IQR) 12 (5 - 25) 12 (5 - 28) 11 (6 - 28)  
EIR 2 6 306  
Parasite rate 13 11 38  
Sero- prevalence   AMA1 54.2 67.2 85.5  
Sero- prevalence   MSP1-19 33.8 56.5 50.4  
 
Characteristics of the Study Population Walukuba Kihihi Nagongera Total 
Study population-  AMA1 183 343 503 1029 
Study population- MSP1-19 92 270 219 581 
Median Age (IQR)  18 (8 – 27) 19 (10 – 38) 12 (6 – 28)  
Percentage of the survey population- AMA1 29.1 43.6 62.7  
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Figure4.31b Summary of the samples selected from the PRISM cross-sectional survey based 
on the OD 0.5 cut off for both AMA-1 and MSP1-19 
 
4.3.3 Modified ELISA to Measure the Avidity index 
DBS collected on Whatman 3MM filter paper and stored at -20°C were eluted as described in 
Chapter 3 section 3.22. Antibodies to MSP1-19 and AMA-1 (3D7 strain) were measured via a 
modified sandwich ELISA (Chapter3, section 3.23) at a final concentration of 1:1000 for MSP1-
19 1:2000 for AMA1. For each sample, a set of two wells were treated with 2M or 5M (GuHCl) 
or PBC (standard ELISA to measure total antibody) to interrupt binding before the development 
of the plate as described in Chapter 3. The avidity index was defined as the percentage of 
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4.3.4 Data Analysis 
Participants were stratified into age groups 1-4, 5-15, and above 15 years. Non-parametric 
comparison of unpaired medians across groups within site and across sites for the different age 
groups was performed using the Mann-Whitney test. Correlations were performed using the 
Pearson test. The analysis was performed using Stata14 (Stata Corp LLC, USA) and Graphpad 
PRISM version 8 (Graphpad Software, USA).  
 
4.4 Results 
4.4.1 Change in age with transmission site at OD 0.5 cut off   
The participants from the PRISM surveys included in this study were based on the OD of the 0.5 
cut-off.  Consistent with sero-prevalence observations in the same surveys, the proportion of 
participants included in the survey for AMA-1 increased with increasing transmission intensity 
(29.1%, 43.6%, and 67.7% for Walukuba, Kihihi and Nagongera, respectively) but not MSP1-
19 (14.6%, 34.5%, and 27.3% for Walukuba, Kihihi and Nagongera respectively) (218).  
Median age significantly increased between the PRISM survey and the study population for the 
low and medium transmission areas Walukuba (12 vs. 18 years, P= 0.0006), Kihihi (12 vs. 19 
years, P>0.0001). Age did not change for the high transmission area of Nagongera (11 vs. 12 
years, p = 0.165). This observation may imply a rapid sero-conversion rate at the high 
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4.4.2 Relationship between age and antibody avidity  
Median avidity index to MSP1-19 at 2M and 5M GuHCl was not significantly different between 
age groups at all three sites. Median avidity index to AMA-1 at 2M was only significantly higher 
at 5-15 years compared to 1-4 years. AT 5M GuHCl median avidity index was not different 
between age groups at all three sites, with the exception of 1-4 versus 5-15-year olds in Walukuba 
(73.6 versus 85.1 p=0.04) (Figure 4.32).  
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Figure 4.32.  Avidity index to MSP1-19 and AMA-1 across age groups. Avidity index was measured as the percentage of 
remaining binding antibodies after 2M or 5M GuHCl treatment, of the total antibody in a modified ELISA assay. The bars 
represent the median and interquartile range.  * = p<0.0
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4.4.3 Relationship between malaria transmission and antibody avidity  
In contrast to the trends observed in antibody levels, the avidity index to MSP1-19 was 
significantly lower in the highest malaria transmission intensity site of Nagongera than Kihihi 
and Walukuba in those over five, at both GuHCl concentrations (2M and 5M) (Figure 4.33). 
There were no significant differences in avidity index between sites in children under five. 
Responses to AMA-1 showed a similar pattern, with avidity index lower in Nagongera and 
Kihihi than Walukuba in those at least five years old at 5M.  There was no evidence of a 
correlation between the avidity index to MSP1-19 and AMA-1 at either GuHCl concentration (r2 
<0.002, p > 0.5 at 2m and 5m GuHCl all three sites). Overall, these findings suggest an inverse 
relationship between the avidity index and transmission intensity and antibody response to 
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Figure 4.33.  Avidity index to MSP1-19 and AMA-1 across transmission sites. Avidity index was measured as the 
percentage of remaining binding antibodies after 2M or 5M GuHCl treatment, of the total antibody in a modified 
ELISA assay. The bars represent the median and interquartile range.  * = p<0.05, ** = p<0.001, *** = p<0.0001
109 
 




P. falciparum Transmission Intensity and the Quality of Antimalarial Antibodies                                                    Isaac Ssewanyana      
  




4.4.1 Summary of Results  
This study sought to determine the influence of P. falciparum exposure on the natural acquisition 
of high avidity antibodies. Avidity was measured to MSP1-19 and AMA-1 antigens in over 1,000 
individuals encompassing a wide range of ages, from 3 sites in Uganda with transmission 
intensities ranging from moderate to extremely high. Our results demonstrated that age had a 
minimal effect on antibody avidity, consistent with previous studies using similar evaluation 
methods, which observed slight or inconsistent age-related differences in avidity to MSP1-19 
and AMA-1 (271,272). Notably, despite higher antibody levels, both antigens' avidity was 
significantly lower at the site of highest P. falciparum transmission intensity in children >5 years 
and adults. These results suggest that affinity maturation to P. falciparum antigens may be 
compromised in the setting of very high, perennial exposure to this parasite.  
 
There are at least two potential explanations for this study’s main findings, which are neither 
exhaustive nor mutually exclusive: 1) near-constant exposure to an antigen may impair 
maturation/persistence of avid antibodies via several potential mechanisms; and 2) recent 
infection may result in the addition of low avid antibodies to the circulation, reducing the 
proportion which has high avidity. 
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4.4.2 Chronic infection may impair germinal center  
Affinity maturation is acquired through somatic hypermutation during germinal center reactions, 
with B cell affinity to antigen driving selection that results in higher affinity antibodies (Figure 
4.34) (275,276). The classical understanding of B cell biology would suggest that repeated 
exposure would be expected to drive several rounds of germinal center reactions, ultimately 
resulting in higher antibody affinities to the pathogen, hence a higher antibody avidity index. In 
contrast, results showed a lower avidity index in participants living in the highest P. falciparum 
transmission site, where exposure to antigen is most frequent. Animal studies suggest that 
germinal center development is temporally ordered, with SLPC emerging from extrafollicular 
differentiation and early germinal centers initially, followed by MBC. Then, weeks to months 
later, LLPC has undergone extensive affinity maturation (199,275).  Many evidence suggests that 
acute and chronic infections may compromise the ultimate development of high-affinity MBC 
and LLPC, which are the source of high-affinity antibodies. (Summarized in Figure 4.34).  Such 
evidence includes (i) interference of germinal center architecture in the spleen (277,278). 
Antigens like the CIDR-α region of the PfMP1 have a mitogenic effect that causes polyclonal 
activation and extrafollicular differentiation of B cells into plasma cells(254,279).  In addition, 
antigens that have repeat domains may drive B cell extrafollicular reaction.  (ii) The presence of 
chronically large antigen loads my result into indiscriminate survival of low-affinity B cell. (iii) 
Acute malaria interferes with follicular helper T cell differentiation that may affect the germinal 
center's integrity and interfere with the selection process (280,281). (iv) Dysregulation of B cell 
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differentiation factors like BAFF may result in skewed germinal center output. (v) P. falciparum 
infection is associated with dysfunction of the B cell compartment, including the accumulation 
of atypical memory B cells (257), which could theoretically result in the inefficient acquisition 
and maintenance of antibody-mediated immunity malaria due to their altered differentiation 
upon stimulation (254). 
 
 
Figure 4.34 Schematic representation of Germinal center reaction showing the processes 
potentially interrupted by P. falciparum infection can result in B cell dysfunction and 
affinity maturation impairment. (i). Malaria antigens like CIDR-α mitogens can result in 
extrafollicular B cell reaction and prevent germinal center formation. (ii) Chronically large antigen load 
my result into a selection of B cell low-affinity B cell receptors. (iii-v) Dysregulation of follicular T helper 
cells and follicular dendritic cells may damage the germinal affect center architecture, survival 
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4.2.3 Status of infection may influence Avidity index   
In the presence of low antigen levels, affinity matured plasma cells that secrete high-affinity 
antibodies should be favored over lower affinity plasma cells for survival. These affinity matured 
plasma cells would, therefore, maintain the blood antibody levels. However, in the presence of 
frequent re-infection, a relatively large antigen load may be more likely to promote survival of 
poorly affinity-matured plasma cells, including T cell-independent or extra-follicular B cell 
reactions.  Furthermore, acute P. falciparum infection is associated with non-specific, polyclonal 
B cell activation that may expand low avidity, short-lived plasma cells (282).  These factors may 
reduce the proportion but not necessarily the titers of high avidity antibodies. In contrast, in the 
absence of recent infection, the antibody pool is predominantly comprised of high avidity 
antibodies generated by LLPC after the contraction of the SLPC. This may explain why 
Ugandans in lower transmission areas, who on average had a longer duration of time since their 
last infection, had higher proportions of highly avid antibodies. 
4.3.4 Relationship between avidity index and immunity  
The impact of the differences in the avidity index observed in this study on acquiring clinical or 
anti-parasite immunity is unknown. While antibody avidity is theoretically important in the 
function of an antibody response (266), there is little empiric data to support the relationship 
between the avidity index and immunity in malaria. Reddy et al. found that individuals with 
higher antibody avidity to P. falciparum antigens were less likely to experience malaria during 
113 
  
Chapter 4:  Antibody Avidity at Different P. falciparum Transmission Sites  
 
P. falciparum Transmission Intensity and the Quality of Antimalarial Antibodies                                                            Isaac Ssewanyana 
 
 
follow-up (193,283). In an RTS, S malaria vaccine trial, investigators did not find an association 
between antibody avidity to circumsporozoite protein and protection after the last dose of 
vaccination among children. Still, they did show that the change in avidity between second and 
third vaccination was associated with a 54% reduced risk of acquiring malaria (284,285).  The 
relationship between avidity measurements and clinical immunity is also complex, with 
numerous factors other than the play's avidity index. A high antibody titer may compensate for 
a low avidity index; therefore, a relatively low avidity index in the presence of high antibody 
levels may not negatively affect naturally acquired immunity.  Clinical data from this study 
shows that acquired immunity develops in children in Nagongera, the study site with the highest 
P. falciparum transmission, based on reductions in disease incidence with age (221).  However, 
it is not clear whether acquired immunity would develop and be maintained more effectively by 
decreasing the nearly continuous exposure to blood-stage parasites at the site, e.g., via 
chemoprevention or reducing transmission using vector control(286).  
4.3.4 Limitations  
This study's cross-sectional nature limited our ability to investigate the mechanisms behind the 
acquisition of antibody avidity. The study looked at only one-time points that do not give 
information about the antibody boost and decay kinetics.  Furthermore, this study only 
investigated responses to two of many P. falciparum proteins. It is not yet well established which 
combinations of responses are most relevant for acquiring immunity.  Also, while providing an 
overall estimate of the proportion of the polyclonal antibody pool, which is highly avid, the 
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ELISA-based methods used in this study could not further dissect the antibodies' binding 
characteristics.   
4.4 Conclusion 
In conclusion, this study showed that avidity to 2 different P. falciparum antigens was lower in 
high versus low transmission intensity areas. The mechanisms behind these findings, as well as 
their clinical consequences, if any, are not yet clear. A more detailed investigation, ideally linked 
to P. falciparum exposure's longitudinal investigation, comprehensive analysis of the B-cell and 










P. falciparum Transmission Intensity and the Quality of Antimalarial Antibodies                                                    Isaac Ssewanyana      
  




As part of my Ph.D., I performed all the laboratory experiments and data analysis in this chapter. 
The PRISM study conducted the longitudinal cohort where samples for this chapter were 
obtained. Lindsay Wu normalized the Luminex data (Chapter 3, section3.3) after I completed 
the experiments. I used the normalized data for the analysis. 
 
P. falciparum infection is associated with a predominantly non-avid IgG 
antibody response that rapidly decays following IRS  
5.1 Introduction  
Several epidemiological studies have shown a correlation between antibodies to different malaria 
antigens with varying forms of malaria immunity, majorly anti-disease immunity independent 
of age, and exposure  (287–289). Furthermore, in-vitro assays have demonstrated that naturally 
acquired antimalarial antibodies can mediate effective effector mechanisms targeting different 
parasite stages in the parasite life cycle (152,290,291).  The growth inhibition assays (GIA) 
measure antibodies' ability to interfere with parasite invasion or growth (124,291).  Inhibition or 
reduction in growth may be a result of blockage of merozoite invasion of the red blood cell(292–
294), inhibition of intra-erythrocyte parasite growth, blockage of parasite egress from infected 
red blood cells (295),  blockage of infected red blood cell from sequestration, mediation of 
destruction of infected red blood cells or inhibition of schizont rupture (296). Antigens like 
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MSP1-19  and AMA-1 have been studied extensively in GIA and have shown an inconsistent 
correlation with protecting clinical disease (290,292,297,298). The GIA has revealed several other 
antigens like EBA175 RIII-V  RIII-V and Rh5, SEA  that are important targets of inhibitory 
antibodies and correlates well with protection and are promising vaccine candidates 
(123,288,299,300). Antibodies opsonize merozoites and infected red blood cells for phagocytosis 
via the Fc receptor (152,298,301). Naturally acquired antibody levels against merozoite surface 
proteins, including MSP2, MSP3, MSPDBL1, and MSPDBL2, were positively correlated with 
phagocytosis in-vitro assays (123,152,302,303). Merozoites opsonized by antibodies in vitro can 
activate neutrophils to produce reactive oxygen species, termed as an antibody-dependent 
respiratory burst (ADRB), and demonstrated with naturally acquired anti-MSP1-19 antibodies 
(304).  Antibodies cooperate with monocytes and Natural killer cells (NK) to mediate antibody-
dependent cellular inhibition (ADCI) (131,305). With this mechanism, antibodies mediate 
infected red blood cell attack indirectly through monocytes and NK cells' activation to release 
chemical factors that mediate parasite killing. Phase 1 vaccine trials of MSP2 and MSP3 were 
associated with the development of Antibody-dependent cellular inhibition (ADCI) mediating 
antibodies (133,306,307).  Antibodies recruit the complement system to promote phagocytosis, 
chemotaxis, and cell lysis. Studies of naturally exposed malaria infections and vaccinated 
volunteers have shown that antibodies bind to merozoites, and infected red blood cells can recruit 
C1q and activate the classical complement cascade leading to parasite lysis (132,134). Naturally 
acquired antibodies to MSP1-19 and MSP2 were shown in vitro to activate the complement 
117 
  
Chapter 5:  Antibody Avidity during high P. falciparum Transmission and near Zero Transmission  
 
P. falciparum Transmission Intensity and the Quality of Antimalarial Antibodies                                                            Isaac Ssewanyana 
 
 
classical pathway and antibodies (132). Complement activation is one of the proposed 
mechanisms of protection mediated by anti-sporozoite vaccine-induced antibodies (134,308).   
 Despite overwhelming evidence supporting the role antibodies play in malaria immunity 
mediated mechanisms, it is also clear that serological assays to date do not always correlate with 
immunity. The obvious arguments are the high polymorphisms, alternative use of different 
antigens for the same function/s, complex expression of antigens during a complex life cycle, all 
of which promote parasite immune evasion. However, there is increasing evidence to suggest 
malaria mediated interruption of the germinal center reaction and B-cell function (309).  
Antibody properties such as isotype composition and affinity play a critical role in the overall 
antibody functional outcome. Still, we have a poor understanding of how these properties are 
acquired, interrupted, or influence antibody function during malaria infection. 
Antibody affinity maturation and class switching are acquired through the germinal center 
reaction. There is evidence discussed in Chapter 4 to indicate that the germinal center may be 
interrupted by P. falciparum infection. Although not fully understood, these interruptions of the 
B cell function associated with P. falciparum infection are strongly suspected to affect antibody 
avidity and maintenance of antibody-mediated immune response against malaria and, 
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We reported previously in Chapter 4 that the avidity index of antibodies against  AMA-1 and 
MSP1-19 was inversely correlated to P. falciparum transmission intensity (310).  The study in 
Chapter 4 compared the avidity index of AMA-1 and MSP1-19 in three cross-sectional surveys 
of different malaria transmission intensities. The study's cross-sectional nature limited our ability 
to gain insight into the mechanisms that drive lower avidity index at the site of highest malaria 
transmission intensity. Furthermore, the two antigens limited our knowledge of avidity 
maturation in the context of a broader antigenic profile.  
5.2 Hypothesis and Aim 
 Based on our results from Chapter 4, where we observed lower median avidity index to AMA-
1 and MAP1-19 among participants from a higher malaria transmission site compared to lower 
transmission sites, we hypothesize that; 
1. Near constant exposure may interfere with affinity maturation 
2. Recent infection may result in low avidity antibodies from short-lived plasma cells  
This Chapter aimed to test the hypothesis, taking advantage of the longitudinal PRISM cohort 
and interruption of malaria transmission by introducing IRS to compare antibody avidity in the 
same individuals during high exposure and near-zero exposure, on a panel of 18 malaria antigens.   
A novel high throughput multiplex bead assay method was optimized and adapted to allow the 
simultaneous measurement of the antibody avidity profile to 18 antigenic targets, spanning 
different compartments of the blood-stage infection, plus a non-malaria control Tetanus toxoid 
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(TT). To date, there has been no method available to allow the simultaneous measurement of 
avidity index to a large number of P. falciparum antigens in a high throughput manner.  
To our knowledge, this is the first study to adopt the multiplex bead assay to evaluate avidity to 
a large panel of 18 malaria antigens. The high throughput assay was based on the established 
ELISA methodology and was adapted for use on the MagPix multiplex platform (Luminex). The 
introduction of IRS in Tororo provided a unique opportunity to investigate the effects a reduction 
in P. falciparum infection would have on naturally acquired antibody responses following one 
year of IRS on a broad panel of malaria antigens from the blood-stage of infection. The avidity 
index, total, and avid (strongly binding antibody pool) IgG responses were analyzed to 
understand the driver of the humoral immune response associated with age and infection status.  
5.3 Methods  
 
5.3.1 Study population and time-points  
In this study, 160 participants enrolled in a longitudinal PRISM cohort were included. These 
were all the children below 11 years and 20% of the adults who had plasma collected during the 
study period.  The introduction of the IRS study informed the study period. The participants 
belonged to age categories 1 – 4 years (40), 5 – 11 years (92), and above 18 years (28). For each 
participant, 4 time-points were included; two pre-IRS time-points. T1 and T2 were taken 12 and 
6 months before the first round of IRS, respectively. T3 and T4 were taken at 6 months and 1-
year after the first  IRS, respectively (Chapter 3, Figure 3.3). 
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5.3.2 Ethical consideration 
Ethical approvals were obtained from the Makerere University School of Medicine Research and 
Ethics Committee (REC REF 2011-203), the Uganda National Council for Science and 
Technology (HS 1074), the LSHTM ethics committee (reference # 6012), and the University of 
California, San Francisco Committee on Human Research (reference 027911). 
5.3.3 Multiplex bead array assay to measure total and avid IgG 
Total IgG responses in diluted plasma samples as1/1000 was measured using the MagPix 
(Luminex Corp, Austin, Texas) multiplex platform to 18 P. falciparum blood-stage antigens and 
TT using protocols as previously described Chapter 3, section 3.29. 
The Luminex assay was modified to measure avid antibody responses, as described in Chapter 
3, section3.2.11.  Basically, one of the two bead wells per sample was reacted with plasma for 
90 minutes at room temp followed by treatment with 2M Guanidine Hydrochloride (GuHCl) for 
20 minutes to displace weakly binding antibodies. The beads were reacted with a secondary 
mouse anti-human IgG antibody labeled with phycoerythrin (PE) to detect antigen-specific 
antibodies present in plasma. The antibodies that remained bound to the bead coupled antigen 
after treatment with 2M GuHCl was referred to as avid IgG pool. The second well followed the 
standard assay to measure total IgG.  The difference between the total IgG and avid IgG pool 
was referred to as the non-avid antibody pool. The avidity index was defined as the percentage 
of avid antibody remaining after treatment and is calculated as follows:  
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5.3.4 Statistical analysis 
The net change in total and avid IgG levels and avidity index during the highest and lowest 
malaria transmission intensity was derived from a paired difference between MFI and AI at T2 
and T4, respectively.  
The association between antibody levels (MFI) for both the total and high avidity IgG with days 
since the last infection or proportion of months free from infection was assessed using the 
generalized estimation equation (GEE) model. GEE  allows regression of repeated measures of 
all 4-time-points per subject, adjusted for age. Infection was defined as positive if blood smear 
microscopy positive or LAMP positive.  The proportion of months free from infection was 
defined as the months out of 12 that a participant was infection-free.  The GEE model analysis 
outcome was regression coefficient (coef) and the 95% confidence intervals (change in log10 
MFI for every day since the last infection).  
Association between total IgG, avid IgG, and avidity index with age was assessed in a GEE 
model, adjusted for days since infection. Age category 1-4 years was the reference, and the 
AI =   
MFI with GuHCl (avid) 
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outcome was coef and 95% confidence interval (log10 change in antibody levels as you transition 
from age category 1-4 to 5-11 or above 18 years). 
Analysis and Figures were performed with Stata version 14 (StataCorp LLC, USA) and 
GraphPad Prism version 7 (Graphpad Software Inc, USA). Changes and associations were 
considered statically significant when 95% confidence intervals did not overlap with zero or P- 
values were less than 0.05. 
 
5.4 Results 
5.4.1 Validation of an antibody avidity assay MagPix multiplex platform 
The first part of the results describes the validation of the Luminex platform to determine 
suitability and reproducibility to measure antibody avidity for malaria antigens. To achieve this, 
we evaluated the impact of the GuHCl chaotropic agent on bead integrity and each of the coupled 
antigens. Once this was established, I focused on defining the optimal conditions for the assay. 
5.4.2 Assay reproducibility to inform use if single well  
The Luminex platform measures every bead's fluorescent intensity, which can be equated to a 
single ELISA well OD. Since at least 100 beads are acquired and the median fluorescence 
intensity (MFI) taken, this can be equivalent to a median of 100 ELISA wells. To test if the 
platform was indeed reproducible, we tested 20 samples duplicated and compared their MFI. A 
high degree of agreement between two duplicate wells on the same plate was observed (Figure 
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5.50a). This data-informed use of one well per sample for the assays. A standard curve 
constructed from hyperimmune plasma pp4 was included on every plate to monitor inter-plate 
variations over time. Figure5.50b confirmed a high degree of reproducibility of the method. 
 
Figure 5.50a Graph showing MFI of representative antigens tested in duplicate on one plate. A total 
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Figure 5.50b Graph showing MFI of representative antigens plate 1 PP4 curve plotted against the 7 
plates. PP4 standard curve at 8, 5X dilution points included on every plate. The standard curve was used 
to normalize variation across plates. 
 
5.4.3 Effect of GuHCl on the properties of magnetic beads 
To perform the avidity assay on the Luminex platform, it was necessary to establish the effect of 
GuHCl on the properties of MagPex microsphere beads. Uncoupled MagPlex microsphere beads 
were treated with 0.5, 1, 2, and 5M GuHCl for 20 minutes at room temperature.  The beads were 
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then washed as per the protocol and acquired using the Magpix machine. All the tested beads 
behaved normally, with each bead detectable in the correct bin. This result implied that GuHCl 
did not affect the core spectral signature or the beads' magnetic properties.  A follow-up 
monoplex assay was then performed. In this,  1000  beads representing 5 distinct bead regions 
in separate duplicate wells were treated with 5M GuHCl (highest concentration previously used 
on the ELISA platform(310))  for 20 minutes in one well with the second well treated with PBS, 
and acquired on the Magpix machine. As before, the beads performed normally, with beads only 
detected in their assigned bins and not in other non-assigned regions. Counts were comparable 
between the GuHCl treated and non-treated wells. These results supported the previous 
conclusion, suggesting that the GuHCl at 5M did not affect the beads' spectral or magnetic 
properties and hence did not affect bead region identification and recovery. 
5.4.3 Effect of GuHCl on the antigens coupled to beads  
Due to the chemical coupling of antigens to the microsphere and for the potential for the GuHCl 
to disrupt this link or damage the bound proteins, it was necessary to determine whether 5M 
GuHCl had an adverse effect on antigens coupled to beads, 20 samples including the positive 
control PP4 were assayed in duplicate.  The duplicate wells containing the coupled beads, 
including all the 18 antigens and TT in a multiplex, were incubated with either 5M GuHCl or 
PBS for 30 minutes. The beads were washed, and the assay was completed following the standard 
method previously described.  There was no difference in the MFI between the wells pre-treated 
with GuHCl and the wells treated with PBS (Figure 5.51a). There was a high positive correlation 
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between the paired wells (Figure 5.512b). This observation confirmed that GuHCl did not 
uncouple antigens from the beads or affect the coupled antigens' antibody-antibody binding 
properties. 
 
8 Figure 5.51a Graph showing MFI for samples tested using GuHCl-treated and untreated antigen 
coupled MagPix microsphere beads. A total of 20 samples were included in this experiment. The results 
are displayed per antigen. One set of the beads were pre-treated with 5M GuHCl for 30 minutes before 
performing the standard assay, and MFI was compared to untreated beads.  
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9 Figure5.51b Scatterplot is showing the correlation between GuHCl-treated and untreated antigen-
coupled MagPlex Microsphere beads.  Based on the combined data of 20 samples for all 18 antigens and 
TT. One of the paired wells was pre-treated with GuHCl, and the second one with PBS for 30 minutes 
and washed before plasma was added. r2 = 0.991, P<0.0001. 
 
5.4.4 Optimal GuHCl concentration and dissociation time 
To further test the avidity assay's performance in the presence of serum, 7 samples with wide-
ranging antibody responses across the antigen panel were selected based on the total IgG data.  
The GuHCl concentration was titrated at 1, 2, and 5M. All three concentrations resulted in the 
dissociation of antigen-specific bound antibodies.  The concentration of 2M was selected for use 
in the main assay due to its wider dynamic range than 5M in most antigens (Figure 5.52).   
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10 Figure 5.52. Dot plots of avidity index at three GuHCl concentrations. 8 plasma 
samples were included at 1/1000.  Concentrations 1M (red) and 2M (blue) had a wide dynamic range in 




To determine the optimal dissociation time, a total of 7 samples were included in a time-series 
experiment where GuHCl at 2M was added to a set of 6 wells per sample and incubated on a 
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shaking platform for 0, 10, 15, 20, 25, and 30 minutes. The assay was terminated as described 
above, and the samples were assayed and acquired on the MagPix machine as per the described 
methods. The avidity index was plotted against the incubation time for each of the samples 
(Figure 5.53).  
 
11 Figure 5.53. Representative graphs to show a change in the avidity index over 
incubation time. Antibody dissociation maximum at 2M GuHCl for 8 plasma at 1/1,000 was achieved 
at 15 minutes, beyond which there was no change in avidity index. 20 minutes incubation time was 
selected for the main assay to minimize inter-well and inter-plate  
 
Maximum dissociation was achieved at 15 minutes, beyond which there was no appreciable 
decrease in MFI or increase in avidity index (Figure 5.53). An incubation period of 20 minutes 
was selected for the main assay as optimal dissociation time. The 20 minutes optimal time would 
allow for differences of up to 5 minutes in timing within wells of the same plate during pipetting 
without affecting the avidity index. This implied that up to five minutes difference in the GuHCl 
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5.4.5 Heterogeneity in Avidity Index  
The avidity index was calculated as the percentage of the avid antibody (MFI with GuHCl) of 
the total (MFI without GuHCl). Only samples whose MFI without GuHCl was between 50 (1.69 
log 10) and 27,000 (4.43 log 10) (Figure 5.54a) were included in the analysis to allow detection 
of changes in MFI after dissociation at the low and high ends. Including all-time-points, there 
was a high heterogeneity in the antigen's avidity index, ranging from near zero to 100 (Figure 
5.54b). There was minimum or no correlation between avidity index total antibody except for 
AMA-1 (Spearman rho 0.67 p<0.0001), Rh2 (Spearman rho 0.51 p<0.0001), and TT (Spearman 
rho 0.67 p<0.0001).  There was a negative correlation between the avidity index and total 
antibody for antigens H103 (-0.39, p<0.0001) and MSP2-CH150/9 (-0.33, p<0.0001). The rest 
of the antigen spearman rho were below 0.28 (Figure 5.54b).  Furthermore, there was no apparent 
trend in avidity index or total antibody levels between iRBC antigens, merozoite surface 
antigens, or merozoite apical complex antigens.  There were differences in median avidity index 
across antigens without considering the antigens' size, protein folding, or epitope valence. Only 
three antigens, AMA-1, MSP1-19, and H103, had their avidity index above 50, similar to the 
non-malaria antigen TT. Some antigens such as Rh4.2, Rh5, SEA, and GLURP RII had their 
median avidity index below 20 (Figure5.54b).  At the individual level, there were trend patterns 
of avidity index across the time-points ranging from steady increase to steady decreasing with 
several patterns from time point to time point (Figure5.54c).  At the individual level, the avidity 
index to TT was relatively similar across time-points,  
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Figure 5.54a Scatter plot of Log10 MFI by antigens. MFI is representative of antibody levels 
measured by MagPix Luminex in a multiplex assay. All data from 4-time-points were included. The 
bars indicate the median and interquartile range. The dash lines indicate the data range (1.69 and 4.43 
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Figure 5.54b Scatter plot of avidity index by antigens. AI is the percentage of the avid 
antibody of the total measured by MagPix Luminex in a multiplex assay. All data from 4-time-points 
were included. The bars indicate the median and interquartile range. The red dash line is the 50-mark, 
and the black dash line the 20-mark. The bars indicate the median and interquartile range. The 
spearman rho shows the Spearman correlation between the avidity index and total antibody MFI. 
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14Figure 5.54c Avidity index of representative antigen for representative participants 
across time-points. T1 and T2 and 6 and 12 months before IRS. T3 and T4 are 6 and 12months after 
the first round of IRS, respectively. 
 
 
5.4.6 Decreased total antibody levels and Increased avidity index between 6 months 
before and 12 after IRS  
To test the hypothesis that reduction in malaria transmission results in increased avidity index 
due to contraction of SPLC that secrete non-avid antibodies, antibody levels were compared 
between T2 when malaria incidence was highest (6 ppy), 6 months before the introduction of 
IRS, and T4 when malaria incidence declined to near zero, 12 months after the first round of 
IRS. Median antibody levels significantly decreased across all malaria antigens (Figure5.55a). 
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Conversely, there was a significant net increase in median avidity index between T2 and T4 
across most blood-stage malaria antigens except for AMA1, Rh5, and GEXP18 (Figure5.55b). 
There were no noticeable trends across the infected red blood cell-associated antigens, merozoite 
apical complex, or merozoite surface antigens. There was no difference in TT's antibody levels 
and avidity index, the non-malaria positive control, between T2 and T4. Overall, these results 
imply that a dramatic reduction in malaria transmission intensity resulted in a general loss of 
antibodies against blood-stage malaria antigens and a general increased avidity index. The 
change in malaria transmission intensity did not affect antibody levels or avidity index of TT. 
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15 Figure 5.55a Comparison of median MFI between T2 and T4. Malaria incidence 
decreased from a peak of 6 episodes per person per year at T2 to near zero at T4 following the IRS 
introduction. MFI represents antibody levels measured by a MagPix Luminex multiplex assay for 18 
malaria blood-stage antigens and non-malaria TT control (in a box). Medians were compared using 
the nonparametric Mann-Whitney U test. P> 0.05 was considered significant and represented by *. 
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16 Figure 5.55b Comparison of median avidity index between T2 and T4. Malaria 
incidence decreased from a peak of 6 episodes per person per year at T2 to near zero at T4 following 
the IRS introduction, 6 months before T2, and 12 months after T4. The avidity index represents the 
percentage of avid antibodies of the total. Medians were compared using the nonparametric Mann-
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5.4.7 Increased avidity index was due to differential net loss in the total pool versus avid 
antibody at 6 months PRE and 12 post-IRS  
To try and understand the factors behind the difference in avidity index between the two-time-
points, changes in total and avid antibody levels were evaluated separately. There was a 
significant general reduction in the total antibody's medians across all antigens (Figure5.56). 
Similarly, there was a significant reduction in the medians of avid antibody levels in all the 
antigens except for MSP2-CH50/9 that increased.  HSP40Ag1, H101, and Hyp2 had a minimal 
decrease in the medians of their avid antibody pools between T2 and T4 (Figure5.56). There was 
no change observed in both the total and the TT's avid antibody levels, between T2 and T4 
(Figure5.56). Since the avid antibody pool was a component of the total, the differences in 
antibody reductions between the total and avid antibody pools were the indirect measure of the 
non-avid antibody pool.  In summary, these findings implied a reduction in both avid and non-
avid antibody pools between T2 when malaria transmission was highest and T4 when it reduced 
to near zero after the impact of IRS. However, the non-avid pool reduced at a greater magnitude 
than the avid, and this preferential loss of the non-avid antibody resulted in an increased avidity 
index. The net antibody reduction between the two-time-points was not observed in TT 
responses. The results agreed with the hypothesis that decreased malaria transmission resulted 
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17 Figure 5.56.  A plot of the net change in MFI between T2 and T4. Malaria incidence 
decreased from a peak of 6 episodes per person per year at T2 to near zero at T4. Log10 MFI is the 
difference in log antibody levels between T2 and T4. The data is represented as the median with 95% CI. 
The horizontal line represents zero.  Below the line is a loss, and above again in antibody levels between 
T2 and T4. Overlapping the zero line is a non-significant difference (p value>0.05). The analysis 
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5.4.8 Avidity index was positively associated with prior malaria infection  
All 4 time-points were included in the GEE to determine the association of avidity index and 
recent infection. The GEE fitted repeated avidity index measures of individuals in a regression 
model to determine linear relationships between avidity index and days since P. falciparum 
infection or the proportion of months free of P. falciparum infection the last 12 months. The 
analysis model included adjustment for age categories 1-4 years, 5-11 years, and above 18 years. 
Infection included both microscopic positive and sub-microscopic positive (LAMP+).  
  In general, there was a significant increase in avidity index associated with days since infection 
(Figure 5.57a). The strongest significant positive association was observed in antigens like 
SBP1, MSP2-Dd2, HSP40Ag1 (Figure 5.57a). Take an example, the coef of SBP1 0.06 (0.05 – 
0.07), the result implied that increase on avidity index by 6.0% (5.0 – 7.0) was independently 
associated with 100 days since last P. falciparum infection. Some antigens like Rh5, Rh2-2030, 
and AMA-1 did not show significant associations but maintained a similar positive trend.  
 Similarly, avidity index was positively associated with the proportion of months free P. 
falciparum infection in the last 12 months, another measure of recent infection, ranging from a 
large significant association in antigens like SBP1, MSP2 Dd2 HSP40Ag1 to antigens with no 
significant association like Rh5, Rh2, and AMA-1(Figure 5.57b). Take a similar example of 
SBP1 coef of 26.2 (18.9 – 33.4), and the result implied that an increase in avidity index by 26.2% 
(95% CI; 18.9 – 33.4) was associated with every month free of infection in the last 12 months. 
Antigens with the largest differences in antibody changes between total and high avidity 
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antibody pool had the largest coef in the avidity index.  There was no observed association 
between avidity index to TT and prior P. falciparum infection. 
 
18 Figure 5.57a Association of avidity index with days since parasitemia adjusted for 
age. The Coaf  (diamonds) and 95% CI (bars)  represents a change in the avidity index every day since 
the last infection. Below the zero red line is a net loss, and above is a net gain in the avidity index 
associated with days since the last infection. Confidence interval overlapping with zero (red dash line) 
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19 Figure 5.57b Association of avidity index with the proportion of months free of 
infection in the last 12 months, adjusted for age. The Coaf  (diamonds) and 95% CI 
(bars)  represent the change in the avidity index with the proportion of months free of infection.  
Below the zero red dash line is a net loss, and above is a net gain n. The confidence interval 
overlapping with zero is statistically non-significant.   The analysis included 160 
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5.4.9 Total and avid antibody levels inversely associated with prior malaria infection   
Overall, there was a significant inverse association of total antibody levels associated with days 
since infection across all the P.falciparum antigens from the GEE analysis modal. The highest 
coef was observed in GLURPRII and lowest in MSP2_CH150 (Figure 5.58a).  Similarly, there 
was a significant inverse association between avid antibody levels with days since infection.  The 
inverse association with days since P. falciparum infection was more pronounced in total than 
the avid antibodies in all P. falciparum antigens. There was an exception for antigens, AMA1, 
and Rh4.2, whose coef of total and avid antibody were largely overlapping (Figure 5.58a). 
Similar trends of an inverse association of the total and the avid antibody with a proportion of 
months free of infection in the last 12 months were observed, as shown in (Figure 5.58b). There 
was no association for total and high avidity antibodies, with days since the last infection, in TT.  
Taken together, these observations implied that the loss of antibodies observed independent of 
age was associated with days since the last infection or with the proportion of months free of 
infection in the last 12 months. The antibodies lost were mainly from the non-avid than avid 
antibody pools. The observations supported the hypothesis that the increased avidity index 
associated with prior infection was due to the differences in antibody decay rates of the avid 
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20 Figure 5.58a Association of Log10MFI with Days since parasitemia. Coaf and 95% CI of 
the total (red), and the avid antibody (blue). Below the zero line is a net loss, and above is a net gain in 
antibody levels associated with days since the last infection. The confidence interval overlapping with 
zero is statistically non-significant.   The analysis included 160 participants at 4 time-points.  
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 21 Figure 5.58b Association of MFI with the proportion of months free of infection in 
the last 12 months.  Coef represents the change in MFI associated with every month free of 
infection. The error bars indicate 95% CI.  Below the zero line is a net loss. Above is a net avidity index 
in antibody levels associated with the proportion of months free of infection in the last 12 months. The 
confidence interval overlapping with zero is statistically non-significant.   The analysis included 160 
participants at 4 time-points.  
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5.50 Changes in avidity index with Age 
Age categories 1-4, 5 – 11, and above 18 years were fitted in a generalized estimation equation 
to determine the association of age with total and avid and avidity index.  The model was adjusted 
for days since parasite infection, and 1 – 4 years was the reference age category. 
Overall, relative to 1- 4 years, both total and avid antibody levels significantly increased in the 
above 18 years age category, in association with days since the last infection, in all the malaria 
antigens. There was minimal change between under 5 and the 5 – 11 age categories (Figure 
5.59a). The magnitude of association with age varied between the total and the avid antibody 
pools. In some antigens, the total coefficient was higher than the avid pools' coefficient, and in 
some other antigens, the total was lower than the avid pool. In some antigens, the magnitudes 
were similar for both total and high avidity. (Figure 5.59a) 
 There was high heterogeneity in high avidity index association with age independent of days 
since the last infection.   In some antigens, age was positively associated with an avidity index 
with significant association observed above 18 years relative to 1 – 4 years. In other antigens, 
age was inversely associated with an avidity index with significant association observed above 
18 years relative to 1 - 4 years. Yet, in some antigens, age was not associated with the avidity 
index. All observations taken together, the data implied that both the total and high avidity 
antibody pools expanded gradually with age, and significant differences only apparent in the 
adults relative to the 1 – 4 years. However, the two antibody pools expanded at different rates in 
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the different antigens. The deferential expansion of the non-avid versus avid pools resulted in 
the high heterogeneity associated with age with an avidity index. (Figures 5.59b-d) 
22 Figure 5.59a Association of avidity index with age.  GEE model adjusted for days 
since the last infection, 1-4 years was reference age. The zero line (dotted line) is a change in 
avidity index as age transition from 1-4 years.  Coef and 95%CI represent the change in the avidity 
index relative to 1-4 years.   Overlap with the confidence interval with zero red line is not a significant 
change in the avidity index relative to 1-4yrs. A total of 160 participants in 3 age groups at 4 time-
points were included in the analysis.  
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23 Figure 5.59b-d Association of the total and the avid antibody with age category in a 
GEE model adjusted for days since the last infection. Age 1-4 years was the reference. The 
zero (dotted line) difference is in antibody levels as age transition from 1-4 years.  Overlap coef and 
95% CI overlap with zero is not a significant change in avidity index relative to 1-4years. A total of 160 
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5.6.1 Results summary 
This study is thought to understand the effect of reducing P. falciparum transmission intensity 
on malaria blood-stage-specific antibody avidity. Measurement of the avidity index was adopted 
and optimized on the MagPix Luminex multiplex platform to simultaneously measure 18 malaria 
blood-stage antigens' avidity index. To our knowledge, this is the first for such a description of 
a multiplex avidity assay, which allows the simultaneous evaluation of the IgG avidity index of 
a large panel of P. falciparum antigens.  
For the first time, I demonstrated in a simple yet informative approach two anti-malarial antibody 
pools, the avid and the non-avid, that had differences in decay rates in the absence of infection 
and acquisition rates with age. The avid antibody pool was the antibody that remained binding 
to an antigen after the GuHCl dissociation treatment step.  The non-avid antibody pool was 
indirectly inferred by comparing the differences between total and avid antibody pools. Since 
the avid antibody pool was a subset of the total, any differences between the total and the avid 
pools were attributed to the non-avid antibody pool. Looking at changes in avid antibody pool 
and total antibody and not just avidity index provided additional insight into the effect of malaria 
infection on antibody acquisition and maintenance in the absence of infection. The avid and non-
avid pools were of different relative compositions within antigens, decayed at different rates 
associated with days since the last infection, and gradually acquainted to varying ages within the 
different antigens.  
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The results showed that when IRS reduced malaria transmission, there was a net loss of both 
non-avid and avid pools of antibodies specific to malaria blood-stage antigens independently 
associated with days since the last infection duration free of disease within 12 months. Compared 
to the avid antibody pool, the preferential loss of the non-avid antibody pool resulted in an 
increased avidity index that was independently associated with time since the last infection or 
duration free of infection in the previous 12 months. Increased avidity index following a 
reduction in infection is consistent with previous findings in malaria infection (311), other 
infections (177,187,312), and vaccination boosts (284,284,313). 
Furthermore, the results showed that both the non-avid and avid antibody pools expanded 
gradually with age.  However, the two antibody pools expanded at different rates in the different 
P. falciparum blood-stage antigens resulting in either increased or decreased or no change in 
avidity index with age, consistent with our previous finding in malaria infection(272,310,314). 
5.6.2 Rapid decay of non-avid antibody pool is due to rapid contraction of SLPC in the 
absence of infection  
There are potential but not exclusive explanations to the observations of distinctive avid and 
non-avid antibody pool composition, and their decay rates associated with days since last 
infection or proportion of months free of infection, and acquisition with age.  
 LLPC produces the avid antibody pool and late germinal center class-switched typical MBC 
that have acquired extensive somatic mutation and affinity selection. On the other hand, the non-
150 
  
Chapter 5:  Antibody Avidity during high P. falciparum Transmission and near Zero Transmission  
 
P. falciparum Transmission Intensity and the Quality of Antimalarial Antibodies                                                            Isaac Ssewanyana 
 
 
avid antibody pool is produced mainly by SLPC from the T-independent extra-follicular reaction 
or the early stages and or impaired germinal center reaction output.  
High avidity index is a result of affinity maturation, a function of somatic mutations, and positive 
selection for high affinity during the germinal center reaction (198,202,315,316). LLPC is the 
terminal output of the temporally ordered germinal center, and residents in the bone marrow 
were maintained for a long time and continuously secrete high-affinity antibodies (317,318).  
LLPC mainly maintains circulating antibody levels long after clearance of infection, hence the 
slower decay rate associated with days since the last infection. On the other hand, SLPC is either 
derived from T-independent B-cell reaction or early germinal center MBC with minimal isotope 
switching and limited somatic hyper-mutations (319). SLPC resides in secondary lymphoid tissue 
and is programmed for mass production of antibodies and short life. To maintain a pool of SLPC 
requires constant production of new ones from continuous B cell activation in response to active 
or chronic infection. Elimination of infection results in the termination of B cell reaction and the 
rapid contraction of the SLPC hence the fast decay rate of non-avid antibody pool associated 
with days since the last infection or the proportion of months free of infection.  Alternative source 
of SLPC is the early output of the germinal center or impaired germinal center that has undergone 
minimal or no somatic mutation and therefore resulting mostly into lower affinity maturation. A 
proportion of the SLPC may be of high avidity intrinsically or from affinity matured MBC and 
these may contribute to the decay of the avid pool in absence of infection. Figure 5.10 
summarizes the dynamics of the B cell population contribution to the antibody pool during 
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infection and in absence of infection.  The chances in the activity of the B cell populations lead 
to changes in avidity index as a result of changes in the relative composition of the avid and the 
non-avid pools.   
 
24 Figure 5.510 Summary of the B cell reaction demonstrating the potential cause of low 
avidity index during chromic infection and high avidity index in the absence of infection.  
The T-independent extra-follicular B cells reaction and early GC reaction result in SLPC that produce 
non-avid antibodies. On the other hand, the LLPC from the late GC output produces avid antibodies. In 
the absence of infection, the SLPC population rapidly contract, and the non-avid antibody pool decays 
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5.6.3 P. falciparum infection promotes the expansion of predominantly SLPC that result 
in short-lived responses  
The median avidity index within malaria antigens was below 50% for all antigens except for 
AMA-1, H103, and MSP1-19 at 2M GuHCl. Although there were individual participants with 
high avidity index per antigen, implying that a large proportion of their antibodies are of the avid 
pool, most individuals were categorized to have non-avid antibodies. This observation may 
imply that most participants had SLPC driven antibody responses predominantly or that many 
LLPC is also non-avid. The differential expansion of both the avid and non-avid antibody pools 
with age may imply relative accumulation of both the high-affinity LLPC and low-affinity MBC 
that rapidly differentiate into SLLC. Even in the classic germinal center function where somatic 
hypermutations and positive selection for affinity occurs, antigenic variation may limit the 
expansion of the avid antibody pool.  Significant loss of P. falciparum-specific antibody titers, 
mostly in children, has been reported in populations in the absence of infection (314,320,321). 
Most recent advances in microarray assay that allow simultaneous probing of many malaria 
antigens reveal a significant loss in the breadth of response to malaria antigens in the absence of 
age-dependent infection, implying inefficient acquisition of  LLPC (255).   On the other hand, 
MBC is reported to be more stably maintained in the absence of infection (322,323). This 
disproportionate acquisition of the memory compartments may contribute to the heterogeneity 
153 
  
Chapter 5:  Antibody Avidity during high P. falciparum Transmission and near Zero Transmission  
 
P. falciparum Transmission Intensity and the Quality of Antimalarial Antibodies                                                            Isaac Ssewanyana 
 
 
in expanding the avid antibody pool and the slow acquisition of immunity to malaria.  Therefore, 
measuring the avid antibody pool in relation to malaria-specific MBC phenotypes may provide 
further insight into memory acquisition and serve as a biomarker of vaccine efficacy. Secondly, 
understanding the mechanisms that drive responses towards the avid antibody pool will inform 
better vaccine design. 
The presence of a low avidity index may not imply that antibodies are not functional. However, 
based on the thermodynamic principle, high titers of non-avid antibodies may be required to 
mediate function compared to avid. Therefore, the observation of predominantly non-avid 
antibodies may imply the requirement of very high antibody titers to achieve antibody-mediated 
protection from malaria as previously observed (324,325).  
5.6.4 Intrinsic antigen properties may affect affinity maturation and antigen suitability 
for use in vaccine designs 
There were differences in avidity index among the P. falciparum antigens. The differences could 
be due to the properties that can affect the number of epitopes, including size, protein folding, 
and conformation. However, the differences between avidity indexes among antigens could as 
well be due to other intrinsic properties. An example is GLURP RII, which is highly 
immunogenic, yet it had a very low avidity index. The poor avidity may be attributed to the 
glutamine repeat, affecting the diversity of binding forces. In such a case, there can be few 
binding options against which affinity can be selected. Rh5, a promising vaccine candidate, is 
another example of an antigen where the avid pool did not expand with age.  Failure to induce 
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avid antibodies may indicate short-lived protection that has already been reported in other 
vaccine candidates like irradiated sporozoite and controlled human malaria infection (CHMI). 
CSP based RTS, S vaccine trials (139,285). Low avidity index was shown to define failure to 
acquire long term immunity in other infections like Mumps and Vibrio cholerae (182,185).   
Therefore, understanding the mechanisms that drive the acquisition of an avid antibody pool may 
improve our understanding of the acquisition of long-term protective immunity and the design 
of better vaccines.  
5.6.5 Limitations 
The study was limited because different GuHCl concentrations can result in different avidity 
index. Therefore, the concentration that is relevant to the antibodies' physiological properties is 
not known. There is likely a wide spectrum of affinities for antibodies to the same epitope that 
is not shown by using one GuHCl concentration. Therefore, the designation of avid and non-
avid is an overly simplistic though still useful way of categorizing responses. Because treatment 
was only for symptomatic malaria as per the Uganda guideline for the standard of care, the period 
post-IRS was not long enough to allow most chronically parasitemic participants to clear the 
infection. Days since parasitemia, especially for time-points T1-3, were mainly from participants 
who were treated for malaria. We included very few symptomatic infection cases, and yet the 
kinetics of participants with frequent symptomatic infections may differ from those who were 
chronically infected. It is also important to note that the single sequence of the recombinant 
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proteins used in the in vitro assay may not reflect the true in vivo responses to parasites with 
multiple variable antigen sequences.   
The MFI is reflective of antibody concentration in the linear zone on the saturation curve. At the 
saturation curve's plateau, antibody concentration differences can not be detected due to the 
maximum MFI limit. The same limitation applies to the measurement of the avidity index. A 
large dissociation may not be detected in MFI changes.  I used a high plasma dilution factor of 
1/1000 to minimize the high antibody concentrations that fall under the curve’s plateau for this 
work.  
The avidity assay on the Luminex platform was based on the long-standing ELISA assay. The 
assay was not validated against the ‘gold standard’ surface plasmon resonance (SPR) because of 
the two techniques' fundamental differences. SPR measures the average dissociation constant 
(Kd) of antibodies, including the low/medium affinity antibodies. In contrast, the chaotropic 
based method measures the proportion of the high-affinity antibodies that resist dissociation. 
Reddy et al. and Kimudu et al. did not find an association between the Kd from SPR and the 
avidity index from the chaotropic method suggesting that the two methods likely measured 
different antibody affinity (270,326). I did not have the budget or ready access to the platform to 
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This study demonstrated two malaria antibody pools distinguished by their avidity, decay rates 
in the absence of infection, and acquisition rate with age. The avid and non-avid composition 
that defines the avidity index was highly heterogynous among individuals and across antigens. 
 Based on these results, I hypothesize that the avid antibody pool is produced primarily by 
LLPC and the non-avid primarily by the SLPC. Therefore, it is critical to understand the 
mechanisms that drive the acquisition and maintenance of the avid antibody titers above the 
protective threshold and the design of better vaccines that induce long-term protection.    
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As part of my Ph.D., I performed all the laboratory experiments and data analysis in this chapter. 
The PRISM study conducted the longitudinal cohort where samples for this chapter were 
obtained. Lindsay Wu normalized the Luminex data (Chapter 3, section3.3) after I completed 
the experiments. I used the normalized data for the analysis. Isabel Rodrigez provided the R 
script I used to produce the antibody decay curves in figure 6-52. 
Differences in the half-life of P. falciparum antigen-specific IgG subclasses are 
associated with age following interruption of exposure by IRS. 
  
6.1 Introduction  
6.1.1 Malaria challenges in the pre-elimination era  
WHO malaria elimination strategy calls for a reduction in malaria mortality rates by 40% and 
90% by 2020 and 2030, respectively, compared to 2015 before global elimination can be realized 
(327). Many countries have accelerated efforts towards implementing this strategy. As a result, 
several of them are transitioning from high to medium or low malaria transmission through 
vector control, active case identification, treatment, and tracking index cases (27). As 
transmission reduces, timely identification of any form of new infections and not just malaria 
cases becomes difficult. Secondly, there is a risk of resurgent epidemics in non-immune 
populations, especially when control measures are relaxed before elimination is achieved (328–
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330). Therefore, surveillance tools for the early detection of new infections or transmission foci 
to inform directed interventions become critical. Furthermore, vaccinations to boost population 
immunity will be critical elements to sustain malaria elimination gains, especially in endemic 
regions where countries or areas within a country will progress at different rates. Serological 
tools are promising surveillance tools due to their low cost and ease of application in remote 
settings (274,331,332). However, a better understanding of the properties of the antibody 
responses measured to the different P.falciparum antigens is required to improve both the design 
and malaria serology products' efficacy. 
Furthermore, the RTS, S vaccine (Mosquirix™), the only malaria vaccine to have progressed to 
phase three clinical trials, did not yield the desired level of efficacy (139,248,333), and correlates 
of the short-lived protection observed are poorly understood (334–337).  
6.1.2 Role of anti-malarial IgG antibodies in immunity to malaria 
 In high transmission settings, severe malaria cases are concentrated in children generally under 
5 years, who gradually become less susceptible to disease despite chronic infection with high 
parasite densities compared to adults (209). The adults rarely get symptomatic but continue to 
acquire and sustain very low parasite densities for long periods, most times, sub-microscopic 
infection (53,338,339). This epidemiological observation of the different malaria immunity 
phenotypes supports the held idea that the acquisition of immunity to malaria is slow and is 
rarely, if at all, sterile (338,340). IgG is the most abundant antibody isotype and the major 
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contributor to acquired immunity to infections including malaria (138,341). Using purified IgG 
from malaria exposed adults, the malaria-ridden recipients recovered from fever and greatly 
reduce the parasite load (138). Based on these observations, the last 50 years have been a race for 
a humoral immunity-based vaccine. Studies investigated malaria-specific IgG responses either 
as markers of exposure (331,342,343), correlates of protection or risk of infection (344,345).  
6.1.3 IgG subclasses can influence the outcome of immunity to infections 
There are four subclasses: IgG1, IgG2, IgG3, and IgG4 (IgG1-4) that have differences in their 
constant region (Fc), particularly in their hinges and upper CH2 domains (165,346). The structural 
differences in IgG subclasses govern their longevity in circulation, translocation across mucosal 
sites, placental transfer, and effector functional properties.  
The IgG subclasses have different affinities to the different variants of Fc gamma receptors 
(FcR; FcγRI, FcγRII, and FcγRIII) that are expressed on B cells, the different innate effector 
cells as well as the complement activators C1q (165). The differential interaction of IgG 
subclasses with the Fcγ receptors and C1q, which act as adapters between the acquired immunity 
and the innate effector mechanism, influence their functional outcome. 
IgG1 and IgG3 are referred to as cytophilic antibodies because of their high affinity for activating 
Fcγ receptors that are expressed on monocytes, macrophages, neutrophils, and natural killer 
cells(347). As a result, they mediate effector mechanisms such as phagocytosis (152,348), 
antibody-dependent cellular inhibition (ADCI), and direct parasite killing by effector cells (349). 
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The cytophilic subclasses also have a high affinity for C1q, a component of the complement 
system that initiates activation of the classical pathway, which results in the assembly of the 
membrane attack complex and complement-mediated phagocytosis (350).  
IgG2 is commonly induced against polysaccharide antigens known to play a critical role in 
immunity to bacterial and viral infections (351). IgG2 is important in immunity to encapsulated 
bacterial infections. Deficiency of IgG2 has been associated with susceptibility to some bacterial 
infections (352,353).  
IgG4 subclass is mainly associated with immune-modulatory mechanisms and is known as a 
regulatory antibody due to its ability to modulate the allergic and inflammatory responses 
mediated by IgE. IgG4 is also reported to be associated with protection from autoimmune 
diseases (354). IgG4 has the poorest affinity for Cq1 and activator Fc receptors compared to 
other subclasses. Instead, IgG4 has a relatively better affinity for the inhibitory Fc receptors, an 
important feature of IgG4 that contributes to its low inflammatory capacity (355). IgG4 has 
mainly been studied in allergy and worm infections, where it is shown to alleviate IgE's 
inflammatory effect (356,357). An increase in the tolerance to bee stings by beekeepers was 
associated with elevated levels of IgG4 (358) 
The effector functions IgG1 and IgG3 have been elegantly demonstrated in vitro assay and 
correlated with immunity.  But very little is known about the role of IgG2 and IgG4 in malaria 
immunity or immune dysfunction.  
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6.14 IgG subclasses, placental transfer, glycosylation and longevity in circulation  
IgG subclasses have different affinities to the neonatal Fc receptor (FcRn) in the acidic endocytic 
vacuole that protects antibodies from degradation and modify their decay half-life and mediate 
placental and gut translocation of maternal antibodies (170,359).  
Recent studies in autoimmunity and allergy mediated disease indicate that glycosylation of the 
Fc region of the IgG subclasses further modify affinities to their receptors and hence their 
stability and function (360,361). In HIV, IgG glycosylation is associated with Fc mediated 
reduction in viral replication and the abnormal glycosylation associated with chronic infection 
(362,363). IgG glycosylation was observed in influenza and tetanus toxoid vaccinations (364). 
However, there is limited knowledge about glycosylation in malaria-specific antibodies and their 
influence on function. 
6.1.5 Evidence IgG subclasses in the immunity to malaria  
The importance of IgG subclasses has been demonstrated in several infections. Many immuno-
epidemiology studies have shown a positive association between levels of cytophilic antibodies, 
IgG1 and IgG3, with naturally acquired immunity (126,128,314,365–368). High IgG2 and low 
IgG4 response to the ring-stage infected erythrocyte surface antigen and the MSP2 alleles were 
associated with reduced infection risk. But this was in individuals possessing the H131 allele of 
FcγRII that has a high affinity for IgG2 (351). In Cameron, high levels of anti-schizont extract 
IgG2 were associated with reduced P. falciparum infection risk in infants below 2 months of age 
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(369). However, in-vitro functional assays have implicated interference of IgG4 in the opsonizing 
function of IgG1and IgG3 in competition assay (301).  The role of IgG2 and IgG4 in the 
protection against malaria is limited and, as such, poorly understood. 
It is also possible that IgG subclasses' relative composition or ratio can affect the immune 
response's protective outcome. In a Kenyan cohort, high levels of IgG1 antibodies related to 
IgG2 and IgG4 were associated with protection from severe malaria. In contrast, high IgG2 to 
IgG1 ratio and IgG3 antibodies were associated with a higher risk of developing severe malaria 
(370). But this kind of IgG subclass combination in immunity to malaria is not well studied and 
could provide more insight on the immunity and immune dysfunction in malaria. 
6.1.6 Evidence of differential malaria-specific IgG subclass switching  
IgG subclasses result from B-cell secondary response to infection mainly in T-dependent 
response in germinal center reaction (202,371,372) and to a lesser extent during extrafollicular T-
independent B cell reaction (319). Antigens are thought to play a role in influencing subclass 
switching profiles. Inflammatory and regulatory cytokines and innate signaling have been 
suggested to influence class switching (204,373). Malaria antigens induce mainly IgG1, and 
IgG3, which can skew towards either IgG1 (AMA-1) or IgG3 (MSP2) or co-dominant, like in 
the case of MSP1-19 (374).   
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6.2 Rationale and aim 
IgG class switching is a function of the germinal center reaction similar to affinity maturation, 
and the germinal center reaction is susceptible to interruption by P. falciparum infection. In 
Chapter 5, we observed preferential expansion of non-avid antibodies that resulted in a low 
avidity index during high malaria transmission intensity that rapidly contracted when the IRS 
implementation interrupted transmission.  However, we do not fully understand the effect of 
chronic P. falciparum infection on IgG subclasses' acquisition and maintenance. Assessment of 
longitudinal antimalarial antibody subclass responses during high malaria transmission and after 
the drastic reduction of transmission using highly effective intervention like IRS provides a 
unique opportunity to gain some insight into how IgG subclasses are acquired maintained. 
Several studies have looked at a few malaria antigens, mainly in cross-sectional studies. The few 
studies have limited our ability to understand the broader picture of the IgG subclasses' dynamics 
with age and exposure changes. Furthermore, understanding the IgG subclasses' kinetics to a 
large panel of P. falciparum antigens during chronic or near-constant exposure to infection and 
in the absence of infection can improve our knowledge on how to improve serological diagnostic 
and surveillance tools. 
This chapter explored a large panel of (18) blood-stage P. falciparum antigens to provide a 
broader insight into specific IgG subclasses' acquisition and maintenance. Antigen-specific total 
IgG and subclasses 1-4 were evaluated on the MagPix (Luminex) multiplex assay, including 18 
recombinant antigens from the malaria blood-stage antigens described in Chapter 3, section 3.21. 
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Plasma samples from 160 participants from the PRISM cohort at 4 time-points; two before 
introducing the IRS and two time-points after introducing the IRS, were assayed (Figure 3.3). 
The IRS introduction offered us a unique opportunity to investigate the effect of a reduction in 
P. falciparum infection to the naturally acquired IgG subclass antibody responses following one 
year of IRS on a broad panel of malaria blood-stage antigens. Total IgG and subclasses antibody 
decay half-lives were estimated and compared. The total IgG and subclasses' sensitivity and 
specificity were compared to determine their potential utilization to improve serological 
diagnostic tool performance to measure recent infection exposure. 
6.3 Methods  
 
6.3 1 Study population and description of PRISM cohort at Nagongera  
In this study, 160 participants enrolled in longitudinal PRISM were included. The participants 
include all children with plasma stored at the four study periods and 20% adults. The participants 
belonged to age categories 1-4 years (40), 5 – 11 years (92), and above 18 years (28). The first 
IRS determined the study period.  For each participant, 4 time-points were included; two pre-
IRS time-points (T1&2) were taken 12 and 6 months before the first round of IRS and T3 and 
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6.3.2 Ethical consideration 
Ethical approval was obtained from the Makerere University School of Medicine Research and 
Ethics Committee (REC REF 2011-203), the Uganda National Council for Science and 
Technology (HS 1074), the LSHTM ethics committee (reference # 6012), and the University of 
California, San Francisco Committee on Human Research (reference 027911). 
Before enrolment into the study, written informed consent was obtained from adult 
parents/guardians of children, and assent from children aged 8 years and older; informed Re-
consent was obtained when enhanced surveillance monthly sampling in participants was 
introduced.  
6.3.3 Luminex Multiplex bead array assay to measure Total IgG 
Total IgG responses to 18 P. falciparum blood-stage antigens and non-malaria positive control 
TT  was measured in plasma diluted at 1/1000 on the MagPix (Luminex Corp, Austin, Texas) 
multiplex bead assay described in Chapter 3 and as previously described elsewhere (234).  
6.3.4 Luminex Multiplex bead array assay to measure IgG1 - 4 
 IgG subclass antibody responses to 18 P. falciparum blood-stage antigens and TT were 
measured in plasma diluted at 1/100 on the Luminex MagPix multiplex platform and detected 
using a two-step biotinylated anti-human IgG subclass secondary antibody and streptavidin- 
phycoerythrin tertiary as previously described (235,236). Each of the IgG subclasses was assayed 
separately for every sample using the same plate layout described in Chapter 3.  
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The read on a Luminex MagPix, after acquiring at least 100 beads/region/ was the median MFI. 
The blank well MFI was deducted from each well to determine the net MFI. Net MFI was 
representative of relative antibody concentration. 
6.3.5 Statistical analysis  
The association between antibody levels (MFI) for total IgG and the subclasses 1 - 4 with days 
since infection were assessed in a generalized estimating equation (GEE) model, adjusted for 
age (375). The GEE allowed estimation of the mean effect of days since the last infection on 
antibody levels using repeated measures per individual at a population level. All four time-points 
were included in the GEE model. Infections were defined as parasite positive if the sample was 
microscopy positive (patent infections) or LAMP+. The GEE model outcomes were regression 
coefficient and 95% confidence intervals (95%CI). Estimated antibody decay half-life was 
derived from the GEE model's coefficient of antibody levels with days since infection (log 
antibody loss per day since infection) by dividing log10 of 2 by coefficient. The result was the 
number of days it takes to lose half the antibody levels since the last day of infection. This half-
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Association between antibody levels for both total and the IgG1 - 4 subclasses with the following 
age categories, 1- 4, 5 -11, and above 18 years, were assessed GEE model and adjusted for days 
since infection. Age category 1- 4 years was the reference, and the outcome was coefficient and 
95% confidence interval (log10 change in antibody levels when transitioning from age categories 
1-4 to 5-11 or above 18 years). 
Comparison of the medians was non-parametric Mann-Whitney T-test. A P-value below 0.05 
was considered a significant difference in medians. 
The sensitivity (true positive) and 100 - specificity (false positive) were determined by the 
receiver operating characteristic curve (ROC) (376,377). Samples were scored as positive if they 
had at least one infection in the last 90 or 180 days or negative if there was no infection in the 
last 90 or 180 days. The outcome was presented as the area under the curve (AUC) and 95%CI. 
Analysis and Figures were performed with Stata version 14 (StataCorp LLC, USA), GraphPad 
Prism version 7 (Graphpad Software Inc, USA), and R studio. Changes and associations were 
considered statically significant when 95% confidence intervals did not overlap zero or P-values 
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6.4 Results  
6.4.1 Relative responses of total and IgG subclasses  
Antibody responses were detected to all 18 P. falciparum antigens to all 4 IgG subclasses. 
Overall, there was a wide dynamic range in all IgG subclasses responses from the negative 
response towards maximum detection Log10 MFI of 4.61 (~ 40,700 MFI) towards the assay's 
saturation limit. Total IgG was tested at a higher dilution of 1/1,000 compared to the IgG 
subclasses at 1/100, but total IgG had higher Log10 MFI than the subclasses (Figure 6.51a - c). 
Although not directly comparable, the median responses were predominantly higher in IgG3 
than the other subclasses in the respective antigens. The exception to this was in AMA1 and Rh2, 
where median responses were higher in IgG1 compared to IgG3 (Figure 6.51b). Maximum 
detectable magnitude of responses in IgG3 was observed in many of the antigens, for example, 
ETRAMP4 Ag2, ETRAMP5 Ag1, EBA140 RIII-V, MSP2 Dd2, and MSP2 CH150/9, where all 
IgG subclass responses were low (Figure 6.51c).  
In general, IgG1 responses were moderate compared to IgG3 in most antigens. The medium log10 
MFI responses were lowest in both IgG2 and IgG4 across all antigens. Still, their maximum 
responses were reaching the maximum detection limit in some antigens like in ETRAMP5Ag1, 
EBA175 RIII-V, GLURP RII, and MSP1-19 (Figure 6.52a - c). 
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There were no noticeable response patterns in different antigen categories of infected red blood 
cells, merozoite apical complex, and merozoite surface antigens (Figure 6.51a-c).  
The observations taken together indicated that the assay conditions were adequate for detecting 
the response across the method's maximum dynamic range. The relatively higher reactivity of 
total IgG than the subclasses can be attributed to the secondary goat anti-human IgG polyclonal 
nature compared to the monoclonal anti-human IgG subclasses. In addition, the differences in 
reactivity between total IgG and the subclasses could be the competition for identical epitopes 
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Figure 6.51a&b. Dot Plot of log10  MFI for by malaria blood-stage antigens categories 
Antibody levels were measured using a MagPix (Luminex) multiplex assay including 18 P. falciparum 
blood-stage antigens and TT. Each dot represents a single sample from 160 participants at 4 time-points. 
The horizontal bar represents the median and 95% CI. (a) Infected red blood cell antigens, (b) Merozoite 
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25 Figure 6.5c. Dot Plot of log10MFI of Merozoite apical complex. Antibody levels were 
measured using a MagPix (Luminex) multiplex assay, including 18 malaria blood-stage antigens and TT. 
Each dot represents a single sample from 160 participants at 4 time-points. The horizontal bar represents 
the median and 95% CI.  
 
 
When the data were fitted in gam plots (Figure 6.52) for MFI responses against days since the 
last infection, all antigens showed a clear decline in antibody responses. All antigens except for 
AMA1 and Rh2 showed IgG3 predominance, and the difference between IgG3 and IgG1 
narrowed with days since the last infection. GLURP RII showed relatively co-dominant 
responses across all 4 subclasses, compared to total IgG. In the longer days since the last 
infection, IgG1 and IgG3 overlapped, implying co-dominance of IgG1 and IgG3 in the absence 
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26 Figure 6.52. GAM plots of estimated best fit Log10MFI responses against days since 
the last infection. The black line represents mean and the colored bands 95%CI. 160 participants at 4 
time-points were included.  
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6.4.2 Association of total IgG and IgG subclasses responses with days since the last 
infection. 
In a GEE model to allow repeated measures per participant, including four time-points and 
adjusting for age category, total IgG and subclasses levels were inversely associated with days 
since the last infection in all the 19 antigens (Figure 6.53a-c). There were differences observed 
in the IgG subclasses' regression coef values that signified the differences in the magnitude of 
association with days since the last infection. The highest negative coefficient values were 
mainly IgG3 compared to total IgG and the other IgG subclasses, across all antigens (Figure 
6.53a-c). Within IgG3, responses against ETRAMP5 Ag1, EBA175 RIII-V, and MSP1-19 had 
the highest negative coefficient values. This observation implied that IgG3 to the P. falciparum 
blood-stage antigens, compared to the total IgG other IgG subclasses, decreased faster in 
association with days since the last infection the decreasing rates were highest in antigens; 
ETRAMP5Ag1, EBA175 RIII-V, and MSP1-19.  
Despite IgG1 levels being lower than IgG3 and much higher than IgG2 and IgG4 by comparing 
median Log10 MFI (Figures 6.51 and 6.52), IgG1 had the least negative coefficient values of the 
four subclasses in most antigens, tending towards or above zero. This observation was consistent 
in AMA-1 and Rh2, where IgG1 was the predominant subclass. This observation implied IgG1 
levels decreased slower than other subclasses in association with days since infection in all 
antigens. The subclass's predominant abundance status did not affect the slower rate of IgG1 
decrease in association with days since the last infection. 
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IgG2 and IgG4 levels were associated with days since the last infection was either weakly or not 
significantly inversely associated with days since the last infection (Figure 6.53a-c).  
Strikingly, GLURP RII had relatively high log10 MFI in IgG2 and IgG4 compared to other 
antigens (Figure 6.52), and the coefficient values were comparable in all the subclasses and total 
IgG. The observation implied that all IgG subclasses to GLURP RII decreased at the same rate 
in association with the last infection days.  
Tetanus toxoid (TT) was included as a non-malaria control, and as expected, there was no 
significant association between antibodies to TT and days since the last infections. 
In summary, these results indicated a reduction in antibody levels for total IgG and subclasses 
that were associated with days since the last P. falciparum infection independent of age, and the 
reductions were specific to antibodies against P. falciparum antigens. The rate of antibody 
reduction associated with days since the last infection was highest in IgG3 compared to other 
subclasses, even in antigens that were predominantly IgG1. GLURP RII was unique because it 
had co-dominance of all 4 subclasses that reduced at a relatively similar rate associated with days 
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Figure 6.53a&b Association of Log10 MFI with days since the last infection. Total IgG 
and IgG subclass was measured using MagPix( Luminex) multiplex assay including 18 P. falciparum 
blood-stage antigens and TT, including 160 participants at 12 and 5 months pre-IRS and 6 and 12 moths 
post-IRS. Malaria incidence decreased from 6ppy to near zero. Four time-points were fitted in the GEE 
model, adjusted for age. The lines show regression coefficient, median, and 95% CI of the total (black), 
IgG1 (red) IgG2 (green), IgG3 (blue), and IgG4 (grey). Infection was determined by microscopy+ or 
LAMP+. Below the zero lines is an inverse association, and above is a positive association. The 
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27 Figure 6.53c Association of MFI with days since the last infection. Total IgG and IgG 
subclass was measured using MagPix( Luminex) multiplex assay including 18 P. falciparum blood-
stage antigens and TT, including 160 participants at 12 and 5 months pre-IRS and 6 and 12 moths post-
IRS. Malaria incidence decreased from 6ppy to near zero. Four time-points were fitted in the GEE 
model, adjusted for age. The lines show regression coefficient, median, and 95% CI of the total (black), 
IgG1 (red) IgG2 (green), IgG3 (blue), and IgG4 (grey). Infection was determined by microscopy+ or 
LAMP+. Below the zero lines is an inverse association, and above is a positive association. The 
confidence interval overlapping with zero was statistically non-significant. 
 
6.4.3 Association of total IgG and IgG subclasses with age in the absence of infection  
To determine the relationship between antibody levels maintained in the absence of infection 
with age, median MFI for a total of 129 sample time-points was compared across three age 
categories of 1 -4 years (37), 5 – 11 years (57), and >18 years (40). 180 days without infection 
was the longest period where all age groups had representative samples. The period of 180 days 
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with no infection was thought to provide an approximate indication of the amount of antibody 
maintained in the absence of infection. Overall the median antibody levels maintained increased 
significantly from the young age category; 1- 4, 5 – 11, and > 18 years in all P. falciparum 
antigens (Figure 6.54).  
IgG1 was the dominant or co-dominant with IgG3 at 1- 4 years and 5-11 years in the absence 
after 180 days since the last infection (Figure 6.54). The trend reversed in adults >18 years, 
where the dominant subclass was IgG3. In antigens, AMA1, and Rh2, IgG1 was the dominant 
subclass in all age groups, including adults >18 years, despite an observed steady increase in 
IgG3 with age (Figure 6.54). 
In summary, these results indicated that malaria-specific IgG1 and IgG3 antibody levels that 
were maintained in the absence of infection in the last 180 days gradually increased with age in 
all 18 antigens. IgG1 was acquired at relatively faster rates at an early age, but the IgG3 pool 
was preferentially expanded faster than IgG1 in adults above18 years compared to 1- 4 years. 
There were exceptions with HSP40 Ag1, AMA-1, and Rh2, where the IgG1 pool remained 
dominant and preferentially expanded at 5-11 years of age relative to 1-4 years. 
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Figure 6.54a&b. Comparison of IgG1 and IgG3 across age categories. IgG1 and IgG3 of 129 samples 
from all time-points with no infection in at least 180 days were compared across age categories 1- 4, 5- 
11, and >18 years. Infection was defined as microscopy+ or LAMP+. The median log10MFI were 
compared between age groups in a non-parametric Mann Whitney test.  
P-value <0.05 was considered significant.  * = significant difference between MFI medians 1-4 and 5-
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28 Figure 6.54c. Log10 MFI IgG1 and IgG3 by age categories. IgG1 and IgG3 of 129 samples from all 
time-points with no infection in at least 180 days were compared across age categories 1- 4, 5- 11, and 
>18 years. Infection was defined as microscopy+ or LAMP+. The median log10MFI were compared 
between age groups in a non-parametric Mann Whitney test.  
P-value <0.05 was considered significant.  * = significant difference between of MFI medians 1-4 and 5-
11years or 1-4 and >18years.  # = significant difference of MFI medians between 5-11years and >18 
years. 
 
6.4.4 Differences in antibody half-life among IgG subclasses in the absence of infection. 
Antibody half-life was calculated from the regression coefficient values of the GEE model of 
log10 MFI and days since the last infection, adjusted for age categories of 0 – 4, 5 – 11, and >18 
years. The coefficient represented log10 antibody loss (for negative coefficient values) or gained 
(for positive coefficient values) each day after the last infection. The number of days to lose or 
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gain 50% of the antibody level after the infection was derived (section 6.35, Equation 2). The 
outcome was the population-level estimate of antibody decay half-life.  
In general, antibodies decayed since the last day of infection. The half-life for total IgG was 
different across the P. falciparum antigens, ranging between 57 days for ETRAMP5 Ag1 and 
148 days for SBP1(Table 6.55). IgG3 had the shortest half-life compared to total IgG and the 
other subclasses within all P. falciparum blood-stage antigens, including AMA-1 and Rh2 that 
were predominantly IgG1 (Figure 6.53 and Table 6.55). 
Among antigens that had the lowest decay half-life for IgG3 below 50 days included ETRAMP5 
Ag1 (mean; 41, 95% CI; 35 - 49), EBA175 RIII-V (mean: 44, 95% CI; 37 - 54), MSP1-19 (mean; 
44, 95% CI; 38 - 54).  
Other IgG subclasses 1, 2, and 4 had longer population-based estimated decay half-life above 
I00 days with very wide confidence intervals suggesting high heterogeneity in half-life over time 
since the last infection. 
Interestingly, GLURP RII antibody decay half-life was comparable across subclasses and means 
IgG1 (mean; 55, 95% CI; 45 – 66), IgG2 (mean; 55, 95% CI; 45 – 74), IgG3 (mean; 51, 95% CI; 
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 6 Table 6.55 Summary of population-based estimates of half-life 
Antigen Total IgG IgG1 IgG2 IgG3 IgG4 
HSP40 Ag 1 80 (67 - 97 ) 155 (97 - 385 ) 254 (168 - 515 ) 77 (63 - 97 ) 286 (161 - 1290 ) 
Etramp4 Ag2 92 (77 - 115 ) 310 (150 - -4770 ) 952 (266 - -605 ) 78 (61 - 109 ) -846 (326 - -184 ) 
Etramp5Ag1 57 (49 - 68 ) 115 (80 - 205 ) 124 (92 - 191 ) 41 (35 - 49 ) 203 (117 - 766 ) 
Hyp2 98 (81 - 122 ) -283 (-4547 - -146 ) -2945 (519 - -383 ) 104 (82 - 140 ) -651 (550 - -204 ) 
SBP1 148 (120 - 192 ) 352 (182 - 5337 ) 277 (183 - 569 ) 72 (60 - 92 ) 7640 (374 - -415 ) 
SEA1 136 (102 - 186 ) -524 (921 - -204 ) 266 (182 - 341 ) 85 (69 - 112 ) -2229 (352 - -341 ) 
AMA-1 95 (77 - 123 ) 83 (65 - 117 ) 245 (171 - 433 ) 65 (53 - 84 ) 854 (155 - -245 ) 
EBA140 RIII-V   86 (72 - 109 ) 170 (115 - 325 ) 998 (286 - -674 ) 61 (50 - 78 ) 1085 (211 - -347 ) 
EBA175 RIII-V   73 (62 - 87 ) 100 (77 - 139 ) 135 (98 - 214 ) 44 (37 - 54 ) 180 (100 - 910 ) 
EBA181 RIII-V   83 (68 - 107 ) 315 (154 - -6194 ) 419 (231 - 2243 ) 70 (56 - 92 ) 210 (121 - 815 ) 
Rh2  100 (82 - 127 ) 85 (68 - 116 ) 321 (209 - 690 ) 74 (60 - 95 ) 668 (150 - -274 ) 
Rh4.2 94 (78 - 121 ) 492 (202 - -1144 ) 589 (272 - -3545 ) 82 (64 - 114 ) -581 (513 - -185 ) 
Rh5 126 (101 - 168 ) -103 (-205 - -68 ) -1210 (466 - -263 ) 133 (86 - 301 ) 882 (227 - -470 ) 
GLURP RII 64 (55 - 77 ) 53 (44 - 66 ) 55 (44 - 73 ) 50 (41 - 66 ) 87 (60 - 154 ) 
H103 105 (86 - 135 ) 581 (234 - -1227 ) 487 (265 - 3031 ) 69 (56 - 91 ) 529 (199 - -807 ) 
MSP1-19 66 (57 - 79 ) 83 (66 - 113 ) 554 (208 - -839 ) 44 (38 - 54 ) -2839 (211 - -184 ) 
MSP2 CH150/9 96 (79 - 123 ) -304 (-1587 - -168 ) 234 (172 - 365 ) 77 (63 - 101 ) 422 (239 - 1783 ) 
MSP2 Dd2 74 (63 - 90 ) -359 (-3168 - -190 ) 197 (155 - 269 ) 96 (79 - 123 ) 503 (267 - 4169 ) 
TT -259(577 - -397 ) -426 (531 - -152 ) 480 (248 - 7201 ) 342(194 - 1420 ) -340 (1510 - -152 ) 
Half-life was derived from the GEE model's coefficient of Log10 MFI and days since the last infection. The positive value indicates 
the number of days it takes for antibody decay by 50%, a negative value indicates the antibody takes to boost by 50%. A 
95%confidence interval that overlap negative and positive values indicate a non-significant change.  A total of 160 participants at 
4-time points were included in the analysis.
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6.4.5 IgG subclass stratify into distinct clusters 
When total IgG was plotted against the subclasses, scatter plots revealed clustering of unique 
subpopulations. When subclasses were plotted against each other, two main distinctive clusters 
were observed in some antigens. When IgG1 was plotted against IgG3, (i) high IgG1 and low/or 
no IgG3 responses (IgG1H3L), and (ii) both high IgG1 and high IgG3 (IgG1H3H). Because the 
clustering was not consistent in all antigens, I ruled out assay artifacts due to anti-human IgG1 
or 3 to bind to some allotypes.  A clear example of clustering can be seen in Rh2, MSP2 CH150/9, 
and MSP2 Dd2 (Figure 6.57). When samples that were IgG1H3L were selected for an antigen, 
individual participants were categorized in the same clusters for all 4 time-points, implying 
individual dependent factors driving the response pattern.  
When IgG1 or IgG3 was plotted against IgG4, 3 distinct clusters were observed; IgG1H4H, 
IgG1L4H, and IgG1H4L example, in Hyp2 (in Figure 6.58). For both AMA1 and Rh2, where IgG1 
is the predominant subclass, the IgG1L4H phenotype was missing. 
Overall, our data indicated that there are cluster expressions based on IgG subclasses, and they 
can be characteristic to individuals and antigen.  The definition of the clusters in the study was 
arbitrary. Further work is required to define the clusters using unsupervised models like 
random forest e analysis and investigate antibody function among the distinct phenotypes.  
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Figure 6.57 Scatter plots of IgG1 against IgG3. IgG1 and IgG3 antibodies against 18 malaria blood-
stage antigens were measured on the MagPix (Luminex) multiplex assay. All 4 time-points for each of 
the 160 participants were included. The red gate is a cluster of samples with low IgG1 and high IgG3 
responses. Blue gate is a cluster of samples with both high IgG1 IgG3 responses. The gates were 
arbitrary based on visual observation. 
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Figure 6.58 Scatter plots of IgG1 against IgG3. IgG1 and IgG4 antibodies against 18 malaria blood-
stage antigens were measured on the MagPix (Luminex) multiplex assay. All 4 time-points for each of 
the 160 participants were included. The red gate includes a cluster of samples with low IgG1 and low 
IgG4 responses. Blue gate is a cluster of samples with both high IgG1 IgG4 responses. Green is high 
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6.4.6 IgG3 showed improved specificity of antigens to predict recent infection compared 
to total and IgG1  
IgG3 was predicted to improve antigens' performance as markers of recent infection due to its 
shorter half-life than total and IgG1 (Table 6.54). ROC curve analysis was performed to 
evaluate the antibody response's ability to antigens to classify an individual by their infection 
status in the last 90 or 180 days since the last infection. Infection definition included both 
patent and sub-patent infection (LAMP positive) samples from all four time-points were 
stratified into either infected at least once in the last 90 or 180 days or not infected during the 
same period. 
Overall, IgG3 had the highest estimated AUC across antigens, IgG1 had the lowest, and total 
IgG fell between IgG3 and IgG1 (Table 6.59). There was a significant negative correlation 
between AUC and estimated half-life. Antigens that had the shortest IgG3 half-life such as 
ETRAMP5Ag1 (Median half-life: 44; AUC: 77), HSP40 AG1 (Median half-life: 77; AUC: 79) 
MSP1-19 (Median half-life: 41; AUC: 79) and EBA175 RIII-V (Median half-life: 45; AUC: 75), 
had the highest AUC (Figure 6.510). Antigens like GLURP RII had a similar half-life between 
total, IgG3 and IgG1 had comparable AUC (Table 6.59). AUC values did not improve 
significantly at 180 days’ time point. Similar results are observed when only T4 is included in 
the analysis but with wider 95% confidence intervals due to the smaller numbers.  
Overall, the results implied that IgG3, even in highly immunogenic antigens like MSP1-19 and 
EBA175 RIII-V, improved antigens' sensitivity to predict recent infections in the last 90 days 
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29 Figure 6.510 ROC curves for antigens ETRAMP5 Ag1, HSP40 Ag1, MSP1-19 for total 
IgG, IGg1, and IgG3.  Samples from 160 participants at 4 time-points were defined as P. falciparum 
positive if the participant was microscopic positive or LAMP positive, and negative if the participant was 
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7 Table 6.511 Summary of AUC for defining infection status at 90 days 
Antigen Total IgG AUC (95% 
CI) 
IgG1 AUC (95% CI) IgG3 AUC (95% CI) 
HSP40 Ag1 0.71 (0.64 - 0.75) 0.56 (0.48 - 0.60) 0.80 (0.75 - 0.84) 
Etramp 4 Ag2 0.73 (0.69 - 0.78) 0.63 (0.57 - 0.68) 0.70 (0.64 - 0.76) 
Etramp 5 Ag1 0.75 (0.70 - 0.80) 0.60 (0.55 - 0.66) 0.77 (0.73 - 0.82) 
Hyp2 0.72 (0.70 - 0.79) 0.45 (0.40 - 0.50) 0.68 (0.62 - 0.73) 
SBP1 0.63 (0.58 - 0.68) 0.53 (0.48 - 0.59) 0.73 (0.68 - 0.79) 
SA-1 0.65 (0.60 - 0.71) 0.53 (0.47 - 0.58) 0.75 (0.71 - 0.80) 
AMA-1 0.73 (0.68 - 0.78) 0.70 (0.65 - 0.76) 0.76 (0.71 - 0.82) 
EBA140 RIII-V   0.70 (0.65 - 0.75) 0.62 (0.57 - 0.68) 0.72 (0.67 - 0.77) 
EBA175 RIII-V   0.75 (0.70- 0.80) 0.69 (0.64 - 0.76) 0.75 (0.70 - 0.80) 
EBA181 RIII-V   0.71 (0.67 - 0.76) 0.56 (0.51 - 0.62) 0.74 (0.69 - 0.80) 
Rh2  0.70 (0.65 - 0.75) 0.68 (0.63 - 0.76) 0.74 (0.70 - 0.80) 
Rh4.2 0.71 (0.66 - 0.76) 0.58 (0.52 - 0.63) 0.71 (0.65 - 0.76) 
Rh5 0.69 (0.64 - 0.74) 0.63 (0.57 - 0.68) 0.59 (0.54 - 0.65) 
GRURP RII 0.73 (0.69 - 0.78) 0.72 (0.67 - 0.77) 0.72 (0.67 - 0.77) 
H103 0.73 (0.68 - 0.78) 0.57 (0.52 - 0.63) 0.73 (0.68 - 0.79) 
PfMSP1-19 0.67 (0.62 - 0.72) 0.61 (0.56 - 0.70) 0.80 (0.75 - 0.84) 
MSP2 CH150/9 0.78 (0.74 - 0.83) 0.20 (0.21 - 0.29) 0.70 (0.65 - 0.76) 
MSP2 Dd2 0.78 (0.73 - 0.82) 0.30 (0.25 - 0.35) 0.71 (0.67 - 0.76) 
Tet Tox 0.39 (0.33 - 0.45) 0.06 (0.03 - 0.08) 0.33 (0.28 - 0.38) 
Area under curve (AUC) values were estimated by the receiver operating characteristic curve (ROC).  Samples from 160 
participants at 4 time-points were defined as P. falciparum positive if the participant was microscopic 
positive or LAMP positive, and negative if the participant was LMAP negative in the last 90 days. Each 
analysis includes 232 negative and 408 positive samples. The sample was defined as P. falciparum negative if the 
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6.5 Discussion  
6.5.1 Summary of results  
This study sought insight into how total IgG and subclasses are acquired with age during high 
malaria transmission intensity and maintained when the transmission was interrupted by the IRS. 
Longitudinal samples from 160 participants from three age categories (1-4, 5-11 and &>18 
years) were included from a larger PRISM cohort (219,221), at two time-points during high 
malaria transmission (12 and 6 months before IRS) and at two time-points after the transmission 
was interrupted to near-zero incidence. (6 and 12 months after the first round of IRS). Malaria 
transmission intensity did not decrease appreciatively to near-zero incidence until 12 months 
after the IRS's first round. (Chapter3, Figure 3.3). Total IgG and IgG1 - 4 antibody responses to 
18 P. falciparum antigens were measured using the MagPix (Lumimex) multiplex assay. The 
antigens were from the P. falciparum life cycle's blood-stage, including infected red blood cells, 
the merozoite apical complex, and merozoite surface.  
Total IgG and subclass antibody responses were observed in all antigens spanning the method's 
full dynamic range. IgG3 was the most dominant antibody relative to the other subclasses except 
for AMA-1 and Rh2, where IgG1 was the dominant subclass. IgG2 and IgG4 had relatively lower 
reactivity to the malaria antigens than the IgG1 and IgG3 subclasses, consistent with the previous 
findings (370,374,378). 
Total IgG and IgG subclass antibody levels were inversely associated with days since the last 
infection, independent of age categories. Generally, IgG3 was observed to have the lowest 
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population level estimated antibody half-life than total IgG and the other subclasses within the 
antigen. In some antigens like HSP40 Ag1, ETRAMP5 Ag1, MSP1-19, IgG3 half-life was lower 
than 50 days. The shorter half-life of P. falciparum specific IgG3 compared to IgG1 was 
previously reported in children (379), and intravenous administration of immunoglobulin (380). 
Antibody levels maintained after 180 days since the last infection was thought to indicate 
memory antibody levels. Furthermore, the dominant subclass antibody memory pool shifted 
from IgG1 in children to IgG3 in the adults except for AMA-1 and Rh2. The antigen-dependent 
subclass dominance and skewing of IgG subclass towards IgG3 with age were observed in 
antigens like MSP1-19, MSP2 Dd2 (374). These observations implied; (i) antigen intrinsic 
factors that influence subclass switching, (ii) early establishment of a predominantly IgG1 
memory, (iii) differential expansion of both IgG1 and IgG3 memory pools with age and or 
exposure that skew towards IgG3 in adulthood. 
Because of the shorter antibody half-life observed, it was hypothesized that IgG3 could improve 
the ability of antibody responses to antigens to measure recent infection. The results presented 
supported this hypothesis. IgG3 improved the sensitivity antigens, outstandingly in 
ETRAMP5Ag1, MSP1-19, and HSP40 AG1, to define if a participant was infected P.falciparum 
in the last 90 days. Infection was defined by a sensitive molecular test (LAMP) to include sub 
patent infections.  Overall, this finding boosts the prospects of using antigens to develop effective 
serology surveillance tools.  
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6.5.2 Determinants of antibody decay Half-life  
The differences in antibody half-life between antigens and subclasses and the predominance of 
subclass IgG1 and IgG3 between antigens and the shift with age were intriguing.  The half-life 
of antibodies transfused into naïve patients are short-lived. IgG3 is reported to have the shortest 
decay half-life 7 days and about 21 days for the other subclasses (381). The classical half-life in 
intravenous transfusion is mainly due to catabolic processes and immunological mechanisms. 
However, in this study, the IgG subclass half-lives observed were longer than the classical ones, 
up to 6 times longer in the shortest half-life observed in IgG3. The difference between the 
classical and observed half-life can be attributed to the secondary nature of the immune response 
that is influenced by several factors including but not limited to pool sizes of (i) LLPC, (ii) SLPC, 
(ii) phenotype composition of MBC, (iv) frequency and or duration of infection, (v) subclass 
interaction with FcRn receptor. 
During acute infection, extrafollicular B cell reaction, MBC activation, and early germinal center 
output result in a pool of SLPC that secret antibodies, increasing the overall antibody levels 
(Figure 6.511) (319,382). However, SLPC declined rapidly in the absence of infection due to 
intrinsic survival mechanisms and cessation of new ones (383). Also, part of the germinal center 
output is the LLPC that migrate to the bone marrow, where they continuously secrete antibodies 
in the absence of infection (317,318). The size of the MBC and the phenotype composition 
influence the accumulation of both the SPLC and LLPC.  MBC can directly differentiate into 
SLPC or initiate a new germinal center reaction upon activation (384). For example, switched 
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IgG+MBC are reported to differentiate into plasma cells preferentially, and the unstitched IgM+ 
MBC rapidly-produce SLPC and readily initiates CG (385). Furthermore, the accumulation of 
atypical MBC that express exhaustion and are difficult to transform into plasma cells in vitro is 
likely to affect the number of MBC that either form GC or plasma cells.   
On the other hand, homeostatic mechanisms remove antibodies via the Fc receptor-mediated 
catabolic process. In addition, target binding effector mechanisms such as phagocytosis, 
complement activation, the formation of immune complexes consumes antibodies (Figure 
6.511).  
The FcRn increases half-life through its antibody recycling property (170). In the absence of 
infection, the half-life depends on the size of the SLPC, LLPC, and the ability FcRn to recycle 
antibodies. Figure 6.511 summarizes the different contributors that determine the antibody pool's 
size during and in the absence of infection.  
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30 Figure 6.511 Illustrate the antibody source and destruction during acute infection and no infection. 
The net balance between the catabolic destruction and production source determines the size of the 
antibody pool. SLPC from the extrafollicular B cell and GC reaction, and the LLPC secrete antibody. In 
the no infection state, the LLPC and catabolic process determine the size of the antibody pool. 
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6.5.3 P. falciparum antigens may induce differential expansion of SLLC, LLPC, and MBC 
phenotypes   
Antigens included in this study had differing total IgG and subclass half-lives. The differences 
in total IgG half-life can be attributed to the composition of the IgG subclasses, the size of the 
LLPC, and the recent boosting of SLPC. For example, AMA-1 and Rh2, which had IgG1 
predominantly, were not necessarily with the longest half-life. Antigens like SBP1, Rh5, and 
SEA had lower antibody levels and longer half-life. The seemingly longer half-life of such 
antigens (Figure 6.511, green) may be due to a general lack of antibody boosting (failure to 
induce new SLPC) during infection. The lack of antigen boosting may be due to the transient 
and or limited expression of antigen quantity above a threshold to trigger a response. The 
alternative explanation could be the establishment of dysfunctional atypical MBC.  
Some antigens like GLURP RII had high antibody levels but with a shorter half-life. Such 
antigens are likely to elicit a large SLPC pool, a large MBC pool, and a small LLPC pool. 
Antibodies against this kind of antigens will have a large difference between the peak antibody 
levels during infection and the memory level maintained in the absence of infection (Figure 
6.511, red).  
On the other hand, there were antigens like AMA-1, whose antibody response has a high titer 
and a longer half-life. Such antigens are likely to elicit both large pools of LLPC and SLPC, 
resulting in boosting during infection but decay much slower due to the minimum difference 
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between the peak boost and the memory level maintained in the absence of infection (Figure 
6.511, blue). 
The differences observed among antigens support the notion that P. falciparum antigens 
differentially influence the B cell responses towards divergent memory compartments may bear 
consequences to the short-lived acquired immunity to malaria thought to require continuous 
exposure (340,386). Malaria-specific MBC were detected in the absence of antibodies implying 
inefficient accumulation of LLPC (322,387). MBC response is important to boost antibody 
response within 3 to 7 days of infection. However, highly invasive merozoites are released in 
large numbers from the liver stage. Maintaining antibody levels is important for the initial control 
of the parasite load and alleviation of disease before the antibody boost from extrafollicular MBC 
response and later germinal center reaction (324).   
Therefore, it is important to understand the factors that influence the memory compartment's 
outcome and antigens' role to inform better malaria vaccine designs that induce antibody titers 
sustained at high concentration and provide durable protection.  
6.5.4 FcRn may influence half-lives of IgG3 compared to IgG1  
 This study showed differences in the half-life among subclasses within antigen, and IgG3 
decayed relatively faster than the other subclasses. The faster decay of IgG3 may be attributed 
to its poor binding to the FcRn in acidic conditions (171,388). This property is critical for 
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protecting IgG from degradation in the endocytotic vacuoles (170). The FcRn receptor is also 
responsible for the placental maternal antibodies.   
 
 
31 6.511 Illustration of the three scenarios of antibody boost and decay profiles.  Red has 
a short half-life. Predominantly from SLPC antibody and very small LLPC pool. Maintain low antibody 
levels, highly boosted during infection, and rapidly decay in the absence of infection. Blue has a long 
half-life due to a large pool of LLPC boosted with a large pool of SSLP and accumulated additional LLPC 
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6.5.5 Slowed acquisition of IgG3 memory  
Cytophilic subclasses IgG1 and IgG3 are thought to play a critical role in antibody-mediated 
protective mechanisms against blood-stage malaria.  IgG3 is thought to play a greater role than 
IgG1 due to IgG3 high affinity for the Fc receptors and C1q compared to IgG1.  Maintenance 
of predominantly IgG1 in the absence of infection in children and IgG3 in adults may imply 
impaired or slowed acquisition of IgG3 LLPC. IgG class switching follows a one-way direction 
(IgG3, 1, 2 to 4) due to its nature of the Fc region's CH domains. IgG2 and IgG4 are referred to 
as terminal subclasses and are thought to have more somatic hypermutation implying extensive 
affinity maturation (389). IgG1 switched MBC will not switch to IgG3, but the results showed a 
shift from IgG1 in children towards IgG3 in adults. Likely, MBC that eventually give rise to 
IgG3+ LLPC is not the early ones that switched to IgG1, IgM+ MBC is most likely the source 
of late IgG3 LLPC, and this may underscore their importance in the slow acquisition of immunity 
to malaria. In some antigens, some adults express only IGg3 without IgG1. In this scenario, the 
absence of IgG1 may imply a total deletion of IgG1 switched MBC or their impairment with age 
or continued exposure. Although cytokines, intrinsic properties of antigens, the toll-like 
receptors (TLR), and microenvironment are implicated in switching (390), it remains unclear 
why switching is biased to IgG1 in children and shifted towards IgG3 in adults. The alternative 
explanation may be the preferential affinity maturation and acquisition of LLPC in the IgG3 than 
IG1. Because of the common epitopes' competitive binding, IgG1 is the most prevalent 
competitively binds epitopes and is therefore quantified in the Luminex assay. However, as IgG3 
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accumulates affinity maturation and the titer increases, IgG1 is outcompeted for the binding sites 
and therefore under quantified. Therefore, the shift from IgG1 to Ig3 with age may be due to the 
preferential affinity maturation in the IgG3 subclass . 
6.5.6 Prospects on using IgG3 as a marker of recent infection 
Results showed early expansion of IgG1 at an early age and a gradual expansion of IgG1 and 
IgG3 with age, biased towards IgG3. Similarly, our results demonstrated that IgG3 decayed with 
a shorter half-life than total IgG and IgG1 in the absence of infection. These two features may 
partly explain the better performance of IgG3 as a marker of recent infection compared to total 
IgG. Infection was defined to include both patent and sub-patent infections, and IgG3 improved 
specificity of a highly reactive protein like MSP1-1from 67% for total IgG to 80% for IgG3. 
This existing finding increases the prospects of designing superior malaria serological diagnostic 
or surveillance tools. The limitation of serological malaria diagnostic tools has always been the 
accumulation of memory with age and exposure that dampens the method's specificity. This 
limitation is likely to continue with IgG3, especially based on the generally increasing 
accumulation of IgG3 with age maintained after 180 days since the last infection. However, 
heterogeneity in the acquisition and maintenance of antibody responses by various malaria 
antigens has been previously observed and explored to identify recent exposure markers (331). 
Using similar microarray and bioinformatics approaches, focusing on IgG3 and exploring 
combination of antigens may result in the discovery of superior tools. 
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6.5.7 Drivers of distinctive antibody clusters 
Previously, a linear relationship, especially between IgG1 and IgG3, was assumed and reported. 
Surprisingly our data revealed distinct clustering when IgG subclasses were plotted against each 
other. Outdating clusters were observed in IgG1 versus IgG3 and  IgG4 versus IgG1 or IgG3. 
Some phenotypes like the IgG1l3h, and co-dominant IgG1h3h seemed to be consistent in some 
individuals at all four time-points. However, after highly stratifying the subpopulations at the 
participant level, the numbers were too small to make any meaningful deductions. Phenotypic 
expression of cell markers and cytokine secretion of T cells, especially T helper, including Tfh 
cells, has been extensively elaborated. T helper cells influence B cell reaction and class 
switching. IgG subclass ratios were previously associated with severe disease. More recently, a 
delayed boost in RTS, S resulted in increased IgG4 and improved efficacy(141). Likely, exposure 
timing and duration, T cell help, and other factors may influence IgG subclass composition, 
which can bear consequences on the immunity phenotype and maintenance. More work is 
required to understand the dynamics and drivers of IgG subclass phenotypes. 
6.5.8 Limitations 
Compared to total IgG, subclass signals were lower even at a higher plasma concentration. The 
low signal was due to monoclonal secondary anti-subclass use compared to the polyclonal anti-
IgG for total antibody. The competitive binding epitopes further compounded subclasses' 
detection levels relative to each other by the different subclasses, resulting in under 
quantification of especially subclass with low affinity and concentration. The estimation 
199 
  
Chapter 6:  IgG Subclasses during high P. falciparum Transmission and near Zero Transmission  
 
P. falciparum Transmission Intensity and the Quality of Antimalarial Antibodies                                                            Isaac Ssewanyana 
 
 
method of decay half-life assumed a constant linear reduction in antibody levels instead of a 
diphasic decay, which may result in the estimation of shorter half-lives. Also, the estimation 
method did not put into account antibody boosting.  
6.6 Conclusions 
 This study demonstrated the acquisition of all four IgG subclasses against malaria antigens 
and IgG1 and 3 being the dominant ones, similar to other findings. The IgG subclasses decayed 
at different rates; IgG3 had the shortest decay half-life. IgG3 memory pool maintained in the 
absence of infection was relatively smaller than IgG1 but expanded preferentially with age to 
become dominant or co-dominant subclass in adults.  As a result of a shorter half-life and slow 
accumulation of memory pool, IgG3 demonstrated improved specificity performance as a 
recent infection marker compared to total IgG. Furthermore, a combination of IgG subclasses 
revealed phenotypes. Additional work is required to explore IgG3 as a diagnostic tool for 
recent exposure and to understand the cause and implication of IgG subclass phenotype.
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7.1.1 Summary of results  
This thesis's first aim (Chapter 4) was to determine the association between P. falciparum 
transmission intensity with P. falciparum specific antibody avidity. To achieve this objective, 
1,029 and 582 samples from three cross-sectional surveys from low (EIR= 2) medium (EIR=6) 
to very high (EIR = 305) transmission intensity were utilized to compare avidity index to AMA-
1 and MSP1-19 across the sites, respectively. The avidity index was measured as a proportion 
of highly binding antibodies that remained after treatment with a chaotropic agent in the modified 
ELISA assay. Results demonstrated that despite higher antibody levels, avidity to both AMA-1 
and MSP1-19 was significantly lower at the site of highest P. falciparum transmission intensity 
in children above 5 years and adults. Age had a minimal effect on antibody avidity.  These 
observations suggest that affinity maturation to P. falciparum antigens may be compromised in 
the setting of high P falciparum transmission.  This observation led to the hypothesis; (i) Recent 
infection may results in low avidity antibodies from predominately SLPC (ii) Near constant 
exposure may interfere with affinity maturation. However, the cross-sectional nature of the study 
limited the ability to explore the two hypothesizes. Secondly, only two malaria antigens were 
included, which limited our ability to generalize the findings.  
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The second objective was inspired by hypothesizes derived from the first aim's results (Chapter 
4). I took advantage of the PRISM longitudinal cohort at Nagongera, a high transmission site, in 
Chapter 4.  IRS was introduced and interrupted transmission drastically to near-zero incidence 
within one year. The interruption of transmission provided the opportunity to measure antibody 
avidity within the same individuals during high P. falciparum prevalence, and malaria 
prevalence was nearly zero. The objective was to determine the effect of interruption in P. 
falciparum transmission by IRS on antibody avidity to a panel of 18 P. falciparum blood-stage 
antigens. The PRISM cohort's uniqueness provided accurate P. falciparum infection 
documentation, up to intervals of one-month active surveillance for patent and sub patent 
infection using light microscopy and LAMP, respectively.  The detailed intensive surveillance 
allowed estimation of days since last infection or proportion of months free of infection for each 
of the 4 time-points; 6 and 12 months pre-IRS and 6- and 12-months post-IRS. The chaotropic 
interruption of antibody binding technique previously established for ELISA was adopted for 
use on the MagPix (Luminex) platform to allow multiplexing. To our knowledge, this was the 
first such description of a multiplex avidity assay that allows the simultaneous evaluation of the 
IgG avidity index of a large panel of P. falciparum antigens. On top of the multiplexing, the 
method’s high dynamic range allowed detection of subtle differences and inclusion of samples 
with low reactivity compared to the ELISA method. 
Generally, across all 18 malaria antigens explored, the avidity index was below 50% for all 
antigens except for AMA1 and Rh2 in most participants. However, there were a few participants 
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with an avidity index above 80% to near 100%. Secondly, the avidity index increased 
significantly after the IRS, and the increase was associated with days since the last infection or 
proportion of months free of infection, independent of age. The increase in avidity index was 
found to be due to the differential decay of the predominantly non-avid antibody pool compared 
to the avid pool. Thirdly, there was high heterogeneity in the avidity index in association with 
age independent of days since the last infection. Avidity index increased in some antigens, 
decreased or remained the same in other antigens in association with age. The heterogeneity was 
due to the differential expansion of both the avid and the non-avid antibody pools in association 
with age.  
Based on the observation of low avidity index, faster decay rates of non-avid compared to avid 
pool in the absence of infection, I postulated that (i) The non-avid pool was produced primarily 
by SLPC that rapidly wane in the absence of infection. (ii) The avid pool is produced primarily 
by LLPC that survive and continually produce antibodies in the absence of infection. These 
findings supported the hypothesis derived from Chapter 4; recent or near-constant exposure 
promotes low avidity antibodies from SLPC. Because most of the individuals had a 
predominantly low avidity index for most antigens, these results strengthen the second 
hypothesis, stating that frequent P. falciparum infection may impair affinity maturation.  
Both affinity maturation and class switching occur during the germinal center reaction. Both 
properties impact antibody-mediated immunity to malaria. The third objective sought to 
determine the effect of interruption of malaria transmission by IRS on the IgG subclass response 
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on a large number of blood-stage malaria antigens. The same cohort samples used in objective 2 
in Chapter 5 were utilized. Total IgG and IgG1-4 antibodies against 18 malaria blood-stage 
antigens were measured on the MagPix (Luminex) multiplex assay. All four IgG subclasses were 
detected in all antigens with no clear pattern between iRBC associated antigens, apical complex, 
or merozoite surface antigens. IgG subclasses decayed at different rates, and IgG3 half-life was 
the shortest of the four subclasses, consistent with previous findings. There was a general 
preferential early acquisition IgG1 maintained after 180 days since infection (antibody memory) 
at the early age, and the antibody memory expansion with age was skewed towards IgG3, 
resulting in a memory predominance of IgG3 over IgG1 in adults for most of the antigens except 
for AMA-1 and Rh2. Due to its shorter half-life, IgG3 improved antigens' specificity as a marker 
of recent infection compared to total IgG or IgG1, even for highly immunogenic antigens like 
MSP1-19. When plotted against each other, IgG subclasses formed distinctive clusters instead 
of linear associations previously reported.  
7.1.2 Does P. falciparum infection interfere with affinity maturation? 
Chapter 4 (Objective 1) showed that malaria antigens' avidity index was inversely associated 
with malaria transmission intensity. Results from Chapter 5 (Objective 2) showed that most 
individuals from a high malaria transmission intensity had low avidity index generally across 18 
blood-stage malaria antigens. The avidity index improved after one year of interrupting malaria 
transmission. Although an overly simplified designation, the results revealed differences in 
decay rates of avid compared to non-avid antibody pools in the absence of infection, implying a 
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difference in sources, primarily LLPC and SLPC, respectively. Furthermore, the accumulation 
of both avid and non-avid pools hence avidity index with age varied across antigens. In a highly 
endemic setting where an individual suffers hundreds of infections in the early years of age, the 
avid pool's accumulation should have been acquired and saturated very early in life. However, 
age had little effect on the avidity index in Chapter 4, and the avid pool only significantly 
increased in adults compared with children 1 - 4 years for most antigens in Chapter 5. Expansion 
of the avid pool happened alongside the expansion of the non-avid pool, and in some antigens, 
the non-avid pool expanding preferentially. Also, results from Chapter 6 showed later acquisition 
of the memory IgG3 subclass compared to IgG1. IgG3 is thought to be superior to IgG1 at 
mediating effector function mechanisms due to a higher affinity for FcR and flexibility of the 
long hinge that improves the binding complex (132,391). The delayed acquisition of the germinal 
center output features like avid antibody pool and IgG3 may imply interruption of B cell reaction 
in P. falciparum infection. 
These findings contribute to the growing evidence of malaria interference of the germinal center 
reaction at different stages, including (i) skewed T-independent extrafollicular B cell response, 
(ii) impairment of the T follicular helper cells population, (iii) disruption of germinal center 
architecture, (iv) interruption of antigen presentation by dendritic and other antigen-presenting 
cells (v) presence of a large chronic volume of antigens that affect affinity selection (vi) chronic 
immune activation. The consequence of these impairments results in (i) skewed memory 
compartments, (ii) accumulation of atypical MBC, (iii) accumulation of IgM+ MBC, (iv) low 
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antibody avidity, (v) poor maintenance of high antibody titers due to short half-life (vi) delayed 
IgG3 memory.  
7.1.3 What is the implication of low antibody avidity (predominantly non-avid antibodies)? 
The presence of a predominantly non-avid antibody pool may reflect the dynamics in the 
acquisition and maintenance of SLPC, LLPC, and MBC phenotypes. Class switched MBC has 
been widely studied in malaria, but most recently non switched IgM+ MBC have been described 
and reported in malaria (385,392). Non-switched IgM+ MBC characterized by fewer somatic 
hypermutations rapidly respond to malaria infection and give rise to IgM and IgG plasmablasts 
within three days of infection(392,393).  Their rapid response in the extrafollicular T independent 
response can be critical in the early boosting of antibody titers and, subsequently, control parasite 
density to alleviate disease outcomes. Secondly, these IgM+ MBC may be important in 
maintaining a large non-avid pool with a high breadth of recognition or wide cross reactivity. 
This attribute of cross-reactivity allows for rapid recognition of high antigenic variation and 
prevents parasite immune evasion. However, the broad reactivity comes at a low avidity cost and 
requires a high antibody titer to mediate function. Therefore, a predominantly non-avid antibody 
pool may reflect the plasticity of the IgM+ MBC or extrafollicular IgG+MBC, a host adaptation 
to counteract the high polymorphism and genetic diversity of the parasite antigens.   This IgM+ 
MBC and extrafollicular IgG+MBC plasticity may be an adaptation that comes at the cost of 
delayed and poor maintenance of acquired immunity. However, whether there is a skewed 
expansion of IgM+ MBC and extrafollicular IgG+MBC in malaria infection and if it affects the 
206 
  
Chapter 7:  Main Discussion   
 
P. falciparum Transmission Intensity and the Quality of Antimalarial Antibodies                                                            Isaac Ssewanyana 
 
 
acquisition of avid antibody and long-term memory is unknown.  In addition, there are germinal 
center independent IgG+MBC (315) that are of low somatic hypermutation. How these contribute 
to the pool of non-avid antibodies is also not known.  
The PRISM cohort provides an opportunity to study malaria-specific MBC phenotypes kinetics 
from the same individuals during high exposure to infection. In the absence of infection, 
properties of MBC such as surface marker phenotypes, class/subclass switching, mutations in 
the V-gene region, their ability to proliferate and differentiate into antibody-forming cells, and 
the relative avidity of the secreted antibodies can be studied. Tetramers can be used to sort 
malaria-specific B cells. To increase the yield, tetramers of several malaria antigens can be used 
to harvest a polyclonal population. B cell receptor class switching, surface markers, can be 
associated with age, malaria exposure history, state of infection, pre and post-IRS, among other 
factors 
The B cells may be sorted further by surface marker phenotypes or B cell receptor subclass, 
sequence the v-gene region, and culture for proliferation and differentiation into antibody-
forming cells. Avidity of the antibodies secreted in culture can be associated with the V-gene 
mutations and the different phenotypes. These features can be related to age, immunity status, 
history of exposure, and effective elimination of IRS exposure.  While peripheral blood MBC 
may not fully tell the full story of the different memory compartment acquisition and 
maintenance, we can gain useful insight into drivers and nature of secondary antibody responses.  
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7.1.4 Does malaria induce short-lived memory compared to other infections? 
The amount of antibody maintained in the absence of infection is the net difference between 
antibody production by LLPC and antibody decay. Therefore, the increased antibody half-life 
can indicate memory since the catabolic decay is a constant in the absence of infection. The rate 
of production from LLPC or differentiating MBC into SLPC determines the rate for decay. 
Chapter 6 results showed that the total IgG half-life for the malaria blood-stage antigens ranged 
between 57 to 120 days compared to a double boost within 259 for TT. While IgG1, 2, and 4 
indicated longer decay half-life with some trends of boosting in some antigens, IgG3 had the 
lowest decay half-life, to as low as 41 days for ETRAMP5 Ag1, for example.  This observation 
implied that total antibody decay was majorly contributed to by IgG3. Other studies have 
reported shorter half-live of antibodies to malaria blood-stage antigens from as low as 6 and 7 
days for IgG1 and IgG3, respectively (379,394), and as high as 157 years for total IgG to Pf 
VAR2CSA (151). The wide differences in half-life could be due to several factors, including the 
methodology and assumption of a constant linear decay than diphasic decay, antigen type, 
population age, and time from infection. All these factors can influence the estimation outcome. 
However, not even the longest half-life estimation of malaria antibodies is comparable to 
estimates for other diseases like measles (over 369 years), MUMPS (124 years ), Rubella (over 
85 years), among others (395). Therefore, a question remains whether malaria impairs memory 
acquisition or alters the acquisition of the memory compartments that bear consequences to 
protective immunity? Studies in African migrants who return to malaria-endemic areas after a 
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long time have increased susceptibility to malaria, although not to the extent seen in malaria 
naïve (396,397). 
Furthermore, the resurgence of malaria and severe forms in adults have been reported in areas 
where effective interventions like IRS and ITN have been discontinued (329,398). Other studies 
have demonstrated maintenance of malaria MBC in the absence of detectable antibodies 
(387,399), implying that the MBC compartment can be acquired and maintained without the 
LLPC compartment. Failure to maintain antibodies may affect immunity due to failure to contain 
the infection within the first 3 to 5 days before secondary B cell reaction results in antibody 
boost.  According to our results, IgG1, 2, and 4 are maintained better than IgG3 in the absence 
of infection. Therefore, the IgG subclasses' composition is likely to alter, and because IgG4, for 
example, can have an antagonistic effect on IgG1 and IgG3 effector function, this alteration 
many affect the potency and effectiveness of the maintaining antibody in the absence of 
infection. IgG subclasses are associated with graft rejection implying their role in modifying the 
immunity outcome (346). More work is required to determine IgG subclass composition's effect 
on effector function like antibody-dependent phagocytosis, cytotoxicity, complement-fixing, or 
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7.1.5 IgG subclass phenotypes and implication in immunity to malaria 
Results in Chapter 6 revealed clustering of IgG subclasses when plotted against each other, more 
clearly in IgG1 VS IgG3 and IgG4 VS IgG1 or IgG3.  The results also indicated differences in 
decay half-life as well as acquisition rates with age. These two features can result in clustering. 
Other factors like T-follicular phenotypes, pro-inflammatory versus non-inflammatory cytokine 
environment, and innate signaling can influence IgG subclass switching patterns among 
individuals(373,390,400,401). However, we already know that IgG subclasses have different 
abilities to mediate the different effector mechanisms. Secondly, the different malaria immunity 
profiles like anti-disease and anti-parasites are mediated by different mechanisms. Therefore, the 
IgG subclass phenotypes are likely important surrogate markers of immunity profiles, historical 
exposure, or predictors of maintenance of immunity or risk of disease. Further work must 
understand the relationship between IgG subclass phenotypes and malaria exposure and 
immunity status. 
7.1.6 Prospects of IgG3 as a diagnostic tool for malaria in the elimination era 
The new UN Sustainable Development Goal 3C calls for reducing malaria mortality and 
morbidity by at least 90%, eliminating malaria in 35  countries by 2030.  To achieve this goal, 
intensive surveillance and timely identification of any infection will be required to target 
treatment. Serology tools provide prospects due to the ease of use in the fields and quick 
turnaround time. These tools may not serve as diagnostic tools, but they will play a big role in 
detecting recent exposure. Results from Chapter 6 showed that IgG3 had a shorter half-life and 
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delayed accumulation of memory antibody pool maintained in the absence of infection with age 
compared to IgG1 and total IgG. These observations implied that despite IgG3 having a shorter 
half-life, it also suffers from the delayed acquisition of LLPC relative to IgG1. Because IgG1 
and IgG3 are the most prevalent subclasses in malaria immune responses, as shown by our results 
and others, detecting only IgG3 can improve malaria antigens' performance to measure recent 
infection. Results in Chapter 6 supported this postulation where IgG3 showed better specificity 
to predict infection on the last 90 days compared to total IgG and IgG1. The results indicated 
that the performance of IgG3 could be equally as good for highly immunogenic antigens like 
MSP1-19 even when infection was defined at the sub-patent level. Because antigens such as 
MSP1-19 are universally reactive, IgG3 offers the prospects of overcoming specificity 
limitations that come with antigens that are not universally reactive. However, our results are 
from a highly endemic area where the infection was drastically interrupted; the kinetics of 
memory compartments and subclasses may be different in such a high perennial transmission 
setting compared to seasonal malaria, low transmission, or near elimination areas. Additional 
work is required, exploring more malaria antigens and different transmission settings. 
7.2 Significance 
 
This thesis showed that frequent infection-induced predominantly non-avid antibodies with 
shorter half-lives supported the hypothesis that chronic near-constant infection may interrupt 
affinity maturation. This bears consequence on the quality of antibody-mediated immunity 
against P. falciparum infection and its longevity. Poor and short-lived efficacy of RTS, S was 
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reported in endemic areas, and this could have been due to the vaccine inducing mainly SLPC.  
If our hypothesis is true, vaccine outcome will improve if vaccination is conducted under 
chemoprophylaxis to allow vaccination to induce complete germinal center reaction and produce 
LLPC.  Secondly, a simple intervention involving intensive malaria prophylaxis following a 
malaria episode may improve avidity maturation and early acquire an effective protective 
immune response. Our results clearly show that measuring IgG3 increases the prospects of using 
serology tools to measure recent infection. Finally, our results indicate that measuring antibody 
quality and quantity instead of quantity alone may provide better correlates of naturally acquired 
or vaccine-induced immunity and its longevity.  
7.3 Conclusions 
 
This thesis aimed to determine the effect of malaria transmission intensity on the antibodies 
against blood-stage malaria properties, namely antibody avidity, and IgG subclasses' 
composition. This was driven by the observation of antibodies' roles in acquired immunity to 
malaria, the slow acquisition of immunity with age, and the increasing evidence supporting the 
interruption of immunity acquisition.  P. falciparum is thought to interrupt immunity 
acquisition partly through the interruption of the germinal center reaction, which is the source 
of both affinity maturation and class switching. We compared the avidity index to AMA-1and 
MSP1-19 in three different transmission settings and observed that the avidity index was 
inversely associated with transmission intensity. We further compared avidity index and IgG 
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subclasses to 18 blood-stage malaria antigens in a longitudinal study where IRS interrupted 
high transmission intensity to near zero after one year. We observed that the increase in avidity 
index with days since the last infection was due to the differential rates of decay of the non-
avid antibody pool compared to the avid pool. The non-avid pool was postulated to be majorly 
produced by SLPC that contracts rapidly in the absence of infection. The avid pool by LLPC 
was maintained in the absence of infection. Heterogeneity in avidity index with age across 
antigens was observed due to differences in expansion of both the avid and non-avid pool with 
association with age.  Furthermore, IgG subclasses decayed at different half-lives, with IgG3 
generally having the shortest half-life. IgG1 pool maintained in the absence of infection was 
preferentially acquired early in age, but IgG3 was preferentially accumulated with age, thus 
explaining the shift in dominance from IgG1 to IgG3.  Consequently, IgG3 performed with 
better specificity as a recent infection marker compared to total IgG and IgG1. When plotted 
against each other, IgG subclasses revealed conspicuous clustering that requires further 
investigation.  This thesis supports the existing notion that P. falciparum interrupts the 
acquisition and maintenance of immunity to malaria.  We provide further evidence of 
predominant production of non-avid antibodies that rapidly decay in the absence of infection 
and the slow accumulation of the avid pools that majorly maintain circulating antibodies in the 
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7.4 Future Direction 
 
The thesis further shows the disproportionate acquisition and maintenance of IgG3 subclasses. 
Further work is required to determine functional differences between IgG1 and IgG3 in malaria 
immunity to understand the implication of the IgG3 memory pool's delayed accumulation. This 
can be done by affinity purification of IgG1 and IgG3 from plasma. The purified antibodies 
can be used in functional antibody assays like parasite growth inhibition and antibody-
mediated complement-fixing. It is also important to understand if IgG1 is functionally 
comparable to IgG3 and their synergy in combination and with IgG subclasses. 
Furthermore, IgG3 showed improved P. falciparum antigen performance as a recent infection 
marker, especially with highly immunogenic antigens like MSP1-19.  Further investigation is 
needed to validate this finding in a larger study and to explore additional antigens and a 
combination of antigens. A serology tool can greatly impact malaria surveillance due to the 
ease of use and cost-effectiveness.  
For the first time, I showed distinct clustering of individuals based on their IgG1, IgG3, and 
IgG4 profiles. This observation needs to be validated in a larger sample size. Also,  factors 
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Further work is required to investigate malaria-specific MBC population phenotypes, class-
switching, and SHM patterns. Characterization of antibody avidity, subclass, and functional 
assays for the antibodies secreted by the MBC in-vitro with age and exposure is required to 
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